fentanyl has been researched along with Neoplasms in 491 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral morphine is frequently used for breakthrough pain but the oral route is not always available and absorption is slow." | 9.41 | Healthcare professionals' views of the use of oral morphine and transmucosal diamorphine in the management of paediatric breakthrough pain and the feasibility of a randomised controlled trial: A focus group study (DIPPER). ( Harrop, E; Howard, RF; Jamieson, L; Johnson, M; Liossi, C; Mott, C; Oulton, K; Skene, SS; Wong, IC, 2021) |
| "A low-dose fentanyl citrate patch was effective in the management of cancer pain in opioid-naïve patients and was well tolerated." | 9.34 | Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain. ( Hashimoto, F; Okawa, K; Tanaka, Y; Terahara, T; Uchida, E; Yamaguchi, S, 2020) |
| "We sought to evaluate the efficacy of using a quick response (QR) code within video education to guide proper use of fentanyl transdermal patches and control pain, depression, and anxiety levels in cancer patients." | 9.34 | Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial. ( Chen, J; Hu, X; Mao, X; Rao, Y; Xuan, Z; Yang, S; Ye, Z; Zhang, Y, 2020) |
| "The optimal dose of fentanyl sublingual spray (FSS) for exertional dyspnea has not been determined." | 9.30 | Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial. ( Azhar, A; Bruera, E; Dalal, S; Dev, R; Driver, L; Haider, A; Hernandez, F; Hui, D; Kilgore, K; Larsson, L; Liu, D; Naberhuis, J; Reddy, A; Reddy, S; Virgilio, A, 2019) |
| "We conducted a pilot study to examine the effect of prophylactic fentanyl buccal tablet (FBT) on exercise-induced dyspnea." | 9.24 | Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial. ( Balachandran, DD; Bruera, E; Frisbee-Hume, S; Hui, D; Kilgore, K; Liu, D; Park, M, 2017) |
| "Purpose Fentanyl sublingual tablets (FST) are a potentially useful alternative to parenteral opioids such as subcutaneous morphine (SCM) to treat severe cancer pain episodes." | 9.24 | Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial. ( Brunelli, C; Caraceni, A; Centurioni, F; Manzoni, A; Pigni, A; Zecca, E, 2017) |
| "In this pilot study, we examined the effect of prophylactic fentanyl pectin nasal spray (FPNS) on exercise-induced dyspnea, physiologic function, and adverse events." | 9.22 | Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial. ( Bruera, E; Hui, D; Kilgore, K; Liu, D; Park, M; Williams, J, 2016) |
| "To determine time to onset, efficacy, feasibility, and safety of transmucosal fentanyl in comparison to immediate-release morphine for the relief of episodic breathlessness." | 9.22 | EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. ( Alt-Epping, B; Cornely, OA; Gärtner, J; Hein, R; Hellmich, M; Kloke, M; Nauck, F; Piel, M; Simon, ST; Voltz, R, 2016) |
| "To evaluate the efficacy of oral transmucosal fentanyl citrate (OTFC) in the treatment of dyspnea on exertion in patients with advanced cancer." | 9.20 | A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer. ( Bruera, E; Correas, MÁ; Moralo, MJ; Pinna, MÁ; Vargas, RM, 2015) |
| " The sublingual fentanyl orally disintegrating tablet is a formulation by which fentanyl can be rapidly absorbed across the oral mucosa producing rapid-onset analgesia, and which may be effective for breakthrough pain treatment." | 9.20 | Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial. ( Gomyo, I; Katakami, N; Ohta, E; Okada, M; Shimoyama, M; Shimoyama, N; Yukitoshi, N, 2015) |
| "Rapid analgesic onset opioids, particularly fentanyl buccal tablet, is preferable for managing breakthrough pain." | 9.20 | Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese c ( Adachi, I; Eguchi, K; Goto, F; Matoba, M; Shima, Y; Takigawa, C; Tanda, S; Yomiya, K; Yoshimoto, T, 2015) |
| "The aims of this study were to explore the efficacy of intranasal fentanyl spray* (INFS) 400 μg to evaluate 12-week tolerability of the nasal mucosa and to explore safety data for all dose strengths of INFS in patients with cancer-related breakthrough pain (BTP)." | 9.20 | Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain. ( Eeg, M; Jaatun, E; Kaasa, S; Kvitberg, M; Popper, L; Thronæs, M, 2015) |
| "To determine the feasibility of conducting a randomized trial of subcutaneous fentanyl in patients with cancer, and examine the effects of fentanyl on dyspnea, walk distance, vital signs, and adverse events." | 9.19 | Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. ( Bruera, E; Chisholm, G; Frisbee-Hume, S; Hui, D; Morgado, M; Reddy, S; Xu, A, 2014) |
| "To investigate the long-term use of fentanyl pectin nasal spray (FPNS) for the treatment of breakthrough pain in cancer (BTPc) in patients receiving regular opioid therapy." | 9.19 | A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain. ( Ellershaw, JE; Perelman, M; Radbruch, L; Revnic, J; Taylor, D; Torres, LM, 2014) |
| "Managing cancer pain often requires opioid medications, such as fentanyl, which is frequently initiated parenterally, and then converted to transdermal form." | 9.19 | Efficacy and safety of a six-hour continuous overlap method for converting intravenous to transdermal fentanyl in cancer pain. ( Bloise, R; Davis, MP; Samala, RV, 2014) |
| "Oromucosal fentanyl is currently used for the treatment of breakthrough pain (BTP) in opioid-treated cancer patients." | 9.19 | A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. ( Bullier, F; Fricova, J; Harabisova, S; Novotna, S; Richterova, E; Trinquet, F; Valentova, K, 2014) |
| "Evaluate analgesic efficacy, functional benefit, and patient satisfaction with fentanyl buccal tablet vs immediate-release oxycodone for breakthrough pain (BTP)." | 9.17 | Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase ( Earl, CQ; Narayana, A; Slevin, KA; Webster, LR; Yang, R, 2013) |
| "This study compared the efficacy and safety of a 3-day-type transdermal fentanyl patch conversion by the rapid titration method to short-acting oral oxycodone for cancer pain." | 9.16 | [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain]. ( Fujio, N; Ishikawa, N; Kameyama, M; Watanabe, H; Yamazaki, K, 2012) |
| "A number of transmucosal fentanyl formulations have been developed for the management of breakthrough cancer pain (BTCP)." | 9.16 | Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. ( Bull, J; Dillaha, L; Geach, J; Parikh, N; Rauck, R; Reynolds, L; Scherlis, M; Stearns, L, 2012) |
| "We recently reported that fentanyl pectin nasal spray (FPNS) provides superior pain relief from breakthrough cancer pain (BTCP) compared with immediate-release morphine sulfate (IRMS), with significant effects by five minutes and clinically meaningful pain relief from 10 minutes postdose." | 9.15 | Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. ( Brooks, D; Davies, A; Elsner, F; Espinosa, J; Fallon, M; Reale, C; Sitte, T, 2011) |
| "This study assessed the long-term safety and tolerability of fentanyl buccal tablet (FBT) in opioid-tolerant patients with cancer and breakthrough pain (BTP) who were either naive to FBT or had completed 1 of 2 previous double-blind, placebo-controlled FBT studies (rollover patients)." | 9.14 | Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. ( Messina, J; Weinstein, SM; Xie, F, 2009) |
| "This trial investigated the efficacy and long-term tolerability of intranasal fentanyl spray (INFS) 50 to 200 microg in the treatment of breakthrough pain in opioid-tolerant patients with cancer." | 9.14 | Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatmen ( Colberg, T; Kaasa, S; Kaczmarek, Z; Kress, HG; Nolte, T; Orońska, A, 2009) |
| "The efficacy of intranasal fentanyl spray (INFS) was compared with that of oral transmucosal fentanyl citrate (OTFC) for the relief of cancer-related breakthrough pain (BTP) in an open-label, crossover trial." | 9.14 | A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. ( Camba, MA; Colberg, T; Davies, A; Mercadante, S; Perkins, P; Poulain, P; Radbruch, L; Sitte, T, 2009) |
| "Fentanyl buccal soluble film (FBSF) has been developed as a treatment of breakthrough pain in opioid-tolerant patients with cancer." | 9.14 | Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. ( Finn, AL; Gever, LN; North, J; Rauck, R; Tagarro, I, 2010) |
| "In this study we evaluated the efficacy and tolerability of sublingual fentanyl (SLF) for breakthrough pain (BTP) in adult opioid-tolerant cancer patients." | 9.14 | Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. ( Derrick, R; Frank-Lissbrant, I; Howell, J; Kälkner, KM; Lennernäs, B; Lennernäs, H, 2010) |
| "This randomized, double-blind, crossover study assessed the efficacy and tolerability of a new rapid onset nasal fentanyl formulation (Fentanyl Pectin Nasal Spray; FPNS) for breakthrough cancer pain (BTCP)." | 9.14 | A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. ( Burton, AW; Gabrail, N; Portenoy, RK; Taylor, D, 2010) |
| "We examined the efficacy and safety of a new transdermal fentanyl citrate patch (HFT-290), which was applied once daily in patients with cancer pain who were receiving a stable dose of once-every-three-day application transdermal fentanyl patch [TDF (72 hr)]." | 9.14 | [A phase II clinical study of once-a-day fentanyl citrate patch in patients with cancer pain--switching from once-every-three-days fentanyl patch to once-a-day fentanyl citrate patch]. ( Hashizume, T; Iseki, M; Iwao, Y; Kitajima, T; Masuda, Y; Matoba, M; Miyazaki, T; Namiki, A; Ogawa, S; Uchida, E, 2010) |
| "The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain." | 9.14 | Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. ( Adile, C; Aielli, F; Ferrera, P; Ficorella, C; Mercadante, S; Porzio, G, 2010) |
| "A novel transdermal matrix patch delivery system for fentanyl has been developed to deliver improved management of cancer pain compared with that obtained using current fentanyl reservoir patches." | 9.13 | Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain. ( Hanaoka, K; Hosokawa, T; Ishida, T; Kitajima, T; Mashimo, S; Miyazaki, T; Namiki, A; Nogami, S; Ogawa, S, 2008) |
| " The patient is a 50-year-old female with widely metastatic breast cancer who developed opioid toxicity when maintenance transdermal fentanyl patch therapy (100 μg patch applied every 72 h) was rotated to subcutaneous hydromorphone infusion to improve pain control." | 9.12 | Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: A case report and review of the literature. ( Chua, D; Jackson, LD; Selby, D; Wortzman, R, 2021) |
| " In this randomized open-label study the influence of tramadol on dose adjustment of transdermal fentanyl in advanced cancer pain control was prospectively evaluated." | 9.12 | Improved cancer pain treatment using combined fentanyl-TTS and tramadol. ( Aloisio, L; Bajocco, C; Ciccozzi, A; Coaccioli, S; Colangeli, A; Marinangeli, F; Paladini, A; Varrassi, G, 2007) |
| "To determine the safety and efficacy of transdermal fentanyl for pain relief in cancer patients and to compare the effects on patients according to whether they had previously received strong opioids, weak opioids or non-opioid analgesia." | 9.11 | Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. ( Bryuzgin, V; Kourteva, G; Tawfik, MO, 2004) |
| "The aim of this observational study was to examine pain management outcomes and quality of life (QoL) measures in cancer patients with intolerable or chronic severe pain transferring from World Health Organization's step I, II, and III analgesics to the transdermal therapeutic fentanyl system (TTS-F)." | 9.11 | Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. ( Georgaki, S; Katsouda, E; Kouloulias, V; Kouvaris, J; Mystakidou, K; Parpa, E; Tsilika, E; Vlahos, L, 2004) |
| "This randomised, multicentre, direct open comparative trial evaluated the efficacy, treatment convenience, tolerability and safety aspects of transdermal therapeutic system (TTS)-fentanyl and sustained-release oral morphine (SRM) in both opioid-naïve patients with moderate-to-severe cancer-related pain and in patients who had already been using opioids for mild-to-moderate pain." | 9.10 | Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. ( Schipper, RM; Smit, JM; van Seventer, R; Wicks, MA; Zuurmond, WW, 2003) |
| "Analgesic treatment with TTS fentanyl used as a single opioid is effective and safe for cancer pain relief, given that is cautiously applied, in patients requiring strong opioid analgesics even if they were naive to strong or mild opioids." | 9.10 | Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids. ( Befon, S; Dardoufas, K; Georgaki, S; Mystakidou, K; Tsilika, E; Vlahos, L, 2002) |
| "The successful use of methadone in cancer pain has been supported by numerous case reports and clinical studies." | 9.10 | Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. ( Derby, S; Fischberg, D; Kornick, C; Manfredi, PL; Moryl, N; Payne, R; Santiago-Palma, J, 2002) |
| "Constipation and the use of laxatives were investigated in patients with chronic cancer pain treated with oral morphine and transdermal fentanyl in an open sequential trial." | 9.09 | Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. ( Grond, S; Kasper, M; Kulbe, C; Lehmann, KA; Loick, G; Radbruch, L; Sabatowski, R, 2000) |
| "Transdermal Fentanyl (TF, Durogesic) is a strong opioid analgesic which is used in the treatment of cancer pain." | 9.09 | [Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)]. ( Gorzelińska, L; Kozikowska, J; Leppert, W; Luczak, J, 2000) |
| "This open-label study evaluated the long-term safety and tolerability of oral transmucosal fentanyl citrate (OTFC) in ambulatory cancer patients with breakthrough pain undergoing cancer care at 32 university- or community-based practices." | 9.09 | Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. ( Berris, R; Busch, MA; Coluzzi, P; Hart, L; Loseth, DB; Lyss, A; Nordbrook, E; Payne, R; Portenoy, RK; Rauck, R; Simmonds, M, 2001) |
| "The effects of sublingual fentanyl citrate (SLFC) were assessed in 11 hospice inpatients with cancer-related breakthrough pain." | 9.09 | Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. ( Zeppetella, G, 2001) |
| "Direct conversion from oral morphine to transdermal fentanyl with a ratio of oral morphine/transdermal fentanyl (100:1 mg) daily was examined in patients with cancer pain." | 9.08 | Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. ( Donner, B; Strumpf, M; Tryba, M; Zenz, M, 1996) |
| "We performed an open-label pilot study to define analgesic efficacy, acceptability, and toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain." | 9.08 | Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study. ( Fidler, P; Hammack, JE; Loprinzi, CL; Mailliard, JA; Michalak, JC; Miser, AW; O'Fallon, JR; Reuter, NF; Rospond, RM; Wilwerding, MB, 1996) |
| "A prospective phase II study was conducted to define the analgesic efficacy, acceptability and toxicity of the transdermal therapeutic system (TTS) of fentanyl in Chinese patients with severe cancer-related pain." | 9.08 | Transdermal fentanyl for severe cancer-related pain. ( Chan, AT; Johnson, PJ; Lam, KK; Leung, TW; Nip, SY; Yeo, W, 1997) |
| "To compare pain-related treatment satisfaction, patient-perceived side effects, functioning, and well-being in patients with advanced cancer who were receiving either transdermal fentanyl (Duragesic, Janssen Pharmaceuticals, Titusville, NJ) or sustained-release oral forms of morphine (MS Contin, Perdue Frederick Co, Norwalk, CT, or Oramorph SR, Roxanne Laboratories, Columbus, OH)." | 9.08 | Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. ( Mahmoud, R; Mathias, SD; Pasta, DJ; Payne, R; Wanke, LA; Williams, R, 1998) |
| "Patients who were 18 years of age or older, receiving the equivalent of at least 60 mg oral morphine or at least 50 microg transdermal fentanyl per day for chronic cancer-related pain, and experiencing at least one episode of breakthrough pain per day were studied." | 9.08 | Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. ( Busch, M; Cleary, J; Farrar, JT; Nordbrock, E; Rauck, R, 1998) |
| "This was a multicenter, randomized, double-blind, dose-titration study in 62 adult cancer patients using transdermal fentanyl for persistent pain." | 9.08 | Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. ( Busch, MA; Christie, JM; Coluzzi, P; Nordbrock, E; Patt, R; Portenoy, RK; Simmonds, M, 1998) |
| "All communications on the use of transdermal fentanyl as well as the recommendations of the manufacturer include the direction that patients should be titrated with a short-acting narcotic to control their cancer pain before they are converted to a fentanyl transdermal therapeutic system (TTS)." | 9.07 | Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients. ( Korte, W; Morant, R, 1994) |
| "In this study, 6 patients with pain from advanced cancer were enrolled in a multicenter, open-label seeding trial of transdermal fentanyl." | 9.07 | Transdermal fentanyl: seeding trial in patients with chronic cancer pain. ( Kedziera, P; Levy, MH; Rosen, SM, 1992) |
| "Patients were entered into an open label study to evaluate the efficacy of transdermal fentanyl as an analgesic for chronic cancer pain." | 9.07 | Transdermal fentanyl for chronic cancer pain: detailed case reports and the influence of confounding factors. ( Hogan, LA; Patt, RB, 1992) |
| "In this study, 11 cancer patients who experienced severe pain were treated with transdermal fentanyl." | 9.07 | Transdermal fentanyl use in hospice home-care patients with chronic cancer pain. ( Herbst, LH; Strause, LG, 1992) |
| "A multicenter study was conducted to determine the patient and physician acceptability of transdermal fentanyl in the management of cancer-related pain." | 9.07 | Management of cancer pain with transdermal fentanyl: phase IV trial, University of Iowa. ( Barcellos, WA; Maves, TJ, 1992) |
| " Only randomized controlled trials on the use of the transdermal fentanyl patch for the treatment of cancer pain were selected." | 8.98 | Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials. ( Ma, TT; Peng, CB; Wang, DD; Zhu, HD, 2018) |
| "Fentanyl buccal tablet (FBT) (FENTORA) is indicated for the management of breakthrough pain (BTP) in patients with cancer pain and who are tolerant to ≥60 mg of oral morphine equivalents, at least with the current availability of the minimal strength of 100 μg." | 8.91 | Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain. ( Mercadante, S, 2015) |
| " This rapid review, commissioned by the National Institute for Health Research, used standard Cochrane methodology to examine adverse effects of morphine, fentanyl, oxycodone, and codeine in cancer pain studies as a close approximation to possible effects in the dying patient." | 8.90 | Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. ( Derry, S; Moore, RA; Wiffen, PJ, 2014) |
| "To determine the analgesic efficacy of transdermal fentanyl for relief of cancer pain, and to assess the adverse events associated with the use of transdermal fentanyl for relief of cancer pain." | 8.89 | Transdermal fentanyl for cancer pain. ( Derry, S; Hadley, G; Moore, RA; Wiffen, PJ, 2013) |
| "The development of intranasal fentanyl (INFS) aimed for a rapid treatment of breakthrough pain (BTP) in cancer patients." | 8.88 | Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain. ( Facius, A; Kaessner, N; Lahu, G; Nave, R; Roepcke, S, 2012) |
| "Oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablets are the first medications developed specifically for the treatment of breakthrough pain in opioid-tolerant patients." | 8.87 | Fentanyl nasal spray for the treatment of cancer pain. ( Gouliamos, A; Mystakidou, K; Panagiotou, I, 2011) |
| "To compare the efficacy of intranasal fentanyl spray (INFS), oral transmucosal fentanyl citrate (OTFC), fentanyl buccal tablet (FBT) and oral morphine (OM) for the treatment of breakthrough cancer pain (BTCP)." | 8.86 | Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. ( Jansen, J; Lenre, M; Nolte, T; Stam, W; Vissers, D, 2010) |
| "Previous meta-analysis suggested that transdermal fentanyl was not inferior to sustained-release oral morphine in treating moderate-severe cancer pain with less adverse effects." | 8.86 | Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis. ( Bi, ZF; Chen, DL; Jiang, ZM; Ma, W; Xie, DR; Yang, Q; Zhang, YD, 2010) |
| "Transdermal fentanyl patches first became available in the early 1990s and provided an innovative treatment for the management of cancer pain." | 8.85 | The role of transdermal fentanyl patches in the effective management of cancer pain. ( Gibbs, M, 2009) |
| "To assess the adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison with slow release oral morphine." | 8.84 | Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. ( Maltoni, M; Raffaeli, W; Sartori, S; Scarpi, E; Tamburini, E; Tassinari, D; Tombesi, P, 2008) |
| "Transdermal buprenorphine has been assessed as a therapy for chronic cancer and non-cancer pain in both clinical and postmarketing surveillance studies." | 8.83 | Transdermal buprenorphine in cancer pain and palliative care. ( Sittl, R, 2006) |
| "The fentanyl buccal tablet (FBT) is a new formulation of fentanyl that uses an effervescent drug delivery system to enhance penetration across the buccal mucosa for the treatment of breakthrough pain in opioid-tolerant patients with cancer." | 8.83 | Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. ( Blick, SK; Wagstaff, AJ, 2006) |
| "To evaluate effectiveness and safety information of transdermal fentanyl (TDF) (Duragesic/Durogesic) and sustained-release oral morphine (SRM) in cancer pain (CP) and chronic non-cancer pain (NCP), a pooled analysis was conducted on datasets of published, open label, uncontrolled (no comparator group) and randomised controlled (with SRM as comparator) studies of TDF." | 8.82 | Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. ( Ahmedzai, SH; Allan, LG; Camacho, F; Clark, AJ; Horbay, GL; Richarz, U; Simpson, K, 2004) |
| "Transdermal fentanyl is a useful opioid-agonist for the treatment of moderate to severe chronic cancer pain." | 8.81 | Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. ( Muijsers, RB; Wagstaff, AJ, 2001) |
| "Transdermal fentanyl appears to be a safe and practical alternative to short-acting analgesics in the treatment of cancer pain." | 8.78 | Transdermal fentanyl in cancer pain. ( Mosser, KH, 1992) |
| "The physicochemical properties, pharmacology, pharmacokinetics, serum concentrations and clinical effects, adverse effects and contraindications, and dosage of transdermally administered fentanyl are described, and clinical studies evaluating the use of a transdermal fentanyl system in the treatment of postoperative pain and chronic cancer-associated pain are reviewed." | 8.78 | Transdermally administered fentanyl for pain management. ( Calis, KA; Corso, DM; Kohler, DR, 1992) |
| "Fentanyl transdermal therapy is a suitable treatment for moderate-to-severe cancer-related pain." | 8.31 | An individualized digital twin of a patient for transdermal fentanyl therapy for chronic pain management. ( Bahrami, F; De Nys, K; Defraeye, T; Rossi, RM, 2023) |
| "After the CAVIDIOPAL study, we carried out an additional analysis to evaluate the impact of individualized management of breakthrough cancer pain, using the analgesic drug fentanyl, on quality of life (QoL) of advanced cancer patients receiving palliative care in Spain." | 8.12 | Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care. ( Abián, MH; Bermudo, CL; Canal-Sotelo, J; Casillas, IR; Mancilla, PG; Maradey, P; Rivero, SG; Rodríguez, AT; Viejo, MN, 2022) |
| "It is recommended not to use transdermal fentanyl (Fe) patches (TFP) in cancer cachexia but TFP may be the only available option for pain." | 8.12 | Transdermal fentanyl to parenteral morphine route switch and drug rotation in refractory cancer cachexia. ( Alabdullateef, SH; Almashiakhi, M; Alsirafy, SA; Elyamany, AM; Hassan, AD, 2022) |
| "Serum fentanyl concentration and the safety and efficacy of once-a-day fentanyl citrate patch were investigated in pediatric and adolescent patients with cancer pain." | 8.02 | An Open-Label Study of the Pharmacokinetics and Tolerability of Once-a-Day Fentanyl Citrate Patch in Japanese Pediatric and Adolescent Patients with Cancer Pain. ( Hashimoto, F; Hiyama, E; Okawa, K; Otaka, K; Terahara, T; Yamaguchi, S, 2021) |
| "The objective of this study was to evaluate the influence of cancer cachexia on pain control in cancer patients receiving a transdermal fentanyl patch (FP) and to investigate whether dry skin was a factor related to cancer cachexia and uncontrolled pain." | 7.96 | Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch. ( Chiba, T; Kimura, S; Kudo, K; Tairabune, T; Takahashi, H; Ueda, H, 2020) |
| "The aim of the study was to evaluate the effectiveness of fentanyl pectin nasal spray (FPNS) in controlling procedural breakthrough cancer pain (BTCP) in advanced cancer patients undergoing radiotherapy." | 7.91 | Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures. ( Aymar, N; Jiménez, E; Mena, A; Mestre, F; Ortiz, I; Pardo, J; Roncero, R; Vidal, M, 2019) |
| "Sublingual fentanyl tablets (SFTs) have been shown to be a safe and effective option in controlling breakthrough cancer pain (BTcP)." | 7.91 | Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets. ( Coma, J; De Sanctis, V; Estivill, P; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Jiménez, AJ; Moya, J; Rodelas, F; Salazar, R; Sanz, A; Tomás, A; Vargas, MI, 2019) |
| "In 2013, oral transmucosal fentanyl was first approved in Japan for reducing breakthrough pain(BTP)." | 7.85 | [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl]. ( Hosonuma, R; Kaneshima, M; Kyosaka, B; Osato, S; Warita, E; Yomiya, K, 2017) |
| "This exploratory study shows that IV Fentanyl can alleviate dyspnea in some patients but is an example of the difficulties conducting dyspnea research." | 7.83 | Intravenous Fentanyl for Dyspnea at the End of Life: Lessons for Future Research in Dyspnea. ( Pang, GS; Qu, LM; Tan, YY; Yee, AC, 2016) |
| "Little is known about the efficacy of low-dose transdermal fentanyl (TDF) patches in opioid-naïve patients with moderate-to-severe cancer pain." | 7.81 | The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. ( Hwang, IG; Kang, JH; Kim, JH; Kim, WS; Lee, HR; Lee, HY; Lee, KE; Oh, SY; Park, K; Park, SH; Park, YS; Song, SY, 2015) |
| "Common adverse symptoms of cancer and chemotherapy are a major health burden; chief among these is pain, with opioids including transdermal fentanyl the mainstay of treatment." | 7.81 | Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl. ( Barratt, DT; Dale, O; Kaasa, S; Klepstad, P; Somogyi, AA, 2015) |
| "It is unknown whether nutritional status influences pain intensity in cancer patients receiving a transdermal fentanyl patch (FP)." | 7.80 | A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch. ( Chiba, T; Kimura, Y; Kudo, K; Tairabune, T; Takahashi, H; Takahashi, K; Wakabayashi, G, 2014) |
| "Morphine, oxycodone, and fentanyl are commonly used to control cancer pain." | 7.80 | Influence of serum albumin levels during opioid rotation from morphine or oxycodone to fentanyl for cancer pain. ( Arakawa, Y; Fukuura, K; Futamura, A; Hayashi, T; Higashiguchi, T; Ikehata, S; Kuki, R; Makihara, T; Matsuzaki, H; Mori, N; Takahashi, H; Yamadaa, S; Yasuda, K, 2014) |
| "Palliative care physicians are accustomed to using transdermal fentanyl patch for cancer pain control but not so familiar with its intravenous administration." | 7.80 | Use of intravenous fentanyl against morphine tolerance in breakthrough cancer pain: a case series and literature review. ( Bruera, E; Hwang, IC; Park, SM, 2014) |
| "Fentanyl pectin nasal spray is a novel intranasal formulation for the management of breakthrough cancer pain in patients taking and tolerant to opioids for persistent cancer pain." | 7.79 | Fentanyl pectin nasal spray: a novel intranasal delivery method for the treatment of breakthrough cancer pain. ( Bulloch, MN; Hutchison, AM, 2013) |
| "Determining the appropriate dose of transdermal fentanyl (TDF) for the alleviation of cancer pain requires determining the factors causing variations in serum fentanyl concentration after TDF treatment." | 7.78 | Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. ( Ebinuma, K; Kokubun, H; Matoba, M; Takayanagi, R; Yago, K; Yamada, Y, 2012) |
| " Compared with other opioids, low-dose fentanyl has been suggested to produce milder side effects such as nausea, constipation, and somnolence." | 7.77 | [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011) |
| "To identify predictive factors requiring high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone to transdermal fentanyl in patients with cancer pain." | 7.77 | Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain. ( Fujimoto, S; Hosokawa, T; Kanbayashi, Y; Konishi, H; Miki, T; Okamoto, K; Otsuji, E; Takagi, T; Taniwaki, M; Yoshikawa, T, 2011) |
| "The FDA has approved a nasal spray formulation of fentanyl (Lazanda-Archimedes) for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy." | 7.77 | Fentanyl nasal spray (Lazanda) for pain. ( , 2011) |
| "The aim of this study is to investigate cancer patients' response and side effects associated with transdermal therapeutic fentanyl (TTS-F), whose pain was hardly controlled by nonweak/weak opioids in Taiwan." | 7.76 | The use of transdermal fentanyl in cancer pain--a compliance study of outpatients in Taiwan. ( Chen, YJ; Chiou, TJ; Hung, CJ; Liu, CY; Su, YC; Tang, Y; Tzeng, WF; Weng, YC, 2010) |
| "For 20 hospitalized patients with cancer pain that could not be controlled by NSAIDs, the fentanyl transdermal patch (1." | 7.76 | Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line. ( Hoya, Y; Okamoto, T; Yanaga, K, 2010) |
| "The fentanyl transdermal matrix patch is approved in Japan for the management of moderate to severe cancer-related pain in adults." | 7.74 | Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain. ( Hoy, SM; Keating, GM, 2008) |
| "To evaluate the efficacy and safety of fentanyl administered by PCA in children with cancer pain." | 7.74 | Safety and efficacy of fentanyl administered by patient controlled analgesia in children with cancer pain. ( Barone, G; Chiaretti, A; Lazzareschi, I; Liotti, L; Riccardi, R; Ruggiero, A, 2007) |
| "This retrospective study identified patients with cancer and noncancer pain who had received > or =1 prescription for fentanyl TD or buprenorphine TD (the all-patients groups) from the German IMS Disease Analyzer-mediplus database, which contains all relevant data concerning drug prescriptions from 400 practices in Germany." | 7.73 | Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. ( Likar, R; Nautrup, BP; Sittl, R, 2005) |
| "The purpose of this study was to compare changes in dosages of transdermal (TD) fentanyl and TD buprenorphine in patients with cancer and non-cancer pain." | 7.73 | Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. ( Nautrup, BP; Nuijten, M; Sittl, R, 2005) |
| " Data from patients with noncancer or cancer pain treated with TD buprenorphine or TD fentanyl for at least 3 months between May 2002 and April 2005 were analyzed." | 7.73 | Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. ( Nuijten, M; Poulsen Nautrup, B; Sittl, R, 2006) |
| "The delayed effects (12-16 hours) of transdermal fentanyl make dose titration difficult during acute exacerbations of cancer pain." | 7.72 | A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain. ( Kornick, CA; Manfredi, PL; O'Brien, PC; Payne, R; Santiago-Palma, J; Schulman, G; Weigand, S, 2003) |
| "(1) Some cancer patients suffer occasional breakthrough pain despite well-conducted opiate treatment, warranting the use of immediate-release oral morphine." | 7.71 | Oral transmucosal fentanyl: new preparation. For breakthrough cancer pain when morphine fails. ( , 2002) |
| "This open compassionate-use prospective registration study evaluated the tolerability, ease of use and applied doses of transdermal (TTS) fentanyl in adult patients with cancer-related pain requiring strong opioid analgesia." | 7.71 | Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. ( Desmedt, M; Lossignol, D; Menten, J; Mullie, A, 2002) |
| "An expert working group of the European Association for Palliative Care has revised and updated its guidelines on the use of morphine in the management of cancer pain." | 7.71 | Morphine and alternative opioids in cancer pain: the EAPC recommendations. ( Casas, JR; Cherny, N; Conno, F; Hanks, GW; Hanna, M; Kalso, E; McQuay, HJ; Mercadante, S; Meynadier, J; Poulain, P; Radbruch, L; Ripamonti, C; Sawe, J; Twycross, RG; Ventafridda, V, 2001) |
| "A transdermal fentanyl patch for the treatment of chronic cancer-related pain is available in four dosages (25, 50, 75, and 100 microg/hr)." | 7.70 | Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. ( Payne, R, 1998) |
| "To study use of Duragesic (fentanyl transdermal system), the only transdermal opioid approved in Canada for treating chronic cancer pain in adults." | 7.69 | Fentanyl transdermal system. Pain management at home. ( Hays, H; Woodroffe, MA, 1997) |
| "These results suggest that steady-state serum concentrations are approached by the second dose of TTS(fentanyl) and that the kinetics are stable with repeated dosing." | 7.68 | Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. ( Foley, KM; Gupta, SK; Inturrisi, CE; Lapin, J; Layman, M; Portenoy, RK; Southam, MA, 1993) |
| "Five cancer patients experienced satisfactory pain relief for periods of 3-156 days using continuous transdermal delivery of the narcotic fentanyl." | 7.67 | Transdermal fentanyl for pain control in patients with cancer. ( Dothage, JA; Miser, AW; Miser, JS; Narang, PK; Sindelar, W; Young, RC, 1989) |
| "Episodic breathlessness is a distressing and difficult to treat symptom because of its short duration." | 7.01 | Intranasal Fentanyl Versus Placebo for Treatment of Episodic Breathlessness in Hospice Patients With Advanced Nonmalignant Diseases. ( Allan, S; Bridge, R; Hewitt, D; Iupati, S, 2021) |
| " Adverse events were somnolence and other events associated with opioids were mostly mild or moderate." | 6.79 | A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients. ( Adachi, I; Eguchi, K; Goto, F; Hamada, S; Kosugi, T; Kunikane, H; Matoba, M; Shima, Y; Shinozaki, K; Takigawa, C; Tanda, S; Yomiya, K; Yoshimoto, T, 2014) |
| "Breakthrough cancer pain (BTcP) is recognized as a clinically significant complication of chronic cancer pain with most BTcP episodes peaking in intensity within a few minutes and lasting for approximately 30 min." | 6.79 | Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. ( España Ximénez de Enciso, I; García Velasco, P; Muñoz Garrido, JC; Velázquez Clavarana, L; Velázquez Rivera, I, 2014) |
| "Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)." | 6.76 | Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011) |
| "Of 139 recruited patients, 69% identified an effective dose of sublingual fentanyl ODT (a dosage that successfully treated all episodes of BTcP over two consecutive days) and entered the maintenance phase, during which they were treated for a median of 149." | 6.76 | Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. ( Derrick, R; Dumble, S; Hassman, D; Howell, J; Nalamachu, S; Wallace, MS, 2011) |
| " Adverse events were recorded throughout." | 6.76 | Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. ( Müller-Schwefe, GH; Überall, MA, 2011) |
| "Fentanyl is an opioid with high lipid solubility, suitable for intravenous, spinal, transmucosal and transdermal administration." | 6.74 | Transdermal fentanyl in cachectic cancer patients. ( Gergov, M; Haakana, S; Heiskanen, T; Kalso, E; Mätzke, S; Vuori, E, 2009) |
| "Breakthrough cancer pain (BTcP) represents an important clinical challenge in the care of patients with cancer." | 6.74 | Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. ( Bartkowiak, AJ; Derrick, R; Hassman, D; Hayes, TG; Howell, J; Nalamachu, S; Rauck, RL; Reyes, E; Tark, M, 2009) |
| " Any adverse events were recorded; four tolerability endpoints, constipation, nausea, daytime drowsiness, and sleeping disturbances, were assessed daily." | 6.73 | A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. ( Heiskanen, T; Hoerauf, KH; Jensen, NH; Krenn, H; Kress, HG; Lundorff, L; Nolte, T; Petersen, R; Rosland, JH; Sabatowski, R; Saedder, EA; Von der Laage, D, 2008) |
| "2% of patients experienced adverse events that were either probably related or very likely to be related to the study drug." | 6.73 | Safety and efficacy of transdermal fentanyl in patients with cancer pain: phase IV, Turkish oncology group trial. ( Aliustaoğlu, M; Altinbaş, M; Altundağ, K; Atahan, L; Cooper, R; Demirkan, B; Kömürcü, S; Manavoğlu, O; Ozdemir, F; Ozkök, S; Pak, Y; Sarihan, S; Turhal, S; Turna, HS; Yavuz, AA; Yaylaci, M, 2007) |
| "In episodes treated with IV-MO, pain intensity decreased from a mean of 6." | 6.73 | Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. ( Casuccio, A; Ferrera, P; Intravaia, G; Mangione, S; Mercadante, S; Villari, P, 2007) |
| " Pharmacokinetic parameters were calculated by noncompartment analysis." | 6.71 | Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. ( Bredenberg, S; Hedner, T; Holmberg, M; Lennernäs, B; Lennernäs, H; Nyström, C, 2005) |
| " Large patient-to-patient variations in pharmacokinetic parameters occurred, although intraindividual variability was limited." | 6.71 | Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ( Bressolle, F; Caumette, L; Culine, S; Garcia, F; Pinguet, F; Poujol, S; Solassol, I, 2005) |
| "The treatment of cancer pain with transdermal fentanyl can be performed as a long-term therapy and result in good pain relief." | 6.69 | Long-term treatment of cancer pain with transdermal fentanyl. ( Donner, B; Raber, M; Strumpf, M; Zenz, M, 1998) |
| "TTS fentanyl was titrated to pain relief, and patients were followed up for as long as 3 months." | 6.69 | A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. ( Hays, H; Moulin, DE; Sloan, PA, 1998) |
| "To treat cancer pain, physicians often decide to jump directly from step 1 of the World Health Organization (WHO) analgesic ladder to step 3." | 6.69 | Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. ( Mattern, C; Uitendaal, MP; Vielvoye-Kerkmeer, AP, 2000) |
| "Midazolam was found to be the drug of preference for the majority of patients." | 6.67 | Midazolam versus fentanyl as premedication for painful procedures in children with cancer. ( Conner, K; Dickson, N; Luzins, J; McGorray, S; Reilly, K; Sandler, ES; Weyman, C, 1992) |
| "However, the treatment of breakthrough pain should be adjusted to suit specific patient requirements." | 6.61 | The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients. ( Brząkała, J; Leppert, W, 2019) |
| " Furthermore, it is a reasonably safe treatment, causing generally mild adverse events not leading to treatment discontinuation." | 6.52 | Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review. ( Escobar, Y; Moya, J; Murillo, M; Rogríguez, D; Urrutia, G, 2015) |
| "Breakthrough cancer pain (BTCP) is common among cancer patients and markedly lowers their quality of life." | 6.49 | Fentanyl for the treatment of tumor-related breakthrough pain. ( Bornemann-Cimenti, H; Sandner-Kiesling, A; Szilagyi, IS; Wejbora, M, 2013) |
| " placebo in the first 30 minutes after dosing (FBT provided an 83% probability of superior pain relief, ODT 66%, and OTFC 73% vs." | 6.49 | Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. ( Bennett, MI; Fullarton, JR; Jandhyala, R, 2013) |
| "Breakthrough cancer pain has been defined as a transitory increase in pain intensity that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain." | 6.48 | Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. ( Mercadante, S, 2012) |
| " Close examination of the existing trials assessing these newer transmucosal preparations reveals significant variation in many study parameters, such as patient selection criteria, severity of breakthrough pain episodes, proportions of patients with a neuropathic pain component, titration protocols, choice of the primary endpoints, protocols for repeat dosing and rescue medication, the separation of treated episodes and the extent of the placebo response, all of which may have affected efficacy results." | 6.47 | Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. ( Elsner, F; Porta-Sales, J; Tagarro, I; Zeppetella, G, 2011) |
| "Fentanyl is a lipophilic, short-acting, synthetic opioid with a piperidine chemical structure." | 6.45 | The role of fentanyl in cancer-related pain. ( Prommer, E, 2009) |
| " FBT utilizes OraVescent technology to improve bioavailability and speed of drug delivery." | 6.44 | Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain? ( Hanna, M; Lecybyl, R, 2007) |
| "Pain is experienced by most cancer patients and represents an important issue in the clinical setting." | 6.44 | Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology. ( Mystakidou, K; Tsiatas, M; Tsilika, E; Vlahos, L, 2007) |
| "Persistent pain is present to some degree throughout the day and primarily is controlled with around-the-clock medication." | 6.42 | Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate. ( Palos, G; Rhiner, M; Termini, M, 2004) |
| " However, clinicians should realize that the manufacturer's recommendations for equianalgesic dosing of transdermal fentanyl may result in initial doses that are too low in some patients, and in a titration period that is too long." | 6.41 | An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. ( Breitbart, W; Chandler, S; Eagel, B; Ellison, N; Enck, RE; Lefkowitz, M; Payne, R, 2000) |
| " The dosing interval for these systems is generally 3 days." | 6.41 | Treatment of cancer pain with transdermal fentanyl. ( Gourlay, GK, 2001) |
| " Regarding adverse events, nausea occurred in 12." | 5.91 | Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain. ( Fujimoto, H; Funato, M; Kawana, M; Kiribayashi, M; Kokubun, H; Kondo, M; Kusakabe, A; Miyasato, A; Nagatani, K; Nakamura, K; Ohno, R; Okamoto, K; Onoda, C; Ozeki, A; Suzuki, N, 2023) |
| "5 mg/kg lignocaine over 15 min, starting approximately 15 min before the surgical incision and fentanyl 0." | 5.69 | A comparison of two techniques of postoperative analgesia: lignocaine-fentanyl intravenous infusion and ropivacaine-fentanyl epidural infusion in patients undergoing cytoreductive cancer surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)- ( Bharati, SJ; Bhatnagar, S; Deo, S; Garg, R; Gupta, N; Kumar, V; Mahendru, K; Mishra, S; Ray, M, 2023) |
| "Cancer pain was observed in 131 of 160 patients with advanced cancer living at home." | 5.56 | [Analysis of Symptoms Relieved in Addition to Pain after Administration of Oxycodone or Morphine to Patients with Advanced Cancer Living at Home]. ( Watanabe, K, 2020) |
| "Adverse drug reactions were registered in 3%." | 5.48 | Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS. ( Gneist, M; Landthaler, R; Masel, EK; Watzke, HH, 2018) |
| "Oral morphine is frequently used for breakthrough pain but the oral route is not always available and absorption is slow." | 5.41 | Healthcare professionals' views of the use of oral morphine and transmucosal diamorphine in the management of paediatric breakthrough pain and the feasibility of a randomised controlled trial: A focus group study (DIPPER). ( Harrop, E; Howard, RF; Jamieson, L; Johnson, M; Liossi, C; Mott, C; Oulton, K; Skene, SS; Wong, IC, 2021) |
| "Fentanyl is an opioid initially developed for parenteral administration." | 5.36 | Formulations of fentanyl for the management of pain. ( Grape, S; Lauer, S; Schug, BS; Schug, SA, 2010) |
| "Intranasal fentanyl (INF) quickly and noninvasively relieves severe pain, whereas intravenous hydromorphone (IVH) reliably treats severe cancer pain but requires vascular access." | 5.34 | Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: A randomized controlled trial. ( Banala, SR; Khattab, OK; Page, VD; Todd, KH; Warneke, CL; Yeung, SJ, 2020) |
| "A low-dose fentanyl citrate patch was effective in the management of cancer pain in opioid-naïve patients and was well tolerated." | 5.34 | Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain. ( Hashimoto, F; Okawa, K; Tanaka, Y; Terahara, T; Uchida, E; Yamaguchi, S, 2020) |
| "We sought to evaluate the efficacy of using a quick response (QR) code within video education to guide proper use of fentanyl transdermal patches and control pain, depression, and anxiety levels in cancer patients." | 5.34 | Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial. ( Chen, J; Hu, X; Mao, X; Rao, Y; Xuan, Z; Yang, S; Ye, Z; Zhang, Y, 2020) |
| " The bioavailability of fentanyl was statistically different according to patient age." | 5.33 | Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. ( Astre, C; Bressolle, F; Caumette, L; Coulouma, R; Culine, S; Garcia, F; Pinguet, F; Solassol, I; Thézenas, S, 2005) |
| "Fentanyl is a synthetic, lipophilic opioid, more potent than morphine, and achieves peak effects after intravenous administration in 5 minutes." | 5.32 | Intravenous fentanyl for cancer pain: a "fast titration" protocol for the emergency room. ( Martins, M; Soares, LG; Uchoa, R, 2003) |
| "Morphine side effects were reduced in some patients who changed to transdermal fentanyl, but there was no reduction in those who needed high-dose morphine for rescue analgesia." | 5.32 | A study of transdermal fentanyl in cancer pain at Aichi-Cancer Center. ( Hasegawa, M; Hosoda, R; Kamiya, Y; Kato, K; Mizaki, T; Nitta, M; Yamazaki, S, 2004) |
| "Most patients suffered from cancer pain and only 11 patients had chronic pain from non-malignant disease." | 5.31 | Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. ( Brunsch-Radbruch, A; Grond, S; Lehmann, KA; Petzke, F; Radbruch, L; Sabatowski, R, 2001) |
| "The optimal dose of fentanyl sublingual spray (FSS) for exertional dyspnea has not been determined." | 5.30 | Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial. ( Azhar, A; Bruera, E; Dalal, S; Dev, R; Driver, L; Haider, A; Hernandez, F; Hui, D; Kilgore, K; Larsson, L; Liu, D; Naberhuis, J; Reddy, A; Reddy, S; Virgilio, A, 2019) |
| "We conducted a pilot study to examine the effect of prophylactic fentanyl buccal tablet (FBT) on exercise-induced dyspnea." | 5.24 | Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial. ( Balachandran, DD; Bruera, E; Frisbee-Hume, S; Hui, D; Kilgore, K; Liu, D; Park, M, 2017) |
| "Purpose Fentanyl sublingual tablets (FST) are a potentially useful alternative to parenteral opioids such as subcutaneous morphine (SCM) to treat severe cancer pain episodes." | 5.24 | Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial. ( Brunelli, C; Caraceni, A; Centurioni, F; Manzoni, A; Pigni, A; Zecca, E, 2017) |
| " The string was "rapid onset opioids" or "transmucosal fentanyl" and "breakthrough cancer pain"." | 5.22 | Bibliometric Network Analysis on Rapid-Onset Opioids for Breakthrough Cancer Pain Treatment. ( Armignacco, A; Carpenedo, R; Cascella, M; Chinè, E; Coluccia, S; Crispo, A; Cuomo, A; Cutugno, F; Forte, CA; Franceschini, G; Gennaro, PD; Migliaccio, L; Monaco, F; Natoli, S; Nocerino, D; Picerno, P; Tafuri, M; Tracey, MC; Vittori, A, 2022) |
| "Guidelines tend to consider morphine and morphine-like opioids comparable and interchangeable in the treatment of chronic cancer pain, but individual responses can vary." | 5.22 | Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids. ( Apolone, G; Azzarello, G; Bandieri, E; Caraceni, A; Cavanna, L; Corli, O; Crispino, C; Di Gregorio, R; Dragani, TA; Floriani, I; Galli, F; Gamucci, T; Greco, MT; Iorno, V; Kaasa, S; Lipari, G; Luzzani, M; Montanari, M; Pacchioni, M; Pavesi, L; Reale, C; Roberto, A; Valenti, D, 2016) |
| "In this pilot study, we examined the effect of prophylactic fentanyl pectin nasal spray (FPNS) on exercise-induced dyspnea, physiologic function, and adverse events." | 5.22 | Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial. ( Bruera, E; Hui, D; Kilgore, K; Liu, D; Park, M; Williams, J, 2016) |
| "To determine time to onset, efficacy, feasibility, and safety of transmucosal fentanyl in comparison to immediate-release morphine for the relief of episodic breathlessness." | 5.22 | EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. ( Alt-Epping, B; Cornely, OA; Gärtner, J; Hein, R; Hellmich, M; Kloke, M; Nauck, F; Piel, M; Simon, ST; Voltz, R, 2016) |
| "To evaluate the efficacy of oral transmucosal fentanyl citrate (OTFC) in the treatment of dyspnea on exertion in patients with advanced cancer." | 5.20 | A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer. ( Bruera, E; Correas, MÁ; Moralo, MJ; Pinna, MÁ; Vargas, RM, 2015) |
| " The sublingual fentanyl orally disintegrating tablet is a formulation by which fentanyl can be rapidly absorbed across the oral mucosa producing rapid-onset analgesia, and which may be effective for breakthrough pain treatment." | 5.20 | Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial. ( Gomyo, I; Katakami, N; Ohta, E; Okada, M; Shimoyama, M; Shimoyama, N; Yukitoshi, N, 2015) |
| " The doses of sublingual fentanyl to treat breakthrough pain were determined from rescue morphine doses by use of conversion ratios." | 5.20 | Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. ( Gomyo, I; Higuchi, H; Kojima, K; Ohta, E; Shimoyama, M; Shimoyama, N; Teramoto, O; Yukitoshi, N, 2015) |
| "Rapid analgesic onset opioids, particularly fentanyl buccal tablet, is preferable for managing breakthrough pain." | 5.20 | Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese c ( Adachi, I; Eguchi, K; Goto, F; Matoba, M; Shima, Y; Takigawa, C; Tanda, S; Yomiya, K; Yoshimoto, T, 2015) |
| "The aims of this study were to explore the efficacy of intranasal fentanyl spray* (INFS) 400 μg to evaluate 12-week tolerability of the nasal mucosa and to explore safety data for all dose strengths of INFS in patients with cancer-related breakthrough pain (BTP)." | 5.20 | Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain. ( Eeg, M; Jaatun, E; Kaasa, S; Kvitberg, M; Popper, L; Thronæs, M, 2015) |
| "To determine the differences by comparing fentanyl and ketamine used in cancer-diagnosed children undergoing painful procedures." | 5.20 | The clinical effect of fentanyl in comparison with ketamine in analgesic effect for oncology procedures in children: a randomized, double-blinded, crossover trial. ( Monsereenusorn, C; Rujkijyanont, P; Traivaree, C, 2015) |
| "To determine the feasibility of conducting a randomized trial of subcutaneous fentanyl in patients with cancer, and examine the effects of fentanyl on dyspnea, walk distance, vital signs, and adverse events." | 5.19 | Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. ( Bruera, E; Chisholm, G; Frisbee-Hume, S; Hui, D; Morgado, M; Reddy, S; Xu, A, 2014) |
| "To investigate the long-term use of fentanyl pectin nasal spray (FPNS) for the treatment of breakthrough pain in cancer (BTPc) in patients receiving regular opioid therapy." | 5.19 | A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain. ( Ellershaw, JE; Perelman, M; Radbruch, L; Revnic, J; Taylor, D; Torres, LM, 2014) |
| "Managing cancer pain often requires opioid medications, such as fentanyl, which is frequently initiated parenterally, and then converted to transdermal form." | 5.19 | Efficacy and safety of a six-hour continuous overlap method for converting intravenous to transdermal fentanyl in cancer pain. ( Bloise, R; Davis, MP; Samala, RV, 2014) |
| "Oromucosal fentanyl is currently used for the treatment of breakthrough pain (BTP) in opioid-treated cancer patients." | 5.19 | A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. ( Bullier, F; Fricova, J; Harabisova, S; Novotna, S; Richterova, E; Trinquet, F; Valentova, K, 2014) |
| "The aim of this randomized, crossover, comparison study was to assess the analgesic and adverse effects of 2 nasal preparations, intranasal fentanyl (INFS) and fentanyl pectin nasal spray (FPNS), for breakthrough pain, given in doses proportional to opioid basal regimen." | 5.19 | Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen. ( Adile, C; Casuccio, A; Mercadante, S; Prestia, G, 2014) |
| "Furthermore, in patients where a shift to a fentanyl patch was possible, good long-term pain control was achieved." | 5.19 | [Opioid induction using rapid release drugs and the shift to fentanyl patches]. ( Ejima, M; Morohashi, T; Nakayama, H; Otsuka, Y; Sasaki, S; Suzuki, N; Terai, E; Tsujikawa, Y; Watanabe, T; Yoshimura, K, 2014) |
| "Evaluate analgesic efficacy, functional benefit, and patient satisfaction with fentanyl buccal tablet vs immediate-release oxycodone for breakthrough pain (BTP)." | 5.17 | Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase ( Earl, CQ; Narayana, A; Slevin, KA; Webster, LR; Yang, R, 2013) |
| "The addition of fentanyl 1 mcg/kg to propofol for brief painful procedures reduces movement, propofol dose, and recovery time." | 5.17 | Prospective randomized crossover evaluation of three anesthetic regimens for painful procedures in children with cancer. ( Anghelescu, DL; Burgoyne, LL; Faughnan, LG; Hankins, GM; Pui, CH; Smeltzer, MP, 2013) |
| "Data were derived from 2 clinical trials (Study 1, n=131; Study 2, n=139) of fentanyl sublingual tablet in patients with cancer-associated breakthrough pain (BTP)." | 5.16 | Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies. ( Hassman, D; Howell, J; Nalamachu, SR; Rauck, RL; Wallace, MS, 2012) |
| "This study compared the efficacy and safety of a 3-day-type transdermal fentanyl patch conversion by the rapid titration method to short-acting oral oxycodone for cancer pain." | 5.16 | [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain]. ( Fujio, N; Ishikawa, N; Kameyama, M; Watanabe, H; Yamazaki, K, 2012) |
| "A number of transmucosal fentanyl formulations have been developed for the management of breakthrough cancer pain (BTCP)." | 5.16 | Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. ( Bull, J; Dillaha, L; Geach, J; Parikh, N; Rauck, R; Reynolds, L; Scherlis, M; Stearns, L, 2012) |
| "Data on the treatment of breakthrough cancer pain (BTcP) in patients receiving methadone therapy are lacking." | 5.15 | The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study. ( Arcuri, E; Ferrera, P; Mercadante, S, 2011) |
| "We recently reported that fentanyl pectin nasal spray (FPNS) provides superior pain relief from breakthrough cancer pain (BTCP) compared with immediate-release morphine sulfate (IRMS), with significant effects by five minutes and clinically meaningful pain relief from 10 minutes postdose." | 5.15 | Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. ( Brooks, D; Davies, A; Elsner, F; Espinosa, J; Fallon, M; Reale, C; Sitte, T, 2011) |
| "The purpose of this trial was to evaluate the effect of long-term treatment with oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine on nausea, emesis and constipation." | 5.14 | Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. ( Kloecker, N; Mueller, M; Nadstawek, J; Schaefer, N; Schenk, M; Schroeck, A; Standop, J; Wirz, S; Wittmann, M, 2009) |
| "This study assessed the long-term safety and tolerability of fentanyl buccal tablet (FBT) in opioid-tolerant patients with cancer and breakthrough pain (BTP) who were either naive to FBT or had completed 1 of 2 previous double-blind, placebo-controlled FBT studies (rollover patients)." | 5.14 | Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. ( Messina, J; Weinstein, SM; Xie, F, 2009) |
| "This trial investigated the efficacy and long-term tolerability of intranasal fentanyl spray (INFS) 50 to 200 microg in the treatment of breakthrough pain in opioid-tolerant patients with cancer." | 5.14 | Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatmen ( Colberg, T; Kaasa, S; Kaczmarek, Z; Kress, HG; Nolte, T; Orońska, A, 2009) |
| "The efficacy of intranasal fentanyl spray (INFS) was compared with that of oral transmucosal fentanyl citrate (OTFC) for the relief of cancer-related breakthrough pain (BTP) in an open-label, crossover trial." | 5.14 | A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. ( Camba, MA; Colberg, T; Davies, A; Mercadante, S; Perkins, P; Poulain, P; Radbruch, L; Sitte, T, 2009) |
| "Fentanyl buccal soluble film (FBSF) has been developed as a treatment of breakthrough pain in opioid-tolerant patients with cancer." | 5.14 | Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. ( Finn, AL; Gever, LN; North, J; Rauck, R; Tagarro, I, 2010) |
| "In this study we evaluated the efficacy and tolerability of sublingual fentanyl (SLF) for breakthrough pain (BTP) in adult opioid-tolerant cancer patients." | 5.14 | Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. ( Derrick, R; Frank-Lissbrant, I; Howell, J; Kälkner, KM; Lennernäs, B; Lennernäs, H, 2010) |
| "This randomized, double-blind, crossover study assessed the efficacy and tolerability of a new rapid onset nasal fentanyl formulation (Fentanyl Pectin Nasal Spray; FPNS) for breakthrough cancer pain (BTCP)." | 5.14 | A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. ( Burton, AW; Gabrail, N; Portenoy, RK; Taylor, D, 2010) |
| "We examined the efficacy and safety of a new transdermal fentanyl citrate patch (HFT-290), which was applied once daily in patients with cancer pain who were receiving a stable dose of once-every-three-day application transdermal fentanyl patch [TDF (72 hr)]." | 5.14 | [A phase II clinical study of once-a-day fentanyl citrate patch in patients with cancer pain--switching from once-every-three-days fentanyl patch to once-a-day fentanyl citrate patch]. ( Hashizume, T; Iseki, M; Iwao, Y; Kitajima, T; Masuda, Y; Matoba, M; Miyazaki, T; Namiki, A; Ogawa, S; Uchida, E, 2010) |
| "The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain." | 5.14 | Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. ( Adile, C; Aielli, F; Ferrera, P; Ficorella, C; Mercadante, S; Porzio, G, 2010) |
| "A novel transdermal matrix patch delivery system for fentanyl has been developed to deliver improved management of cancer pain compared with that obtained using current fentanyl reservoir patches." | 5.13 | Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain. ( Hanaoka, K; Hosokawa, T; Ishida, T; Kitajima, T; Mashimo, S; Miyazaki, T; Namiki, A; Nogami, S; Ogawa, S, 2008) |
| " The patient is a 50-year-old female with widely metastatic breast cancer who developed opioid toxicity when maintenance transdermal fentanyl patch therapy (100 μg patch applied every 72 h) was rotated to subcutaneous hydromorphone infusion to improve pain control." | 5.12 | Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: A case report and review of the literature. ( Chua, D; Jackson, LD; Selby, D; Wortzman, R, 2021) |
| " This is the first study to investigate the absorption profile of fentanyl buccal tablet (FBT) - an effervescent formulation of fentanyl indicated for the management of breakthrough pain in opioid-tolerant cancer patients - in patients with or without oral mucositis." | 5.12 | Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. ( Darwish, M; Jiang, JG; Kirby, M; Robertson, P; Tracewell, W, 2007) |
| " In this randomized open-label study the influence of tramadol on dose adjustment of transdermal fentanyl in advanced cancer pain control was prospectively evaluated." | 5.12 | Improved cancer pain treatment using combined fentanyl-TTS and tramadol. ( Aloisio, L; Bajocco, C; Ciccozzi, A; Coaccioli, S; Colangeli, A; Marinangeli, F; Paladini, A; Varrassi, G, 2007) |
| "To determine the safety and efficacy of transdermal fentanyl for pain relief in cancer patients and to compare the effects on patients according to whether they had previously received strong opioids, weak opioids or non-opioid analgesia." | 5.11 | Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. ( Bryuzgin, V; Kourteva, G; Tawfik, MO, 2004) |
| "The aim of this observational study was to examine pain management outcomes and quality of life (QoL) measures in cancer patients with intolerable or chronic severe pain transferring from World Health Organization's step I, II, and III analgesics to the transdermal therapeutic fentanyl system (TTS-F)." | 5.11 | Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. ( Georgaki, S; Katsouda, E; Kouloulias, V; Kouvaris, J; Mystakidou, K; Parpa, E; Tsilika, E; Vlahos, L, 2004) |
| "Although recent studies suggest that opioid rotation could be an effective treatment strategy for morphine-induced delirium, there have been no prospective studies to investigate the treatment effects of opioid rotation using fentanyl." | 5.11 | Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. ( Akechi, T; Ikenaga, M; Matsubara, T; Miyoshi, I; Morita, T; Onishi, H; Tajima, T; Takigawa, C; Tani, K; Uchitomi, Y, 2005) |
| "The study objective was to determine whether switching patients from morphine to transdermal fentanyl resulted in a reduction of morphine-associated side effects, and an improvement in cognitive function and patients' well being while maintaining adequate pain and symptom control." | 5.10 | Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care. ( McNamara, P, 2002) |
| "This randomised, multicentre, direct open comparative trial evaluated the efficacy, treatment convenience, tolerability and safety aspects of transdermal therapeutic system (TTS)-fentanyl and sustained-release oral morphine (SRM) in both opioid-naïve patients with moderate-to-severe cancer-related pain and in patients who had already been using opioids for mild-to-moderate pain." | 5.10 | Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. ( Schipper, RM; Smit, JM; van Seventer, R; Wicks, MA; Zuurmond, WW, 2003) |
| "Analgesic treatment with TTS fentanyl used as a single opioid is effective and safe for cancer pain relief, given that is cautiously applied, in patients requiring strong opioid analgesics even if they were naive to strong or mild opioids." | 5.10 | Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids. ( Befon, S; Dardoufas, K; Georgaki, S; Mystakidou, K; Tsilika, E; Vlahos, L, 2002) |
| "The successful use of methadone in cancer pain has been supported by numerous case reports and clinical studies." | 5.10 | Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. ( Derby, S; Fischberg, D; Kornick, C; Manfredi, PL; Moryl, N; Payne, R; Santiago-Palma, J, 2002) |
| ") morphine and fentanyl with respect to pain control and side effects using a 6-day randomized, double-blind, cross-over design." | 5.09 | A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. ( Brooksbank, M; Fazekas, B; Hunt, R; Thorne, D, 1999) |
| "Constipation and the use of laxatives were investigated in patients with chronic cancer pain treated with oral morphine and transdermal fentanyl in an open sequential trial." | 5.09 | Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. ( Grond, S; Kasper, M; Kulbe, C; Lehmann, KA; Loick, G; Radbruch, L; Sabatowski, R, 2000) |
| "Transdermal Fentanyl (TF, Durogesic) is a strong opioid analgesic which is used in the treatment of cancer pain." | 5.09 | [Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)]. ( Gorzelińska, L; Kozikowska, J; Leppert, W; Luczak, J, 2000) |
| "This open-label study evaluated the long-term safety and tolerability of oral transmucosal fentanyl citrate (OTFC) in ambulatory cancer patients with breakthrough pain undergoing cancer care at 32 university- or community-based practices." | 5.09 | Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. ( Berris, R; Busch, MA; Coluzzi, P; Hart, L; Loseth, DB; Lyss, A; Nordbrook, E; Payne, R; Portenoy, RK; Rauck, R; Simmonds, M, 2001) |
| "Therapeutic fentanyl blood levels are reached approximately 12-16 hours after the initial application of transdermal fentanyl patches." | 5.09 | A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. ( Khojainova, N; Kornick, CA; Manfredi, PL; Payne, R; Primavera, LH; Santiago-Palma, J, 2001) |
| "The effects of sublingual fentanyl citrate (SLFC) were assessed in 11 hospice inpatients with cancer-related breakthrough pain." | 5.09 | Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. ( Zeppetella, G, 2001) |
| "Direct conversion from oral morphine to transdermal fentanyl with a ratio of oral morphine/transdermal fentanyl (100:1 mg) daily was examined in patients with cancer pain." | 5.08 | Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. ( Donner, B; Strumpf, M; Tryba, M; Zenz, M, 1996) |
| "We performed an open-label pilot study to define analgesic efficacy, acceptability, and toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain." | 5.08 | Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study. ( Fidler, P; Hammack, JE; Loprinzi, CL; Mailliard, JA; Michalak, JC; Miser, AW; O'Fallon, JR; Reuter, NF; Rospond, RM; Wilwerding, MB, 1996) |
| "A prospective phase II study was conducted to define the analgesic efficacy, acceptability and toxicity of the transdermal therapeutic system (TTS) of fentanyl in Chinese patients with severe cancer-related pain." | 5.08 | Transdermal fentanyl for severe cancer-related pain. ( Chan, AT; Johnson, PJ; Lam, KK; Leung, TW; Nip, SY; Yeo, W, 1997) |
| "To compare pain-related treatment satisfaction, patient-perceived side effects, functioning, and well-being in patients with advanced cancer who were receiving either transdermal fentanyl (Duragesic, Janssen Pharmaceuticals, Titusville, NJ) or sustained-release oral forms of morphine (MS Contin, Perdue Frederick Co, Norwalk, CT, or Oramorph SR, Roxanne Laboratories, Columbus, OH)." | 5.08 | Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. ( Mahmoud, R; Mathias, SD; Pasta, DJ; Payne, R; Wanke, LA; Williams, R, 1998) |
| "Patients who were 18 years of age or older, receiving the equivalent of at least 60 mg oral morphine or at least 50 microg transdermal fentanyl per day for chronic cancer-related pain, and experiencing at least one episode of breakthrough pain per day were studied." | 5.08 | Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. ( Busch, M; Cleary, J; Farrar, JT; Nordbrock, E; Rauck, R, 1998) |
| "This was a multicenter, randomized, double-blind, dose-titration study in 62 adult cancer patients using transdermal fentanyl for persistent pain." | 5.08 | Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. ( Busch, MA; Christie, JM; Coluzzi, P; Nordbrock, E; Patt, R; Portenoy, RK; Simmonds, M, 1998) |
| "All communications on the use of transdermal fentanyl as well as the recommendations of the manufacturer include the direction that patients should be titrated with a short-acting narcotic to control their cancer pain before they are converted to a fentanyl transdermal therapeutic system (TTS)." | 5.07 | Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients. ( Korte, W; Morant, R, 1994) |
| "Transdermal fentanyl is a new fentanyl delivery system recently approved by the FDA for use in patients with chronic pain." | 5.07 | Transdermal fentanyl: clinical trial at the University of Colorado Health Sciences Center. ( Slover, R, 1992) |
| "In this study, 6 patients with pain from advanced cancer were enrolled in a multicenter, open-label seeding trial of transdermal fentanyl." | 5.07 | Transdermal fentanyl: seeding trial in patients with chronic cancer pain. ( Kedziera, P; Levy, MH; Rosen, SM, 1992) |
| "Patients were entered into an open label study to evaluate the efficacy of transdermal fentanyl as an analgesic for chronic cancer pain." | 5.07 | Transdermal fentanyl for chronic cancer pain: detailed case reports and the influence of confounding factors. ( Hogan, LA; Patt, RB, 1992) |
| "In this study, 11 cancer patients who experienced severe pain were treated with transdermal fentanyl." | 5.07 | Transdermal fentanyl use in hospice home-care patients with chronic cancer pain. ( Herbst, LH; Strause, LG, 1992) |
| "A multicenter study was conducted to determine the patient and physician acceptability of transdermal fentanyl in the management of cancer-related pain." | 5.07 | Management of cancer pain with transdermal fentanyl: phase IV trial, University of Iowa. ( Barcellos, WA; Maves, TJ, 1992) |
| " Fentanyl is a lipophilic opioid commonly proposed for intranasal use among pediatric patients, but no studies have been conducted yet about intranasal use of other available opioids for management of pediatric cancer pain." | 5.01 | Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies. ( Attinà, G; Capozza, MA; Mastrangelo, S; Maurizi, P; Ruggiero, A; Triarico, S, 2019) |
| " Only randomized controlled trials on the use of the transdermal fentanyl patch for the treatment of cancer pain were selected." | 4.98 | Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials. ( Ma, TT; Peng, CB; Wang, DD; Zhu, HD, 2018) |
| "Fentanyl buccal tablet (FBT) (FENTORA) is indicated for the management of breakthrough pain (BTP) in patients with cancer pain and who are tolerant to ≥60 mg of oral morphine equivalents, at least with the current availability of the minimal strength of 100 μg." | 4.91 | Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain. ( Mercadante, S, 2015) |
| " This rapid review, commissioned by the National Institute for Health Research, used standard Cochrane methodology to examine adverse effects of morphine, fentanyl, oxycodone, and codeine in cancer pain studies as a close approximation to possible effects in the dying patient." | 4.90 | Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. ( Derry, S; Moore, RA; Wiffen, PJ, 2014) |
| "To determine the analgesic efficacy of transdermal fentanyl for relief of cancer pain, and to assess the adverse events associated with the use of transdermal fentanyl for relief of cancer pain." | 4.89 | Transdermal fentanyl for cancer pain. ( Derry, S; Hadley, G; Moore, RA; Wiffen, PJ, 2013) |
| "The original review included four studies (393 participants), all concerned with the use of oral transmucosal fentanyl citrate (OTFC) in the management of breakthrough pain." | 4.89 | Opioids for the management of breakthrough pain in cancer patients. ( Davies, AN; Zeppetella, G, 2013) |
| "The development of intranasal fentanyl (INFS) aimed for a rapid treatment of breakthrough pain (BTP) in cancer patients." | 4.88 | Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain. ( Facius, A; Kaessner, N; Lahu, G; Nave, R; Roepcke, S, 2012) |
| "Transdermal buprenorphine and fentanyl are now established for moderate-to-severe cancer pain." | 4.87 | Transdermal opioids for cancer pain. ( Ahmedzai, SH; Cachia, E, 2011) |
| "Oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablets are the first medications developed specifically for the treatment of breakthrough pain in opioid-tolerant patients." | 4.87 | Fentanyl nasal spray for the treatment of cancer pain. ( Gouliamos, A; Mystakidou, K; Panagiotou, I, 2011) |
| "To compare the efficacy of intranasal fentanyl spray (INFS), oral transmucosal fentanyl citrate (OTFC), fentanyl buccal tablet (FBT) and oral morphine (OM) for the treatment of breakthrough cancer pain (BTCP)." | 4.86 | Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. ( Jansen, J; Lenre, M; Nolte, T; Stam, W; Vissers, D, 2010) |
| "Previous meta-analysis suggested that transdermal fentanyl was not inferior to sustained-release oral morphine in treating moderate-severe cancer pain with less adverse effects." | 4.86 | Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis. ( Bi, ZF; Chen, DL; Jiang, ZM; Ma, W; Xie, DR; Yang, Q; Zhang, YD, 2010) |
| "Fentanyl, a short-acting synthetic pure opiate, offers an excellent option for the treatment of cancer and chronic pain." | 4.86 | Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications. ( Mystakidou, K; Panagiotou, I, 2010) |
| "Transdermal fentanyl patches first became available in the early 1990s and provided an innovative treatment for the management of cancer pain." | 4.85 | The role of transdermal fentanyl patches in the effective management of cancer pain. ( Gibbs, M, 2009) |
| "To assess the adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison with slow release oral morphine." | 4.84 | Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. ( Maltoni, M; Raffaeli, W; Sartori, S; Scarpi, E; Tamburini, E; Tassinari, D; Tombesi, P, 2008) |
| "Four studies (393 participants) met the inclusion criteria, all were concerned with the use of oral transmucosal fentanyl citrate (OTFC) in the management of breakthrough pain." | 4.83 | Opioids for the management of breakthrough (episodic) pain in cancer patients. ( Ribeiro, MD; Zeppetella, G, 2006) |
| "Transdermal buprenorphine has been assessed as a therapy for chronic cancer and non-cancer pain in both clinical and postmarketing surveillance studies." | 4.83 | Transdermal buprenorphine in cancer pain and palliative care. ( Sittl, R, 2006) |
| "The fentanyl buccal tablet (FBT) is a new formulation of fentanyl that uses an effervescent drug delivery system to enhance penetration across the buccal mucosa for the treatment of breakthrough pain in opioid-tolerant patients with cancer." | 4.83 | Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. ( Blick, SK; Wagstaff, AJ, 2006) |
| " Evidence presented in this review shows encouraging results following the administration of methadone, fentanyl or ketamine to patients with difficult pain problems." | 4.82 | Morphine is not the only analgesic in palliative care: literature review. ( Wootton, M, 2004) |
| "To evaluate effectiveness and safety information of transdermal fentanyl (TDF) (Duragesic/Durogesic) and sustained-release oral morphine (SRM) in cancer pain (CP) and chronic non-cancer pain (NCP), a pooled analysis was conducted on datasets of published, open label, uncontrolled (no comparator group) and randomised controlled (with SRM as comparator) studies of TDF." | 4.82 | Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. ( Ahmedzai, SH; Allan, LG; Camacho, F; Clark, AJ; Horbay, GL; Richarz, U; Simpson, K, 2004) |
| "According to the World Health Organization (WHO) guidelines for patients with moderate or severe pain, morphine has been used as a "gold standard" treatment for cancer pain." | 4.82 | [Basic studies on cancer pain control]. ( Narita, M; Niikura, K; Ozaki, M; Suzuki, T; Yajima, Y, 2005) |
| "In this article, three aspects of recent issues in cancer pain management such as pain assessment, drowsiness with morphine, and problem in home care setting." | 4.81 | [Issues in cancer pain management]. ( Hoka, S; Matoba, M; Murakami, S, 2001) |
| "Transdermal fentanyl is a useful opioid-agonist for the treatment of moderate to severe chronic cancer pain." | 4.81 | Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. ( Muijsers, RB; Wagstaff, AJ, 2001) |
| " Because all nurses must keep up to date on basic principles of assessment, pain management, and current pharmacologic and nonpharmacologic approaches to pain, AJN and Home Healthcare Nurse are proud to provide our readers with important information about pain management and a new medication recently approved by the FDA: oral transmucosal fentanyl citrate (Actiq)." | 4.80 | Managing breakthrough cancer pain: a new approach. ( Kedziera, P; Rhiner, M, 1999) |
| " The development of a transdermal fentanyl system provided an opportunity to add fentanyl to the armamentarium of strong opioids available for the treatment of cancer pain." | 4.79 | Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy. ( Southam, MA, 1995) |
| "Transdermal fentanyl appears to be a safe and practical alternative to short-acting analgesics in the treatment of cancer pain." | 4.78 | Transdermal fentanyl in cancer pain. ( Mosser, KH, 1992) |
| "The physicochemical properties, pharmacology, pharmacokinetics, serum concentrations and clinical effects, adverse effects and contraindications, and dosage of transdermally administered fentanyl are described, and clinical studies evaluating the use of a transdermal fentanyl system in the treatment of postoperative pain and chronic cancer-associated pain are reviewed." | 4.78 | Transdermally administered fentanyl for pain management. ( Calis, KA; Corso, DM; Kohler, DR, 1992) |
| " Treatment was administered using bicalutamide and leuprorelin acetate, while a transdermal fentanyl (TDF) was applied for pain relief." | 4.31 | Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating. ( Ishii, H; Kanai, A; Kokubun, H; Tabata, KI, 2023) |
| "Fentanyl, a highly potent synthetic opioid used in cancer and non-cancer pain, is approved for various routes of administration." | 4.31 | Abuse, dependence and withdrawal associated with fentanyl and the role of its (designated) route of administration: an analysis of spontaneous reports from Europe. ( Bantel, C; Hoffmann, F; Jobski, K, 2023) |
| "Fentanyl transdermal therapy is a suitable treatment for moderate-to-severe cancer-related pain." | 4.31 | An individualized digital twin of a patient for transdermal fentanyl therapy for chronic pain management. ( Bahrami, F; De Nys, K; Defraeye, T; Rossi, RM, 2023) |
| "After the CAVIDIOPAL study, we carried out an additional analysis to evaluate the impact of individualized management of breakthrough cancer pain, using the analgesic drug fentanyl, on quality of life (QoL) of advanced cancer patients receiving palliative care in Spain." | 4.12 | Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care. ( Abián, MH; Bermudo, CL; Canal-Sotelo, J; Casillas, IR; Mancilla, PG; Maradey, P; Rivero, SG; Rodríguez, AT; Viejo, MN, 2022) |
| "It is recommended not to use transdermal fentanyl (Fe) patches (TFP) in cancer cachexia but TFP may be the only available option for pain." | 4.12 | Transdermal fentanyl to parenteral morphine route switch and drug rotation in refractory cancer cachexia. ( Alabdullateef, SH; Almashiakhi, M; Alsirafy, SA; Elyamany, AM; Hassan, AD, 2022) |
| "Serum fentanyl concentration and the safety and efficacy of once-a-day fentanyl citrate patch were investigated in pediatric and adolescent patients with cancer pain." | 4.02 | An Open-Label Study of the Pharmacokinetics and Tolerability of Once-a-Day Fentanyl Citrate Patch in Japanese Pediatric and Adolescent Patients with Cancer Pain. ( Hashimoto, F; Hiyama, E; Okawa, K; Otaka, K; Terahara, T; Yamaguchi, S, 2021) |
| "The objective of this study was to evaluate the influence of cancer cachexia on pain control in cancer patients receiving a transdermal fentanyl patch (FP) and to investigate whether dry skin was a factor related to cancer cachexia and uncontrolled pain." | 3.96 | Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch. ( Chiba, T; Kimura, S; Kudo, K; Tairabune, T; Takahashi, H; Ueda, H, 2020) |
| "Oral transmucosal fentanyl has been indicated for the management of breakthrough pain in patients with cancer." | 3.96 | [A Case Report of Impaired Consciousness in a Patient after Receiving the Fourth Dose of Fentanyl Sublingual Tablet]. ( Kono, T; Satomi, M, 2020) |
| " In this study we evaluated the development and treatment of opioid induced constipation (OIC), and OIC resolving effect of methylnaltrexone for different opioid subtypes in daily clinical practice." | 3.91 | Optimal treatment of opioid induced constipation in daily clinical practice - an observational study. ( Beeker, A; Berkhof, J; Neefjes, ECW; Rhodius, CA; Ten Oever, D; van den Berg, HP; van der Vliet, HJ; van der Vorst, MJDL; van der Wijngaart, H; Verheul, HMW, 2019) |
| "The aim of the study was to evaluate the effectiveness of fentanyl pectin nasal spray (FPNS) in controlling procedural breakthrough cancer pain (BTCP) in advanced cancer patients undergoing radiotherapy." | 3.91 | Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures. ( Aymar, N; Jiménez, E; Mena, A; Mestre, F; Ortiz, I; Pardo, J; Roncero, R; Vidal, M, 2019) |
| "Sublingual fentanyl tablets (SFTs) have been shown to be a safe and effective option in controlling breakthrough cancer pain (BTcP)." | 3.91 | Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets. ( Coma, J; De Sanctis, V; Estivill, P; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Jiménez, AJ; Moya, J; Rodelas, F; Salazar, R; Sanz, A; Tomás, A; Vargas, MI, 2019) |
| "Among Japanese palliative care physicians, using oxycodone for cancer dyspnea was relatively popular practice, whereas fentanyl was not." | 3.91 | The Current Practice of Opioid for Cancer Dyspnea: The Result From the Nationwide Survey of Japanese Palliative Care Physicians. ( Matsuda, Y; Matsunuma, R; Mori, M; Suzuki, K; Watanabe, H; Yamaguchi, T, 2019) |
| "In 2013, oral transmucosal fentanyl was first approved in Japan for reducing breakthrough pain(BTP)." | 3.85 | [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl]. ( Hosonuma, R; Kaneshima, M; Kyosaka, B; Osato, S; Warita, E; Yomiya, K, 2017) |
| " Group 1 was consisted of 353 patients whose basal cancer pain of intensity 4-7 NRS was treated weak opiates (basal analgetic- fixed combination of tramadol/paracetamol (37." | 3.85 | Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care. ( Husic, S; Imamovic, S; Matic, S; Sukalo, A, 2017) |
| "The incidence of delirium was compared among 114 patients who had started morphine, oxycodone, or fentanyl injection at Shizuoka Cancer Center between June 2012 and September 2014." | 3.85 | Incidence of Delirium Among Patients Having Cancer Injected With Different Opioids for the First Time. ( Ishikawa, H; Matsumoto, T; Mori, K; Omae, K; Osaka, I; Sato, T; Shino, M; Tanaka, R, 2017) |
| "This exploratory study shows that IV Fentanyl can alleviate dyspnea in some patients but is an example of the difficulties conducting dyspnea research." | 3.83 | Intravenous Fentanyl for Dyspnea at the End of Life: Lessons for Future Research in Dyspnea. ( Pang, GS; Qu, LM; Tan, YY; Yee, AC, 2016) |
| "We collected OFL and plasma samples from 64 cancer patients on controlled-release (CR) oral morphine, CR oral oxycodone, or transdermal (TD) fentanyl for pain." | 3.81 | Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain. ( Gunnar, T; Heiskanen, T; Kalso, EA; Langel, K; Lillsunde, P, 2015) |
| "Little is known about the efficacy of low-dose transdermal fentanyl (TDF) patches in opioid-naïve patients with moderate-to-severe cancer pain." | 3.81 | The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. ( Hwang, IG; Kang, JH; Kim, JH; Kim, WS; Lee, HR; Lee, HY; Lee, KE; Oh, SY; Park, K; Park, SH; Park, YS; Song, SY, 2015) |
| " Oxycodone and fentanyl, in relation to the symptoms studied, seem to be safe as used and titrated in routine cancer pain care." | 3.81 | Renal function and symptoms/adverse effects in opioid-treated patients with cancer. ( Christrup, L; Dale, O; Davies, A; Ekholm, O; Kaasa, S; Klepstad, P; Kurita, GP; Lundström, S; Sjøgren, P, 2015) |
| "Common adverse symptoms of cancer and chemotherapy are a major health burden; chief among these is pain, with opioids including transdermal fentanyl the mainstay of treatment." | 3.81 | Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl. ( Barratt, DT; Dale, O; Kaasa, S; Klepstad, P; Somogyi, AA, 2015) |
| "Fentanyl is widely used to relieve cancer pain." | 3.81 | Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer. ( Bista, SR; Good, P; Hardy, J; Haywood, A; Lobb, M; Norris, R; Tapuni, A, 2015) |
| "This study aimed to investigate whether CYP3A4/5 genetic variants, together with clinical and patient factors, influence serum fentanyl and norfentanyl concentrations and their ratio in cancer pain patients receiving transdermal fentanyl." | 3.80 | Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. ( Bandak, B; Barratt, DT; Christrup, LL; Dale, O; Kaasa, S; Klepstad, P; Somogyi, AA; Tuke, J, 2014) |
| "Instanyl® (intranasal fentanyl spray) is a novel treatment for breakthrough pain (BTP) in cancer patients." | 3.80 | The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study. ( Eeg, M; Greisen, H; Kongsgaard, UE, 2014) |
| "It is unknown whether nutritional status influences pain intensity in cancer patients receiving a transdermal fentanyl patch (FP)." | 3.80 | A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch. ( Chiba, T; Kimura, Y; Kudo, K; Tairabune, T; Takahashi, H; Takahashi, K; Wakabayashi, G, 2014) |
| "Morphine, oxycodone, and fentanyl are commonly used to control cancer pain." | 3.80 | Influence of serum albumin levels during opioid rotation from morphine or oxycodone to fentanyl for cancer pain. ( Arakawa, Y; Fukuura, K; Futamura, A; Hayashi, T; Higashiguchi, T; Ikehata, S; Kuki, R; Makihara, T; Matsuzaki, H; Mori, N; Takahashi, H; Yamadaa, S; Yasuda, K, 2014) |
| "Palliative care physicians are accustomed to using transdermal fentanyl patch for cancer pain control but not so familiar with its intravenous administration." | 3.80 | Use of intravenous fentanyl against morphine tolerance in breakthrough cancer pain: a case series and literature review. ( Bruera, E; Hwang, IC; Park, SM, 2014) |
| " The past decade has seen clinical trials of transmucosal opioid formulations for breakthrough pain in cancer (BTPc), beginning with oral transmucosal fentanyl citrate (OTFC), followed by fentanyl buccal tablet and intranasal fentanyl spray, and most recently sublingual fentanyl tablet, fentanyl buccal soluble film, and fentanyl pectin nasal spray." | 3.79 | Evidence-based treatment of cancer-related breakthrough pain with opioids. ( Zeppetella, G, 2013) |
| "Fentanyl pectin nasal spray is a novel intranasal formulation for the management of breakthrough cancer pain in patients taking and tolerant to opioids for persistent cancer pain." | 3.79 | Fentanyl pectin nasal spray: a novel intranasal delivery method for the treatment of breakthrough cancer pain. ( Bulloch, MN; Hutchison, AM, 2013) |
| "Determining the appropriate dose of transdermal fentanyl (TDF) for the alleviation of cancer pain requires determining the factors causing variations in serum fentanyl concentration after TDF treatment." | 3.78 | Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. ( Ebinuma, K; Kokubun, H; Matoba, M; Takayanagi, R; Yago, K; Yamada, Y, 2012) |
| "Three transmucosal fentanyl products have recently been licensed for cancer-related breakthrough pain: a sublingual tablet, a buccal/sublingual tablet and a nasal spray." | 3.77 | How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion. ( England, R; Maddocks, M; Manderson, C; Wilcock, A; Zadora-Chrzastowska, S, 2011) |
| " Compared with other opioids, low-dose fentanyl has been suggested to produce milder side effects such as nausea, constipation, and somnolence." | 3.77 | [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011) |
| "To identify predictive factors requiring high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone to transdermal fentanyl in patients with cancer pain." | 3.77 | Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain. ( Fujimoto, S; Hosokawa, T; Kanbayashi, Y; Konishi, H; Miki, T; Okamoto, K; Otsuji, E; Takagi, T; Taniwaki, M; Yoshikawa, T, 2011) |
| "The FDA has approved a nasal spray formulation of fentanyl (Lazanda-Archimedes) for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy." | 3.77 | Fentanyl nasal spray (Lazanda) for pain. ( , 2011) |
| "The aim of this study is to investigate cancer patients' response and side effects associated with transdermal therapeutic fentanyl (TTS-F), whose pain was hardly controlled by nonweak/weak opioids in Taiwan." | 3.76 | The use of transdermal fentanyl in cancer pain--a compliance study of outpatients in Taiwan. ( Chen, YJ; Chiou, TJ; Hung, CJ; Liu, CY; Su, YC; Tang, Y; Tzeng, WF; Weng, YC, 2010) |
| "For 20 hospitalized patients with cancer pain that could not be controlled by NSAIDs, the fentanyl transdermal patch (1." | 3.76 | Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line. ( Hoya, Y; Okamoto, T; Yanaga, K, 2010) |
| "This study involved 10 patients (5 male and 5 female) with cancerous abdominal pain, for whom the original opioid regimen was switched to morphine alone or continued in combination with morphine." | 3.76 | Ten cases of palliation of cancer pain with morphine. ( Iwasaki, M; Mikami, M; Nishiumi, N; Tokuda, Y; Yamamoto, S; Yoshino, K, 2010) |
| "The aim of this study was to evaluate the equianalgesic ratio of transdermal buprenorphine (TD BUP) with oral morphine and TD fentanyl in a sample of consecutive cancer patients receiving stable doses of 120-240 mg of oral morphine or 50-100 microg of TD fentanyl, reporting adequate pain and symptom control." | 3.75 | Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. ( Casuccio, A; Giarratano, A; Mercadante, S; Tirelli, W, 2009) |
| "Although fentanyl patches (FP) designed to sustain plasma fentanyl concentrations for 3 days are used in many patients for continuous relief of moderate to severe cancer pain, there are some cases in which effective pain relief is sustained less than for 3 days, and in which plasma fentanyl concentrations rapidly decrease at the third day after the application." | 3.74 | [Measurement of amount of fentanyl remaining in used patches: investigation of clinical factors affecting the remaining amounts in 4 patients]. ( Iguchi, H; Kojima, M; Ohta, T; Yamamoto, K, 2008) |
| "The fentanyl transdermal matrix patch is approved in Japan for the management of moderate to severe cancer-related pain in adults." | 3.74 | Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain. ( Hoy, SM; Keating, GM, 2008) |
| "Fentanyl is a potent synthetic narcotic analgesic administered in the form of a transdermal patch for the management of chronic pain." | 3.74 | LC-MS/MS analysis of fentanyl and norfentanyl in a fatality due to application of multiple Durogesic transdermal therapeutic systems. ( Coopman, V; Cordonnier, J; Pien, K; Van Varenbergh, D, 2007) |
| "To evaluate the efficacy and safety of fentanyl administered by PCA in children with cancer pain." | 3.74 | Safety and efficacy of fentanyl administered by patient controlled analgesia in children with cancer pain. ( Barone, G; Chiaretti, A; Lazzareschi, I; Liotti, L; Riccardi, R; Ruggiero, A, 2007) |
| " Patients with far advanced cancer often suffer from sweating and cachexia, which may have negative effects on the absorption of transdermal fentanyl." | 3.74 | Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study. ( Clemens, KE; Klaschik, E, 2007) |
| "Indigent patients without prescription coverage trended toward reporting more cancer pain, received lower doses of transdermal fentanyl, and trended to lower adherence to pain regimens due to financial reasons." | 3.74 | Influence of prescription benefits on reported pain in cancer patients. ( Amadio, WJ; Bryan, M; De La Rosa, N; Hill, AM; Wieder, R, 2008) |
| "This retrospective study identified patients with cancer and noncancer pain who had received > or =1 prescription for fentanyl TD or buprenorphine TD (the all-patients groups) from the German IMS Disease Analyzer-mediplus database, which contains all relevant data concerning drug prescriptions from 400 practices in Germany." | 3.73 | Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. ( Likar, R; Nautrup, BP; Sittl, R, 2005) |
| "The purpose of this study was to compare changes in dosages of transdermal (TD) fentanyl and TD buprenorphine in patients with cancer and non-cancer pain." | 3.73 | Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. ( Nautrup, BP; Nuijten, M; Sittl, R, 2005) |
| "There is a trend to use fentanyl patch as first-choice strong opioid in cancer patients in situations such as titration phase, in the presence of instable pain, and in the absence of dysphagia or gastrointestinal symptoms where the use of oral morphine is, however, not contraindicated." | 3.73 | Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. ( Brunelli, C; Campa, T; De Conno, F; Fagnoni, E; Ripamonti, C, 2006) |
| "The use of fentanyl patches has become accepted as standard in Germany for the treatment of chronic and cancer pain." | 3.73 | [Medico-legal aspects of the use of fentanyl patches]. ( Zimmermann, M, 2006) |
| " Data from patients with noncancer or cancer pain treated with TD buprenorphine or TD fentanyl for at least 3 months between May 2002 and April 2005 were analyzed." | 3.73 | Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. ( Nuijten, M; Poulsen Nautrup, B; Sittl, R, 2006) |
| "The delayed effects (12-16 hours) of transdermal fentanyl make dose titration difficult during acute exacerbations of cancer pain." | 3.72 | A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain. ( Kornick, CA; Manfredi, PL; O'Brien, PC; Payne, R; Santiago-Palma, J; Schulman, G; Weigand, S, 2003) |
| "Partial opioid substitution with fentanyl and moderate levels of hydration had no significant preventive effects on the occurrence of agitated delirium in the last week on a mass level." | 3.72 | Agitated terminal delirium and association with partial opioid substitution and hydration. ( Inoue, S; Morita, T; Tei, Y, 2003) |
| "(1) Some cancer patients suffer occasional breakthrough pain despite well-conducted opiate treatment, warranting the use of immediate-release oral morphine." | 3.71 | Oral transmucosal fentanyl: new preparation. For breakthrough cancer pain when morphine fails. ( , 2002) |
| "This open compassionate-use prospective registration study evaluated the tolerability, ease of use and applied doses of transdermal (TTS) fentanyl in adult patients with cancer-related pain requiring strong opioid analgesia." | 3.71 | Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. ( Desmedt, M; Lossignol, D; Menten, J; Mullie, A, 2002) |
| "An expert working group of the European Association for Palliative Care has revised and updated its guidelines on the use of morphine in the management of cancer pain." | 3.71 | Morphine and alternative opioids in cancer pain: the EAPC recommendations. ( Casas, JR; Cherny, N; Conno, F; Hanks, GW; Hanna, M; Kalso, E; McQuay, HJ; Mercadante, S; Meynadier, J; Poulain, P; Radbruch, L; Ripamonti, C; Sawe, J; Twycross, RG; Ventafridda, V, 2001) |
| "Oral morphine is the treatment first recommended for nociceptive pain insufficiently relieved by WHO level I and II analgesics." | 3.71 | [New Level III opioids of the World Health Organization]. ( Laval, G; Mallaret, M; Sang, B; Villard, ML, 2002) |
| "A transdermal fentanyl patch for the treatment of chronic cancer-related pain is available in four dosages (25, 50, 75, and 100 microg/hr)." | 3.70 | Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. ( Payne, R, 1998) |
| "To study use of Duragesic (fentanyl transdermal system), the only transdermal opioid approved in Canada for treating chronic cancer pain in adults." | 3.69 | Fentanyl transdermal system. Pain management at home. ( Hays, H; Woodroffe, MA, 1997) |
| "These results suggest that steady-state serum concentrations are approached by the second dose of TTS(fentanyl) and that the kinetics are stable with repeated dosing." | 3.68 | Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. ( Foley, KM; Gupta, SK; Inturrisi, CE; Lapin, J; Layman, M; Portenoy, RK; Southam, MA, 1993) |
| "Five children with cancer pain were given continuous intrathecal morphine or fentanyl infusion associated with bupivacaine 0." | 3.68 | [Intrathecal morphine therapy in children with cancer]. ( Ganansia, MF; Lejus, C; Meignier, M; Testa, S, 1992) |
| "Five cancer patients experienced satisfactory pain relief for periods of 3-156 days using continuous transdermal delivery of the narcotic fentanyl." | 3.67 | Transdermal fentanyl for pain control in patients with cancer. ( Dothage, JA; Miser, AW; Miser, JS; Narang, PK; Sindelar, W; Young, RC, 1989) |
| " The efficacy and safety of the sedations including sedation time intervals, nausea score, vomiting episodes, pain score, adverse effects, and parent's satisfaction were evaluated." | 3.11 | The efficacy and safety of midazolam with fentanyl versus midazolam with ketamine for bedside invasive procedural sedation in pediatric oncology patients: A randomized, double-blinded, crossover trial. ( Lertvivatpong, N; Malaithong, W; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Traivaree, C, 2022) |
| "Episodic breathlessness is a distressing and difficult to treat symptom because of its short duration." | 3.01 | Intranasal Fentanyl Versus Placebo for Treatment of Episodic Breathlessness in Hospice Patients With Advanced Nonmalignant Diseases. ( Allan, S; Bridge, R; Hewitt, D; Iupati, S, 2021) |
| "In this small study in palliative cancer patients under real-life clinical conditions, the influence of CYP3A on fentanyl variability was investigated." | 2.90 | Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. ( Bardenheuer, HJ; Burhenne, J; Geist, MJP; Mikus, G; Skopp, G; Ziesenitz, VC, 2019) |
| "Morphine was associated with the less negative impact of pain on the ability to walk and normal work, and tendency on activity (BPI-SF) and lower consumption of rescue morphine." | 2.90 | Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl. ( Leppert, W; Nosek, K, 2019) |
| "The significant improvement in the number of patients experiencing little or no pain, accompanied by a lower number of non-severe side effects, suggests that FBT is a valid, practical and safe method of procedural analgesia." | 2.82 | A phase II study on the efficacy and safety of procedural analgesia with fentanyl buccal tablet in cancer patients for the placement of indwelling central venous access systems. ( Bedin, S; Bertuzzi, C; Bortolussi, R; Caserta, M; Colussi, AM; Fabiani, F; Fantin, D; Fracasso, A; Gussetti, D; Matovic, M; Morabito, A; Polesel, J; Roscetti, A; Santantonio, C; Zanier, C; Zotti, P, 2016) |
| "Breakthrough cancer pain (BTCP) is associated with decreased satisfaction with around-the-clock opioid therapy." | 2.80 | Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain. ( Barker, J; Dillaha, L; Parikh, N; Rauck, R; Stearns, L, 2015) |
| "Opioid-tolerant patients with chronic cancer-related pain who experienced up to four breakthrough pain episodes daily were randomized to a starting dose of 100 or 200 μg for the titration period." | 2.80 | Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain. ( Davies, A; Jarosz, J; Kleeberg, UR; Kress, HG; Mercadante, S; O'Brien, T; Poulain, P; Schneid, H, 2015) |
| " Adverse events were somnolence and other events associated with opioids were mostly mild or moderate." | 2.79 | A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients. ( Adachi, I; Eguchi, K; Goto, F; Hamada, S; Kosugi, T; Kunikane, H; Matoba, M; Shima, Y; Shinozaki, K; Takigawa, C; Tanda, S; Yomiya, K; Yoshimoto, T, 2014) |
| " Pharmacokinetic parameters were calculated, and adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (version 3." | 2.79 | Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain. ( Fujii, M; Fujiwara, K; Kobayashi, K; Saito, S; Saito, T; Shimada, K, 2014) |
| "Breakthrough cancer pain (BTcP) is recognized as a clinically significant complication of chronic cancer pain with most BTcP episodes peaking in intensity within a few minutes and lasting for approximately 30 min." | 2.79 | Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. ( España Ximénez de Enciso, I; García Velasco, P; Muñoz Garrido, JC; Velázquez Clavarana, L; Velázquez Rivera, I, 2014) |
| " Various retrospective studies comparing dosage changes of buprenorphine and fentanyl patches in persistent pain patients have been completed; however, no long-term prospective, randomized, clinical study has compared the effectiveness of these patches." | 2.78 | A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. ( Chowdhury, S; Mitra, F; Shelley, M; Williams, G, 2013) |
| "2201 cancer pain patients were included." | 2.77 | Lack of association between genetic variability and multiple pain-related outcomes in a large cohort of patients with advanced cancer: the European Pharmacogenetic Opioid Study (EPOS). ( Fayers, P; Fladvad, T; Kaasa, S; Klepstad, P; Skorpen, F, 2012) |
| "A total of 82 cancer patients with BTcP who were receiving strong opioids in doses of at least 60 mg of oral morphine equivalents and having acceptable background analgesia, were selected for a multicenter unblinded study." | 2.77 | Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. ( Adile, C; Aielli, F; Casuccio, A; Gatti, A; Lo Presti, C; Mercadante, S; Porzio, G, 2012) |
| "Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)." | 2.76 | Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011) |
| "Of 139 recruited patients, 69% identified an effective dose of sublingual fentanyl ODT (a dosage that successfully treated all episodes of BTcP over two consecutive days) and entered the maintenance phase, during which they were treated for a median of 149." | 2.76 | Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. ( Derrick, R; Dumble, S; Hassman, D; Howell, J; Nalamachu, S; Wallace, MS, 2011) |
| " The adverse reactions to the 1-day formulation observed in this study were similar to those previously reported for the Durotep MT Patch (the "3-day formulation")." | 2.76 | [Clinical study of one-day fentanyl patch in patients with cancer pain--evaluation of the efficacy and safety in relation to treatment switch from opioid analgesic therapy]. ( Hanaoka, K; Sakata, H; Tomioka, T; Yoshimura, T, 2011) |
| "Dose titration of the 1-day formulation was accomplished in a short period in patients with cancer pain who had been previously untreated with opioid analgesics; the efficacy of the formulation for pain control after repeated dosing was comparable to that of the 3-day formulation, and its tolerability was good." | 2.76 | [Double-blind parallel-group dose-titration study comparing a fentanyl-containing patch formulated for 1-day application for the treatment of cancer pain with Durotep MT Patch]. ( Hanaoka, K; Sakata, H; Tomioka, T; Yoshimura, T, 2011) |
| " Adverse events were recorded throughout." | 2.76 | Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. ( Müller-Schwefe, GH; Überall, MA, 2011) |
| " The dosage used was 50% of that indicated in equipotency conversion tables." | 2.74 | Opioids switching with transdermal systems in chronic cancer pain. ( Aurilio, C; Barbarisi, M; Grella, E; Pace, MC; Passavanti, MB; Pota, V; Sansone, P, 2009) |
| "Fentanyl is an opioid with high lipid solubility, suitable for intravenous, spinal, transmucosal and transdermal administration." | 2.74 | Transdermal fentanyl in cachectic cancer patients. ( Gergov, M; Haakana, S; Heiskanen, T; Kalso, E; Mätzke, S; Vuori, E, 2009) |
| "Breakthrough cancer pain (BTcP) represents an important clinical challenge in the care of patients with cancer." | 2.74 | Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. ( Bartkowiak, AJ; Derrick, R; Hassman, D; Hayes, TG; Howell, J; Nalamachu, S; Rauck, RL; Reyes, E; Tark, M, 2009) |
| " Any adverse events were recorded; four tolerability endpoints, constipation, nausea, daytime drowsiness, and sleeping disturbances, were assessed daily." | 2.73 | A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. ( Heiskanen, T; Hoerauf, KH; Jensen, NH; Krenn, H; Kress, HG; Lundorff, L; Nolte, T; Petersen, R; Rosland, JH; Sabatowski, R; Saedder, EA; Von der Laage, D, 2008) |
| "2% of patients experienced adverse events that were either probably related or very likely to be related to the study drug." | 2.73 | Safety and efficacy of transdermal fentanyl in patients with cancer pain: phase IV, Turkish oncology group trial. ( Aliustaoğlu, M; Altinbaş, M; Altundağ, K; Atahan, L; Cooper, R; Demirkan, B; Kömürcü, S; Manavoğlu, O; Ozdemir, F; Ozkök, S; Pak, Y; Sarihan, S; Turhal, S; Turna, HS; Yavuz, AA; Yaylaci, M, 2007) |
| "In episodes treated with IV-MO, pain intensity decreased from a mean of 6." | 2.73 | Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. ( Casuccio, A; Ferrera, P; Intravaia, G; Mangione, S; Mercadante, S; Villari, P, 2007) |
| "Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise." | 2.73 | Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. ( Aielli, F; Casuccio, A; Ferrera, P; Ficorella, C; Fulfaro, F; Gebbia, V; Mangione, S; Mercadante, S; Porzio, G; Riina, S; Verna, L; Villari, P, 2008) |
| "Buprenorphine causes limited respiratory depression with a ceiling effect at higher doses, while fentanyl causes dose-dependent respiratory depression with apnoea at high dose levels." | 2.72 | Opioid-induced respiratory effects: new data on buprenorphine. ( Dahan, A, 2006) |
| " Fourteen patients receiving strong opioids who had increased their dosage more than 100% in the last week unsuccessfully were randomly chosen to add a second opioid to the first using an initial equivalent dosage of 20% of the previous therapy." | 2.71 | Addition of a second opioid may improve opioid response in cancer pain: preliminary data. ( Casuccio, A; Ferrera, P; Mercadante, S; Villari, P, 2004) |
| "Methadone was initiated 8-24 hours after fentanyl withdrawal, depending on the patient's previous opioid doses (from < 100 microg per hour to > 300 microg per hour)." | 2.71 | Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. ( Benítez-Rosario, MA; Feria, M; Martín-Ortega, JJ; Martínez-Castillo, LP; Salinas-Martín, A, 2004) |
| " Pharmacokinetic parameters were calculated by noncompartment analysis." | 2.71 | Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. ( Bredenberg, S; Hedner, T; Holmberg, M; Lennernäs, B; Lennernäs, H; Nyström, C, 2005) |
| " Large patient-to-patient variations in pharmacokinetic parameters occurred, although intraindividual variability was limited." | 2.71 | Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ( Bressolle, F; Caumette, L; Culine, S; Garcia, F; Pinguet, F; Poujol, S; Solassol, I, 2005) |
| " In the 16 who received fentanyl for > or =3 months until death, the median dose was unchanged (100 microg/h) 3 months before death and at death; 8/16 required no dosage change." | 2.70 | Long-term observations of patients receiving transdermal fentanyl after a randomized trial. ( Ahmedzai, SH; Brooks, D; Davis, C; Nugent, M, 2001) |
| "The treatment of cancer pain with transdermal fentanyl can be performed as a long-term therapy and result in good pain relief." | 2.69 | Long-term treatment of cancer pain with transdermal fentanyl. ( Donner, B; Raber, M; Strumpf, M; Zenz, M, 1998) |
| "TTS fentanyl was titrated to pain relief, and patients were followed up for as long as 3 months." | 2.69 | A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. ( Hays, H; Moulin, DE; Sloan, PA, 1998) |
| " (2) To estimate the pediatric pharmacokinetic parameters of TTS-fentanyl." | 2.69 | Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates. ( Collins, JJ; Dunkel, IJ; Gupta, SK; Inturrisi, CE; Lapin, J; Palmer, LN; Portenoy, RK; Weinstein, SM, 1999) |
| "To treat cancer pain, physicians often decide to jump directly from step 1 of the World Health Organization (WHO) analgesic ladder to step 3." | 2.69 | Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. ( Mattern, C; Uitendaal, MP; Vielvoye-Kerkmeer, AP, 2000) |
| "TTS fentanyl was shown to be an effective, safe and simple method for long-term pain relief in cancer patients and presents an interesting novel option in the treatment of cancer pain." | 2.68 | Transdermal fentanyl in combination with initial intravenous dose titration by patient-controlled analgesia. ( Lehmann, KA; Zech, DF, 1995) |
| "Initial dose finding in patients with cancer pain who are started on TTS fentanyl (Duragesic, TTS-F) is often unsatisfactory with currently recommended doses and intervals." | 2.68 | Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. ( de Stoutz, N; Korte, W; Morant, R, 1996) |
| "Fentanyl was associated with significantly less constipation (p < 0." | 2.68 | Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. ( Ahmedzai, S; Brooks, D, 1997) |
| "Forty of 47 cancer patients completed the study with 20 patients in each group." | 2.68 | Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. ( Chang, CL; Chiu, GL; Tsao, CJ; Wong, JO, 1997) |
| "Midazolam was found to be the drug of preference for the majority of patients." | 2.67 | Midazolam versus fentanyl as premedication for painful procedures in children with cancer. ( Conner, K; Dickson, N; Luzins, J; McGorray, S; Reilly, K; Sandler, ES; Weyman, C, 1992) |
| "However, the treatment of breakthrough pain should be adjusted to suit specific patient requirements." | 2.61 | The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients. ( Brząkała, J; Leppert, W, 2019) |
| "Flares of breathlessness are accompanied by degrees of psychological distress, although it is unclear whether psychological factors may precede or be induced by EB." | 2.58 | Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management. ( Mercadante, S, 2018) |
| "Fentanyl is a strong opioid that is available for various administration routes, and which is widely used to treat cancer-related pain." | 2.55 | A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. ( Koolen, SL; Kuip, EJ; Mathijssen, RH; van der Rijt, CC; Zandvliet, ML, 2017) |
| "The management of cancer pain presents manifold challenges: even though background pain is adequately controlled, patients frequently experience episodes of acute pain exacerbation known as breakthrough cancer pain (BTcP)." | 2.53 | Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering. ( Candeletti, S; Romualdi, P, 2016) |
| "Use of prescription opioids for cancer pain according to the World Health Organization analgesic ladder has been accepted in Japan." | 2.52 | [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients]. ( Kawakami, J; Naito, T, 2015) |
| " Furthermore, it is a reasonably safe treatment, causing generally mild adverse events not leading to treatment discontinuation." | 2.52 | Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review. ( Escobar, Y; Moya, J; Murillo, M; Rogríguez, D; Urrutia, G, 2015) |
| "Quality pain management for cancer survivors is complicated by the fact that cancer-related pain can be due to the tumor, surgery, radiation, and/or chemotherapy." | 2.50 | Understanding the cancer pain experience. ( Schreiber, JA, 2014) |
| " These dosage forms offer overlapping yet distinct pharmacokinetic advantages to allow more choices for physicians and patients in the management of breakthrough cancer pain." | 2.50 | Clinical and pharmacokinetic considerations of novel formulations of fentanyl for breakthrough cancer pain. ( Chen, C; Gupta, A, 2014) |
| "Breakthrough cancer pain (BTCP) is common among cancer patients and markedly lowers their quality of life." | 2.49 | Fentanyl for the treatment of tumor-related breakthrough pain. ( Bornemann-Cimenti, H; Sandner-Kiesling, A; Szilagyi, IS; Wejbora, M, 2013) |
| "Breakthrough cancer pain has been defined as a transitory increase in pain intensity that occurs despite relatively stable and adequately controlled background pain." | 2.49 | [Management of breakthrough cancer pain]. ( Sláma, O, 2013) |
| "Fentanyl is a synthetic opioid characterized by rapid absorption and start of the analgesic effects." | 2.49 | Optimal management of breakthrough cancer pain (BCP). ( Antón, A; Casas, A; Cruz, JJ; Escobar, Y; Gálvez, R; Juliá, J; López, R; Mañas, A; Margarit, C; Zaragozá, F, 2013) |
| " placebo in the first 30 minutes after dosing (FBT provided an 83% probability of superior pain relief, ODT 66%, and OTFC 73% vs." | 2.49 | Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. ( Bennett, MI; Fullarton, JR; Jandhyala, R, 2013) |
| " The primary outcome was improvement in PID during the first 60 min after dosing (15-60 min)." | 2.48 | Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis. ( Fullarton, J; Jandhyala, R, 2012) |
| "Breakthrough cancer pain has been defined as a transitory increase in pain intensity that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain." | 2.48 | Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. ( Mercadante, S, 2012) |
| "The pain experienced by cancer patients can be managed in 70-90% of cases by the World Health Organisation protocol for cancer pain." | 2.47 | [Solutions for the clinical problems of analgesics for cancer pain treatment in Japan]. ( Kokubun, H; Matoba, M; Yago, K; Yamada, Y, 2011) |
| "Despite advances in the management of cancer pain, through the application of modern, evidence-based, multimodality management and the availability of new treatment options, recent European surveys have indicated that the diagnosis and treatment of BTcP is still suboptimal." | 2.47 | Integrated strategies for the successful management of breakthrough cancer pain. ( Dickman, A, 2011) |
| "Breakthrough pain is characterized by a sudden onset and rapid increase in the pain level and should be treated with correspondingly rapidly effective opioids." | 2.47 | [Cancer breakthrough pain. Indications for rapidly effective opioids]. ( Bardenheuer, HJ; Kessler, J, 2011) |
| "The usual management of cancer related breakthrough pain is with supplemental doses of analgesics (commonly opioids) at a dose proportional to the total around-the-clock opioid dose." | 2.47 | Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. ( Zeppetella, G, 2011) |
| " Close examination of the existing trials assessing these newer transmucosal preparations reveals significant variation in many study parameters, such as patient selection criteria, severity of breakthrough pain episodes, proportions of patients with a neuropathic pain component, titration protocols, choice of the primary endpoints, protocols for repeat dosing and rescue medication, the separation of treated episodes and the extent of the placebo response, all of which may have affected efficacy results." | 2.47 | Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. ( Elsner, F; Porta-Sales, J; Tagarro, I; Zeppetella, G, 2011) |
| "Fentanyl is a potent opioid with a short duration of action." | 2.46 | Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer. ( Chwieduk, CM; McKeage, K, 2010) |
| "The treatment of BTP in cancer patients receiving opioids is principally based on the use of opioids, preferentially with a short onset." | 2.45 | Treatment strategies for cancer patients with breakthrough pain. ( Casuccio, A; Fulfaro, F; Mercadante, S, 2009) |
| "Fentanyl is a lipophilic, short-acting, synthetic opioid with a piperidine chemical structure." | 2.45 | The role of fentanyl in cancer-related pain. ( Prommer, E, 2009) |
| "Up to 80% of people with cancer experience pain at some time during their illness, and most will need opioid analgesics." | 2.44 | Opioids in people with cancer-related pain. ( Quigley, C, 2008) |
| "Breakthrough pain is a prevalent and serious problem in patients with cancer." | 2.44 | A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. ( Farrar, JT; Fisher, K; Hagen, NA; Victorino, C, 2007) |
| " FBT utilizes OraVescent technology to improve bioavailability and speed of drug delivery." | 2.44 | Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain? ( Hanna, M; Lecybyl, R, 2007) |
| "Pain is experienced by most cancer patients and represents an important issue in the clinical setting." | 2.44 | Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology. ( Mystakidou, K; Tsiatas, M; Tsilika, E; Vlahos, L, 2007) |
| "As a result of improved survival in cancer and the transfer of care from hospital to primary care, community nurses are taking increasing responsibility for the management of patients at all stages of the disease." | 2.44 | Actiq: an effective oral treatment for cancer-related breakthrough pain. ( Laverty, D, 2007) |
| "Studies of populations with chronic cancer pain have shown a high prevalence of breakthrough pain (BTP), defined as transitory, severe flares of pain that occur on a background of otherwise controlled, persistent pain." | 2.44 | Fentanyl buccal tablet. ( Darwish, M; Fine, PG; Messina, J, 2008) |
| "Pain in older cancer patients is a common event, and many times it is undertreated." | 2.44 | Management of pain in the older person with cancer. Part 2: treatment options. ( Bruera, E; Delgado-Guay, MO, 2008) |
| " Long-acting oral opioids supply satisfactory analgesia at more convenient dosing intervals." | 2.43 | Advances in opioid therapy and formulations. ( Walsh, D, 2005) |
| "Breakthrough pain in patients with cancer is a common problem with characteristics that make it difficult to treat." | 2.43 | Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review. ( Gordon, DB, 2006) |
| " manufacturer's recommendations for equilalagesic dosing of transdermal fentanyl may result in initial doses that produce subtherapeutic levels and unrelieved pain in some patients." | 2.43 | Transdermal opioids for cancer pain. ( Skaer, TL, 2006) |
| "Breakthrough pain is a common problem in patients with cancer, and is associated with significant morbidity among this group of patients." | 2.43 | Cancer-related breakthrough pain. ( Davies, AN, 2006) |
| "Persistent pain is present to some degree throughout the day and primarily is controlled with around-the-clock medication." | 2.42 | Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate. ( Palos, G; Rhiner, M; Termini, M, 2004) |
| " Regular pain assessments combined with appropriate analgesic administration at regular dosing intervals, adjunctive drug therapy for control of adverse effects and associated symptoms, and nonpharmacological interventions are recommended." | 2.42 | Cancer pain management in children. ( Mercadante, S, 2004) |
| "Breakthrough pain affects at least two-thirds of cancer patients at some point during their illness (Portenoy and Hagen, 1990; di Palma et al, 2000)." | 2.41 | The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain. ( Rees, E, 2002) |
| " However, clinicians should realize that the manufacturer's recommendations for equianalgesic dosing of transdermal fentanyl may result in initial doses that are too low in some patients, and in a titration period that is too long." | 2.41 | An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. ( Breitbart, W; Chandler, S; Eagel, B; Ellison, N; Enck, RE; Lefkowitz, M; Payne, R, 2000) |
| " The dosing interval for these systems is generally 3 days." | 2.41 | Treatment of cancer pain with transdermal fentanyl. ( Gourlay, GK, 2001) |
| "Tramadol is a centrally acting analgesic drug; it has an agonist effect on mu 1 receptors of opioids and acts also by inhibiting the re-uptake of noradrenaline and serotonine which activates descending monoaminergic inhibitory pathways." | 2.40 | [Treatment of pain in oncology]. ( De Conno, F; Polastri, D, 1997) |
| "Pain is the most feared symptom for patients diagnosed with cancer." | 2.40 | Current strategies for pain control. ( Ahmedzai, S, 1997) |
| "The high prevalence of pain in cancer patients has been appreciated for a long time." | 2.40 | Practice guidelines for cancer pain therapy. Issues pertinent to the revision of national guidelines. ( Payne, R, 1998) |
| "When pain is relieved inadequately by opioid analgesics given in a dose that causes intolerable side effects despite routine measures to control them, treatment with the same opioid by an alternative route or with an alternative opioid administered by the same route should be considered." | 2.40 | Opioid rotation for cancer pain: rationale and clinical aspects. ( Mercadante, S, 1999) |
| "Cancer pain is a significant issue in terminally ill cancer patients (TICPs)." | 1.91 | Differences in Fentanyl Requirements in Terminally Ill Cancer Patients. ( Fujiwara, N; Ishiki, H; Nojima, M; Shimada, N; Tojo, A; Watanabe, A, 2023) |
| "In comparison with other tumors, in patients with MM BTcP was more predictable (p=0." | 1.91 | Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study. ( Caraceni, A; Cuomo, A; Mammucari, M; Marchetti, P; Mediati, RD; Mercadante, S; Natoli, S; Tonini, G, 2023) |
| " Regarding adverse events, nausea occurred in 12." | 1.91 | Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain. ( Fujimoto, H; Funato, M; Kawana, M; Kiribayashi, M; Kokubun, H; Kondo, M; Kusakabe, A; Miyasato, A; Nagatani, K; Nakamura, K; Ohno, R; Okamoto, K; Onoda, C; Ozeki, A; Suzuki, N, 2023) |
| "Main adverse drug events were nausea and vomiting, somnolence, and confusion." | 1.72 | Tolerance of Fentanyl Pectin Nasal Spray for Procedural Pain in Geriatric Patients. ( Baudrant, M; Bedouch, P; Cracowski, JL; Drevet, S; Gavazzi, G; Gibert, P; Grevy, A; Maindet, C; Maljean, L; Mitha, N; Payen, M; Tiffet, T; Zerhouni, N, 2022) |
| "In order to find a correlation between Fentanyl action on pain and inter-individual variability in different cancer patients, the pharmacokinetic characterization of the drug becomes essential." | 1.72 | Fentanyl pharmacokinetics in blood of cancer patients by Gas Chromatography - Mass Spectrometry. ( Andrisano, V; Davani, L; De Simone, A; Maltoni, M; Montanari, S; Ricci, M; Terenzi, C, 2022) |
| "Morphine was most prescribed in 2010 but had decreased prevalence (-9." | 1.72 | Trends in strong opioid prescription for cancer patients in Japan from 2010 to 2019: an analysis with large medical claims data. ( Miyashita, M; Murakami, Y; Oba, MS; Takahashi, R, 2022) |
| "The risk of addiction in patients with cancer with a relatively good prognosis is a challenge." | 1.72 | Long-term analgesic pharmacotherapy in addiction to intranasal fentanyl. ( Cialkowska-Rysz, A; Olczak, B; Zaforemska, A, 2022) |
| "A retrospective cohort of cancer patients who died between 2011 and 2014 and were exposed as outpatient to a strong opioid analgesic in the last year of life was identified in the Echantillon Généraliste de Bénéficiaires (a 1/97th random sample of the French general population)." | 1.72 | Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors. ( Chu, TH; Lapeyre-Mestre, M; Palmaro, A; Rueter, M, 2022) |
| "Cancer pain was observed in 131 of 160 patients with advanced cancer living at home." | 1.56 | [Analysis of Symptoms Relieved in Addition to Pain after Administration of Oxycodone or Morphine to Patients with Advanced Cancer Living at Home]. ( Watanabe, K, 2020) |
| "Fentanyl efficacy was not statistically related to age, gender, cancer type, previous opioid treatment, steroid and midazolam doses and PPS." | 1.51 | Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients. ( Benítez-Rosario, MA; González-Dávila, E; Rosa-González, I; Sanz, E, 2019) |
| "Adverse drug reactions were registered in 3%." | 1.48 | Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS. ( Gneist, M; Landthaler, R; Masel, EK; Watzke, HH, 2018) |
| " Chronic use of pain medications and older age were predictors of inadequate pain control postoperatively." | 1.48 | Factors Associated with Inadequate Pain Control among Postoperative Patients with Cancer. ( Al-Najar, M; Darawad, M; El-Aqoul, A; Obaid, A; Ramadan, M; Yacoub, E, 2018) |
| "Our objective was to assess the effect of sublingual fentanyl tablets (SFTs) on pain relief, quality of life, and adverse effects in patients with cancer pain, according to cancer stage and background opioid regimen." | 1.48 | Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication. ( Coma, J; De Sanctis, V; Estivill, P; Ferreras, J; Folch, J; Fuentes, J; Guitart, J; Jiménez, AJ; Moya, J; Rodelas, F; Salazar, R; Sanz, A; Tomás, A; Vargas, MI, 2018) |
| " TIRF use was mainly related to background opioid dosage and the patient's self-sufficiency in taking medication." | 1.48 | Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer. ( Calvieri, A; Casale, G; Dardeli, A; Eusepi, G; Giannarelli, D; Magnani, C; Mastroianni, C; Restuccia, MR, 2018) |
| " Nausea, vomiting, somnolence, and dizziness were the most frequent treatment-related adverse events (AEs), and all AEs were grade 1 (mild) or 2 (moderate)." | 1.48 | Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients. ( Cho, HN; Koo, DH; Kwon, MY; Lee, SS; Lee, YG; Oh, S, 2018) |
| "Thirty-nine palliative cancer patients with levels of 25-hydroxyvitamin D < 75 nmol/L were supplemented with vitamin D 4000 IE/day, and were compared to 39 untreated, matched "control"-patients from a previous study at the same ward." | 1.46 | Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections-Results from a matched case-control study. ( Bergqvist, J; Björkhem-Bergman, L; Helde-Frankling, M; Höijer, J, 2017) |
| "The risk for developing infection increased by 2% per 10 mg increase in the daily OME." | 1.46 | Contribution of Opiate Analgesics to the Development of Infections in Advanced Cancer Patients. ( Cheng, XJ; Guan, BQ; Hao, JL; Ji, K; Liu, WS; Shao, YJ; Wang, K, 2017) |
| " This study investigated the patterns of opioid prescribing and characterized the dosing and duration of opioid use in patients with noncancer and cancer pain." | 1.46 | Dose and Duration of Opioid Use in Patients with Cancer and Noncancer Pain at an Outpatient Hospital Setting in Malaysia. ( Choy, LW; Ismail, CR; Rahman, NA; Zin, CS, 2017) |
| "We examined 87 hospitalized end-of-life cancer patients who were given betamethasone for relief of CRF at our hospital between January 2008 and January 2014." | 1.46 | Predictors of the Usefulness of Corticosteroids for Cancer-Related Fatigue in End-of-Life Patients. ( Hosokawa, T; Kanbayashi, Y, 2017) |
| "The recommended dosing interval for transdermal fentanyl is every 72 h." | 1.43 | A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch. ( Hirayama, Y; Horiuchi, I; Ishitani, K; Kato, J; Koike, K; Kusakabe, T; Machino, T; Mihara, H; Nagasako, T; Nishisato, T; Terui, T; Yamakage, M, 2016) |
| " A population pharmacokinetic model was developed and evaluated using non-linear mixed-effects modelling." | 1.43 | Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. ( Abrantes, JA; de Bruijn, P; Falcão, A; Jönsson, S; Kuip, EJ; Mathijssen, RH; Oosten, AW; van der Rijt, CC, 2016) |
| " Nonetheless, careful deliberation is necessary because of the slow effects and difficulty with dosage adjustment." | 1.43 | [Use of Transdermal Fentanyl in a Hospital]. ( Kikuchi, N; Sako, A; Watanabe, A; Yoshida, S; Yoshikawa, Y, 2016) |
| "Dyspnea is a prognostic factor that affects the quality of life of terminal cancer patients, and many reports have described opioid treatment for dyspnea alleviation." | 1.43 | Combined Effect of Opioids and Corticosteroids for Alleviating Dyspnea in Terminal Cancer Patients: A Retrospective Review. ( Hayakawa, T; Maeda, T, 2016) |
| "Breakthrough cancer pain is defined as a transient exacerbation of pain that occurs spontaneously or in response to a trigger, despite stable and controlled background pain." | 1.42 | Breakthrough cancer pain: a comparison of surveys with European and Canadian patients. ( Bedard, G; Buchanan, A; Chow, E; Davies, A; Hawley, P; McDonald, R; Popovic, M; Wong, E, 2015) |
| " The modification of propofol dosage in the group of patients under study is not necessary when TCI-guided administration of propofol by means of the Schnider model is used." | 1.42 | Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery. ( Bienert, A; Grześkowiak, E; Kaliszan, R; Kut, K; Plenzler, E; Przybyłowski, K; Szczesny, D; Tyczka, J; Wiczling, P, 2015) |
| "Breakthrough pain affects 40%-90% of patients with cancer pain." | 1.42 | Use of nasal fentanyl for cancer pain: A pharmacoepidemiological study. ( Borchgrevink, PC; Fredheim, OM; Mahic, M; Skurtveit, S, 2015) |
| "The state of opioid consumption among cancer patients has never been comprehensively investigated in Japan." | 1.42 | Accuracy of using Diagnosis Procedure Combination administrative claims data for estimating the amount of opioid consumption among cancer patients in Japan. ( Higashi, T; Iwamoto, M; Kawaguchi, T; Matoba, M; Miura, H; Tanaka, S; Yamashita, I; Yoshida, S; Yoshimoto, T, 2015) |
| "Postoperative pain was measured by visual analogue scale (VAS) method." | 1.42 | Correlation of ADRB1 rs1801253 Polymorphism with Analgesic Effect of Fentanyl After Cancer Surgeries. ( Liu, C; Sui, Z; Tian, Y; Wang, C; Wei, W; Yang, R; Zhao, C, 2015) |
| "IV-PCA provided timely, safe and useful analgesia for patients with severe breakthrough pain and may be useful to help titration of opioids, weaning to oral analgesia and to decide for interventional procedures." | 1.40 | Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study. ( Ashmawi, HA; Cascudo, GM; de Santana Neto, J; Guimaraes, GM; Neto, JO; Sousa, AM, 2014) |
| "Pain is a symptom of cancer and is categorized in two forms: background pain to be treated with analgesics, and breakthrough cancer pain (BTcP), which needs drug treatment on demand." | 1.40 | Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain. ( Oradei, M; Ruggeri, M; Turriziani, A, 2014) |
| "The use of TDF for the treatment of cancer pain is not associated with impairment in cognitive performance." | 1.40 | [The cognitive effects of using transdermal fentanyl in cancer pain]. ( Ali, A; Bilen, A; Turgut, N; Türkmen, A; Unlü, N, 2014) |
| "Pruritus was not associated to any factor." | 1.39 | Orphan symptoms in advanced cancer patients followed at home. ( Adile, C; Aielli, F; Casuccio, A; Fusco, F; Mercadante, S; Porzio, G; Valle, A, 2013) |
| "Uncontrolled prescription for non-cancer pain must be criticized due to the problem of addiction." | 1.39 | [Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society]. ( Heuser-Grannemann, E; Junker, U; Schenk, M; Wiese, CH; Wirz, S; Zimmermann, M, 2013) |
| " The plasma concentration of fentanyl normalized with the measured absorption rate was significantly higher in the CYP3A5*3/*3 group than in the *1/*1 and *1/*3 groups (p = 0." | 1.38 | Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. ( Kawakami, J; Mino, Y; Naito, T; Ohnishi, K; Takashina, Y; Yagi, T, 2012) |
| "FPNS is indicated for the treatment of breakthrough pain in cancer patients who are tolerant to opioid therapy for their underlying persistent cancer pain." | 1.38 | Fentanyl pectin nasal spray for breakthrough cancer pain. ( Gabrail, N; Taylor, DR, 2012) |
| "Demographic data, cancer type, duration of pain, side effects, visual analog scale (VAS) score, treatment assessment scale (TAS) score, TDF dosage, and the number of patients in whom therapy has been terminated were recorded." | 1.38 | [Comparison of transdermal fentanyl for the management of cancer pain in adults and elders]. ( Ali, A; Alkan, I; Altan, A; Bilen, A, 2012) |
| "This study involved 320 cancer patients from four Northern European countries." | 1.37 | Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. ( Andersen, S; Buchanan, A; Damkier, A; Davies, A; Nauck, F; Radbruch, L; Sjolund, KF; Stenberg, M; Vejlgaard, T; Zeppetella, G, 2011) |
| "Fentanyl is an opioid initially developed for parenteral administration." | 1.36 | Formulations of fentanyl for the management of pain. ( Grape, S; Lauer, S; Schug, BS; Schug, SA, 2010) |
| " To determine the dosing frequency of sustained-release opioids (morphine, oxycodone, and transdermal fentanyl) and the prevalence of end-of-dose failure in clinical practice, a patient-reported survey was performed." | 1.36 | The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study. ( Ahn, JS; Kim, DY; Kim, SY; Ryoo, BY; Shin, DB; Song, HS; Yim, CY, 2010) |
| "Breakthrough pain is defined as transitory flares of pain." | 1.36 | Recent development in therapeutics for breakthrough pain. ( Davis, MP, 2010) |
| " 33 patients in terminal stage of carcinoma, who had been treated by transdermal fentanyl due to their excruciating pain (7-10 mark on numerical scale) with initial dosage of 25 microg as a strong opiate analgesic, were monitored within the time period of 10 days." | 1.36 | Treatment of severe cancer pain by transdermal fentanyl. ( Husić, S; Ljuca, D, 2010) |
| "Incidence of newly diagnosed cancers is also the second highest in the Gulf with 11%." | 1.36 | Historical perspectives and trends in the management of pain for cancer patients in oman. ( Mahfudh, SS, 2010) |
| "Pain is an important and often under-treated symptom of life-threatening illness." | 1.35 | [Analgesics and palliative care]. ( Mathieu, N; Tuna, T, 2008) |
| "Fentanyl has been used for cancer pain in transdermal formulation." | 1.35 | Validated LC coupled to ESI-MS/MS analysis for fentanyl in human plasma and UV analysis in applied reservoir transdermal patches using a simple and rapid procedure. ( Kagawa, Y; Kawakami, J; Mino, Y; Naito, T; Takashina, Y, 2009) |
| "Cancer pain is common, occurring in up to 60% of patients and opioid conversion may be required for effective pain management." | 1.35 | Inconsistencies in opioid equianalgesic ratios: clinical and research implications. ( Kutner, JS; Linnebur, SA; O'Bryant, CL; Yamashita, TE, 2008) |
| "Children with solid tumors outside the central nervous system were likely to receive more opioids, be given multiple different opioids, and receive opioids in the last month." | 1.35 | Opioid use in palliative care of children and young people with cancer. ( Childs, M; Collins, GS; Goldman, A; Hain, R; Hewitt, M, 2008) |
| "The fentanyl patch was equally divided by drawing a line on the side on which the product name and dose were written." | 1.35 | [Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain]. ( Hoka, S; Kokubun, H; Matoba, M; Okazaki, M; Yago, K, 2008) |
| "The fentanyl patch is a useful agent to control severe cancer pain because of excellent analgesic effect, less adverse effects and more convenience as well as itsundesirable characteristics when transition of patients to home-care is considered or oral administration should be avoided." | 1.34 | [Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations]. ( Akiyama, Y; Iseki, M; Ishii, K; Izawa, R; Miyazaki, T; Tani, Y; Yamaguchi, S, 2007) |
| "Fentanyl patches were removed and the first of three daily doses of methadone was started concurrently." | 1.34 | Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. ( Casuccio, A; Ferrera, P; Gambaro, V; Mercadante, S; Villari, P, 2007) |
| " Six patients receiving TTS BU were switched to TTS FE and then rotated back to TTS BU with the same dosing considerations." | 1.34 | Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. ( Aielli, F; Casuccio, A; Ficorella, C; Fulfaro, F; Intravaia, G; Mangione, S; Mercadante, S; Porzio, G; Riina, S; Verna, L, 2007) |
| "Many Japanese cancer patients experience severe pain although they and their families hope to be pain free at the end of their lives." | 1.34 | Toward freedom from cancer pain in Japan. ( Otsuka, K; Yasuhara, H, 2007) |
| "The vast majority of patients with cancer pain are prescribed opioids in oral formulation." | 1.33 | [Parenteral opioids in end-of-life care in cancer patients]. ( Hattori, S; Kimura, N; Noguchi, T; Takatani, J, 2005) |
| " The bioavailability of fentanyl was statistically different according to patient age." | 1.33 | Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. ( Astre, C; Bressolle, F; Caumette, L; Coulouma, R; Culine, S; Garcia, F; Pinguet, F; Solassol, I; Thézenas, S, 2005) |
| "The efficacy and QOL in a cancer pain patient who converted to transdermal fentanyl from low-dose morphine (n=5) or high-dose morphine (n=5) were retrospectively compared." | 1.33 | [Direct conversion from low-dose morphine to transdermal fentanyl: efficacy for cancer pain and quality of life]. ( Akashi, T; Aoki, T; Tachibana, M; Yamazaki, M, 2006) |
| "Fentanyl is a synthetic, lipophilic opioid, more potent than morphine, and achieves peak effects after intravenous administration in 5 minutes." | 1.32 | Intravenous fentanyl for cancer pain: a "fast titration" protocol for the emergency room. ( Martins, M; Soares, LG; Uchoa, R, 2003) |
| "For patients without cancer, rates of therapy switching at 6 months were 10." | 1.32 | Therapy switching in patients receiving long-acting opioids. ( Berger, A; Delea, TE; Goodman, S; Hoffman, DL; Oster, G; Seifeldin, R, 2004) |
| "Morphine side effects were reduced in some patients who changed to transdermal fentanyl, but there was no reduction in those who needed high-dose morphine for rescue analgesia." | 1.32 | A study of transdermal fentanyl in cancer pain at Aichi-Cancer Center. ( Hasegawa, M; Hosoda, R; Kamiya, Y; Kato, K; Mizaki, T; Nitta, M; Yamazaki, S, 2004) |
| " No systemic adverse events were noted; two patients reported nasal itching or discomfort on first use that disappeared with repeated use." | 1.31 | An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. ( Zeppetella, G, 2000) |
| " Various strategies have been proposed to estimate safe and effective starting doses of methadone when rotating from morphine and hydromorphone; however, there are no guidelines for estimating safe and effective starting doses of methadone when rotating from fentanyl." | 1.31 | Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. ( Fischberg, DJ; Khojainova, N; Kornick, C; Manfredi, P; Payne, R; Primavera, LH; Santiago-Palma, J, 2001) |
| "Most patients suffered from cancer pain and only 11 patients had chronic pain from non-malignant disease." | 1.31 | Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. ( Brunsch-Radbruch, A; Grond, S; Lehmann, KA; Petzke, F; Radbruch, L; Sabatowski, R, 2001) |
| "Yet, surveys of nurses' knowledge of cancer pain management reveal serious knowledge deficits that could adversely affect the care of patients with cancer pain." | 1.30 | Nurses' knowledge about equianalgesia and opioid dosing. ( Ferrell, BR; McCaffery, M, 1997) |
| "Both morphine and fentanyl were used." | 1.30 | Nurse-controlled analgesia using a patient-controlled analgesia device: an alternative strategy in the management of severe cancer pain in children. ( Cooper, MG; Kanagasundaram, SA; Lane, LJ, 1997) |
| "To assess the effect of opioid substitution (substituting one member of the opioid class for another) on the incidence and severity of adverse effects in palliative care patients who experience unacceptable, refractory adverse effects when taking an opioid drug." | 1.30 | Opioid substitution to reduce adverse effects in cancer pain management. ( Ashby, MA; Jackson, KA; Martin, P, 1999) |
| "Fentanyl was changed to the more potent synthetic opioid sufentanil in 2 patients for whom the fentanyl dose necessitated too large a volume for the portable syringe driver in use." | 1.29 | Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. ( Ashby, M; Brooksbank, M; Coleman, A; Grigson, J; Lees, J; Paix, A; Thorne, D, 1995) |
| " infusion in the palliative care setting, which necessitates careful titration of dosage according to individual clinical response." | 1.29 | Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients. ( Abbott, F; Maddocks, I; McLean, S; Miller, RS; Parker, D; Peterson, GM, 1995) |
| "In animals without tumors, the temperature subcutaneously on the foot was 0." | 1.29 | Use of the vasodilator sodium nitroprusside during local hyperthermia: effects on tumor temperature and tumor response in a rat tumor model. ( Dahl, O; Krossnes, BK; Mella, O, 1996) |
| "Ten patients with advanced cancer and breakthrough pain between the ages of 39 and 78 received oral transmucosal fentanyl citrate (10-15 micrograms/kg) 4 or 5 times each over 2 days (42 total administrations) in an open study." | 1.28 | An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. ( De Boer, JA; Fine, PG; Marcus, M; Van der Oord, B, 1991) |
| "Alfentanil was used for analgesia and atracurium for muscle paralysis in both." | 1.27 | Anaesthesia and acute dermatomyositis/polymyositis. ( Campbell, IT; Ganta, R; Mostafa, SM, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (2.04) | 18.7374 |
| 1990's | 71 (14.46) | 18.2507 |
| 2000's | 155 (31.57) | 29.6817 |
| 2010's | 215 (43.79) | 24.3611 |
| 2020's | 40 (8.15) | 2.80 |
| Authors | Studies |
|---|---|
| Takemura, M | 1 |
| Niki, K | 1 |
| Okamoto, Y | 1 |
| Matsuda, Y | 2 |
| Omae, T | 1 |
| Takagi, T | 2 |
| Ueda, M | 1 |
| Kondo, A | 1 |
| Murakami, T | 1 |
| Fujii, T | 1 |
| Tatsumi, M | 1 |
| Ueda-Sakane, Y | 1 |
| Ueda, Y | 1 |
| Yamauchi, I | 1 |
| Ogura, M | 1 |
| Taura, D | 1 |
| Inagaki, N | 1 |
| Oto, Y | 2 |
| Momo, K | 2 |
| Uchikura, T | 1 |
| Tanaka, K | 2 |
| Sasaki, T | 2 |
| Demuth, M | 1 |
| Hiyama, E | 1 |
| Yamaguchi, S | 3 |
| Okawa, K | 2 |
| Hashimoto, F | 2 |
| Otaka, K | 1 |
| Terahara, T | 2 |
| Rodríguez, AT | 1 |
| Viejo, MN | 1 |
| Maradey, P | 1 |
| Canal-Sotelo, J | 1 |
| Mancilla, PG | 1 |
| Rivero, SG | 1 |
| Casillas, IR | 1 |
| Abián, MH | 1 |
| Bermudo, CL | 1 |
| Cascella, M | 1 |
| Monaco, F | 1 |
| Nocerino, D | 1 |
| Chinè, E | 1 |
| Carpenedo, R | 1 |
| Picerno, P | 1 |
| Migliaccio, L | 1 |
| Armignacco, A | 1 |
| Franceschini, G | 1 |
| Coluccia, S | 1 |
| Gennaro, PD | 1 |
| Tracey, MC | 1 |
| Forte, CA | 1 |
| Tafuri, M | 1 |
| Crispo, A | 1 |
| Cutugno, F | 1 |
| Vittori, A | 1 |
| Natoli, S | 2 |
| Cuomo, A | 5 |
| Guastella, V | 1 |
| Delorme, J | 1 |
| Chenaf, C | 1 |
| Authier, N | 1 |
| Yomiya, K | 5 |
| Maljean, L | 1 |
| Gavazzi, G | 1 |
| Gibert, P | 1 |
| Grevy, A | 1 |
| Payen, M | 1 |
| Zerhouni, N | 1 |
| Tiffet, T | 1 |
| Cracowski, JL | 1 |
| Mitha, N | 1 |
| Maindet, C | 1 |
| Baudrant, M | 1 |
| Bedouch, P | 1 |
| Drevet, S | 1 |
| Silva-Dos-Santos, A | 1 |
| Costa, S | 1 |
| Moitinho, M | 1 |
| Montanari, S | 1 |
| Davani, L | 1 |
| Terenzi, C | 1 |
| Maltoni, M | 2 |
| Andrisano, V | 1 |
| De Simone, A | 1 |
| Ricci, M | 1 |
| Takahashi, R | 1 |
| Miyashita, M | 1 |
| Murakami, Y | 1 |
| Oba, MS | 1 |
| Monsereenusorn, C | 2 |
| Malaithong, W | 1 |
| Lertvivatpong, N | 1 |
| Photia, A | 1 |
| Rujkijyanont, P | 2 |
| Traivaree, C | 2 |
| Ishii, H | 3 |
| Kokubun, H | 7 |
| Tabata, KI | 3 |
| Kanai, A | 3 |
| Watanabe, A | 3 |
| Shimada, N | 2 |
| Ishiki, H | 2 |
| Fujiwara, N | 2 |
| Nojima, M | 2 |
| Tojo, A | 2 |
| Jobski, K | 3 |
| Bantel, C | 2 |
| Hoffmann, F | 2 |
| Kwon, MY | 2 |
| Lee, MY | 1 |
| Han, YJ | 1 |
| Lee, SH | 1 |
| Kim, EJ | 1 |
| Park, S | 1 |
| Lee, YG | 2 |
| Koo, DH | 2 |
| Mercadante, S | 31 |
| Caraceni, A | 4 |
| Mammucari, M | 2 |
| Marchetti, P | 2 |
| Mediati, RD | 1 |
| Tonini, G | 1 |
| Bahrami, F | 1 |
| Rossi, RM | 1 |
| De Nys, K | 1 |
| Defraeye, T | 1 |
| Mahendru, K | 1 |
| Garg, R | 1 |
| Bharati, SJ | 1 |
| Kumar, V | 1 |
| Gupta, N | 1 |
| Mishra, S | 1 |
| Bhatnagar, S | 1 |
| Ray, M | 1 |
| Deo, S | 1 |
| Kawana, M | 1 |
| Miyasato, A | 1 |
| Funato, M | 1 |
| Nagatani, K | 1 |
| Suzuki, N | 2 |
| Onoda, C | 1 |
| Fujimoto, H | 1 |
| Ohno, R | 1 |
| Kusakabe, A | 1 |
| Kiribayashi, M | 1 |
| Nakamura, K | 2 |
| Kondo, M | 1 |
| Ozeki, A | 1 |
| Okamoto, K | 2 |
| Bansal, S | 1 |
| Mittal, S | 1 |
| Tiwari, P | 1 |
| Jain, D | 1 |
| Arava, S | 1 |
| Hadda, V | 1 |
| Mohan, A | 1 |
| Malik, P | 1 |
| Pandey, RM | 1 |
| Khilnani, GC | 1 |
| Guleria, R | 1 |
| Madan, K | 1 |
| Alsirafy, SA | 2 |
| Alabdullateef, SH | 1 |
| Elyamany, AM | 1 |
| Hassan, AD | 1 |
| Almashiakhi, M | 1 |
| Moryl, N | 2 |
| Bokhari, A | 1 |
| Griffo, Y | 1 |
| Hadler, R | 1 |
| Koranteng, L | 1 |
| Filkins, A | 1 |
| Zheng, T | 1 |
| Horn, SD | 1 |
| Inturrisi, CE | 3 |
| Olczak, B | 1 |
| Zaforemska, A | 1 |
| Cialkowska-Rysz, A | 1 |
| Geist, MJP | 1 |
| Ziesenitz, VC | 1 |
| Bardenheuer, HJ | 2 |
| Burhenne, J | 1 |
| Skopp, G | 1 |
| Mikus, G | 1 |
| Chiba, T | 2 |
| Takahashi, H | 3 |
| Tairabune, T | 2 |
| Kimura, S | 1 |
| Ueda, H | 1 |
| Kudo, K | 2 |
| Watanabe, K | 1 |
| Jackson, LD | 1 |
| Wortzman, R | 1 |
| Chua, D | 1 |
| Selby, D | 1 |
| Banala, SR | 1 |
| Khattab, OK | 1 |
| Page, VD | 1 |
| Warneke, CL | 1 |
| Todd, KH | 1 |
| Yeung, SJ | 1 |
| Ghafoor, I | 1 |
| Siddiqui, A | 1 |
| Hafeez, H | 1 |
| Usman, HM | 1 |
| Nagata, T | 1 |
| Tsuge, E | 1 |
| Kobayashi, K | 2 |
| Shimada, K | 2 |
| Amezcua, V | 1 |
| Doello, K | 1 |
| González-Callejas, D | 1 |
| Uchida, E | 2 |
| Tanaka, Y | 1 |
| Fares, KM | 1 |
| Mohamed, SA | 1 |
| Abd El-Rahman, AM | 1 |
| AbdeLemam, RM | 1 |
| Osman, AMM | 1 |
| Ye, Z | 1 |
| Chen, J | 1 |
| Zhang, Y | 1 |
| Hu, X | 1 |
| Xuan, Z | 1 |
| Yang, S | 1 |
| Mao, X | 1 |
| Rao, Y | 1 |
| Satomi, M | 1 |
| Kono, T | 1 |
| Iupati, S | 1 |
| Bridge, R | 1 |
| Allan, S | 1 |
| Hewitt, D | 1 |
| Jamieson, L | 2 |
| Harrop, E | 2 |
| Johnson, M | 1 |
| Liossi, C | 1 |
| Mott, C | 1 |
| Oulton, K | 1 |
| Skene, SS | 1 |
| Wong, IC | 1 |
| Howard, RF | 1 |
| Chu, TH | 1 |
| Rueter, M | 1 |
| Palmaro, A | 1 |
| Lapeyre-Mestre, M | 1 |
| Kaneshima, M | 1 |
| Kyosaka, B | 1 |
| Warita, E | 1 |
| Hosonuma, R | 1 |
| Osato, S | 1 |
| Guitart, J | 4 |
| Vargas, MI | 4 |
| De Sanctis, V | 4 |
| Folch, J | 4 |
| Salazar, R | 4 |
| Fuentes, J | 4 |
| Coma, J | 4 |
| Ferreras, J | 4 |
| Moya, J | 5 |
| Tomás, A | 4 |
| Estivill, P | 4 |
| Rodelas, F | 4 |
| Jiménez, AJ | 4 |
| Sanz, A | 3 |
| Choy, TH | 1 |
| Ho, WHP | 1 |
| Wong, ICK | 1 |
| Hui, D | 6 |
| Kilgore, K | 3 |
| Frisbee-Hume, S | 2 |
| Park, M | 3 |
| Liu, D | 5 |
| Balachandran, DD | 1 |
| Bruera, E | 13 |
| Cheng, PTM | 1 |
| Hawley, P | 2 |
| Masel, EK | 1 |
| Landthaler, R | 1 |
| Gneist, M | 1 |
| Watzke, HH | 1 |
| Helde-Frankling, M | 1 |
| Höijer, J | 1 |
| Bergqvist, J | 1 |
| Björkhem-Bergman, L | 1 |
| Husic, S | 2 |
| Imamovic, S | 1 |
| Matic, S | 1 |
| Sukalo, A | 1 |
| El-Aqoul, A | 1 |
| Obaid, A | 1 |
| Yacoub, E | 1 |
| Al-Najar, M | 1 |
| Ramadan, M | 1 |
| Darawad, M | 1 |
| Santos, RFD | 1 |
| Bliacheriene, F | 1 |
| Sarti, FM | 1 |
| Schuster, M | 1 |
| Bayer, O | 1 |
| Heid, F | 1 |
| Laufenberg-Feldmann, R | 1 |
| Wang, DD | 1 |
| Ma, TT | 1 |
| Zhu, HD | 1 |
| Peng, CB | 1 |
| Benítez-Rosario, MA | 2 |
| Rosa-González, I | 1 |
| González-Dávila, E | 1 |
| Sanz, E | 1 |
| Magnani, C | 1 |
| Giannarelli, D | 1 |
| Calvieri, A | 1 |
| Dardeli, A | 1 |
| Eusepi, G | 1 |
| Restuccia, MR | 1 |
| Mastroianni, C | 1 |
| Casale, G | 1 |
| Neefjes, ECW | 1 |
| van der Wijngaart, H | 1 |
| van der Vorst, MJDL | 1 |
| Ten Oever, D | 1 |
| van der Vliet, HJ | 1 |
| Beeker, A | 1 |
| Rhodius, CA | 1 |
| van den Berg, HP | 1 |
| Berkhof, J | 1 |
| Verheul, HMW | 1 |
| Brząkała, J | 1 |
| Leppert, W | 3 |
| Pardo, J | 1 |
| Mena, A | 1 |
| Jiménez, E | 1 |
| Aymar, N | 1 |
| Ortiz, I | 1 |
| Roncero, R | 1 |
| Mestre, F | 1 |
| Vidal, M | 2 |
| Triarico, S | 1 |
| Capozza, MA | 1 |
| Mastrangelo, S | 1 |
| Attinà, G | 1 |
| Maurizi, P | 1 |
| Ruggiero, A | 2 |
| Yamaguchi, T | 1 |
| Matsunuma, R | 1 |
| Suzuki, K | 1 |
| Mori, M | 1 |
| Watanabe, H | 2 |
| Hernandez, F | 1 |
| Larsson, L | 1 |
| Naberhuis, J | 1 |
| Virgilio, A | 1 |
| Reddy, S | 3 |
| Reddy, A | 4 |
| Dalal, S | 1 |
| Haider, A | 3 |
| Driver, L | 1 |
| Azhar, A | 1 |
| Dev, R | 2 |
| Arthur, JA | 1 |
| Smith, U | 1 |
| Vaughan-Adams, N | 1 |
| Williams, J | 3 |
| Nosek, K | 1 |
| Kako, J | 1 |
| Kajiwara, K | 1 |
| Noto, H | 1 |
| Oosono, Y | 1 |
| Kobayashi, M | 1 |
| Grassin-Delyle, S | 1 |
| Naline, E | 1 |
| Devillier, P | 1 |
| Perelman, M | 4 |
| Leake, S | 1 |
| Dietrich, E | 2 |
| Gums, JG | 2 |
| Zeppetella, G | 11 |
| Porzio, G | 7 |
| Aielli, F | 7 |
| Averna, L | 1 |
| Ficorella, C | 4 |
| Casuccio, A | 16 |
| Bilen, A | 4 |
| Ali, A | 4 |
| Baturay, F | 2 |
| Ozcan, B | 1 |
| Altan, A | 3 |
| McWilliams, K | 1 |
| Fallon, M | 2 |
| Bornemann-Cimenti, H | 2 |
| Wejbora, M | 2 |
| Szilagyi, IS | 2 |
| Sandner-Kiesling, A | 2 |
| Meissner, W | 1 |
| Sabatowski, R | 4 |
| Beutlhauser, T | 1 |
| Oeltjenbruns, J | 1 |
| Schäfer, M | 1 |
| Sláma, O | 1 |
| Gong, XD | 1 |
| Wang, JY | 1 |
| Liu, F | 1 |
| Yuan, HH | 1 |
| Zhang, WY | 1 |
| Guo, YH | 1 |
| Jiang, B | 1 |
| Xu, A | 1 |
| Chisholm, G | 1 |
| Morgado, M | 1 |
| Webster, LR | 1 |
| Slevin, KA | 1 |
| Narayana, A | 1 |
| Earl, CQ | 1 |
| Yang, R | 2 |
| Ketterer, W | 1 |
| Hadley, G | 1 |
| Derry, S | 2 |
| Moore, RA | 2 |
| Wiffen, PJ | 2 |
| Kosugi, T | 1 |
| Hamada, S | 1 |
| Takigawa, C | 3 |
| Shinozaki, K | 1 |
| Kunikane, H | 1 |
| Goto, F | 2 |
| Tanda, S | 2 |
| Shima, Y | 2 |
| Matoba, M | 9 |
| Adachi, I | 2 |
| Yoshimoto, T | 4 |
| Eguchi, K | 2 |
| Valle, A | 2 |
| Fusco, F | 1 |
| Adile, C | 7 |
| Taylor, D | 3 |
| Radbruch, L | 8 |
| Revnic, J | 3 |
| Torres, LM | 4 |
| Ellershaw, JE | 2 |
| Davies, AN | 4 |
| Sousa, AM | 1 |
| de Santana Neto, J | 1 |
| Guimaraes, GM | 1 |
| Cascudo, GM | 1 |
| Neto, JO | 1 |
| Ashmawi, HA | 1 |
| Pinna, MÁ | 1 |
| Moralo, MJ | 1 |
| Correas, MÁ | 2 |
| Vargas, RM | 1 |
| Samala, RV | 1 |
| Bloise, R | 1 |
| Davis, MP | 3 |
| Saito, T | 1 |
| Fujii, M | 1 |
| Saito, S | 1 |
| Fujiwara, K | 1 |
| Corli, O | 2 |
| Roberto, A | 2 |
| Velázquez Rivera, I | 1 |
| Muñoz Garrido, JC | 1 |
| García Velasco, P | 1 |
| España Ximénez de Enciso, I | 1 |
| Velázquez Clavarana, L | 1 |
| Barratt, DT | 2 |
| Bandak, B | 1 |
| Klepstad, P | 5 |
| Dale, O | 3 |
| Kaasa, S | 8 |
| Christrup, LL | 1 |
| Tuke, J | 1 |
| Somogyi, AA | 2 |
| Novotna, S | 1 |
| Valentova, K | 1 |
| Fricova, J | 1 |
| Richterova, E | 1 |
| Harabisova, S | 1 |
| Bullier, F | 1 |
| Trinquet, F | 1 |
| Kongsgaard, UE | 2 |
| Eeg, M | 2 |
| Greisen, H | 1 |
| Prestia, G | 1 |
| Juebner, M | 1 |
| Fietzke, M | 1 |
| Beike, J | 1 |
| Rothschild, MA | 1 |
| Bender, K | 1 |
| Didwaniya, N | 1 |
| Gottumukkala, RS | 1 |
| England, R | 1 |
| Maddocks, M | 1 |
| Manderson, C | 1 |
| Zadora-Chrzastowska, S | 1 |
| Wilcock, A | 1 |
| Jandhyala, R | 3 |
| Fullarton, J | 1 |
| Fladvad, T | 1 |
| Fayers, P | 1 |
| Skorpen, F | 1 |
| Ruggeri, M | 1 |
| Turriziani, A | 1 |
| Oradei, M | 1 |
| Ryazhenov, VV | 1 |
| Abuzarova, GR | 1 |
| Gorokhova, SG | 1 |
| Emchenko, IV | 1 |
| Matveev, NV | 1 |
| Kimura, Y | 1 |
| Wakabayashi, G | 1 |
| Takahashi, K | 1 |
| Fullarton, JR | 2 |
| Bennett, MI | 2 |
| Shimoyama, N | 2 |
| Gomyo, I | 2 |
| Katakami, N | 2 |
| Okada, M | 1 |
| Yukitoshi, N | 2 |
| Ohta, E | 2 |
| Shimoyama, M | 2 |
| Schreiber, JA | 1 |
| Zucco, F | 1 |
| Bonezzi, C | 1 |
| Fornasari, D | 1 |
| Rauck, R | 5 |
| Parikh, N | 2 |
| Dillaha, L | 2 |
| Barker, J | 1 |
| Stearns, L | 2 |
| Sasaki, S | 1 |
| Morohashi, T | 1 |
| Otsuka, Y | 1 |
| Ejima, M | 1 |
| Tsujikawa, Y | 1 |
| Yoshimura, K | 1 |
| Terai, E | 1 |
| Nakayama, H | 1 |
| Watanabe, T | 1 |
| Kleeberg, UR | 2 |
| Davies, A | 7 |
| Jarosz, J | 2 |
| Poulain, P | 4 |
| O'Brien, T | 2 |
| Schneid, H | 2 |
| Kress, HG | 4 |
| Bedard, G | 1 |
| McDonald, R | 1 |
| Buchanan, A | 2 |
| Popovic, M | 1 |
| Wong, E | 1 |
| Chow, E | 1 |
| Unlü, N | 1 |
| Turgut, N | 1 |
| Türkmen, A | 1 |
| Knight, AD | 1 |
| Heiskanen, T | 3 |
| Langel, K | 1 |
| Gunnar, T | 1 |
| Lillsunde, P | 1 |
| Kalso, EA | 1 |
| Chen, C | 1 |
| Gupta, A | 1 |
| Vellucci, R | 2 |
| Cortegiani, A | 2 |
| Villari, P | 6 |
| Teramoto, O | 1 |
| Kojima, K | 1 |
| Higuchi, H | 1 |
| Pang, GS | 1 |
| Qu, LM | 1 |
| Tan, YY | 1 |
| Yee, AC | 1 |
| Caruselli, A | 1 |
| Meli, MR | 1 |
| Bellavia, G | 1 |
| Tuttolomondo, A | 1 |
| Doulton, B | 1 |
| Kang, JH | 1 |
| Oh, SY | 1 |
| Song, SY | 1 |
| Lee, HY | 1 |
| Kim, JH | 1 |
| Lee, KE | 1 |
| Lee, HR | 1 |
| Hwang, IG | 1 |
| Park, SH | 1 |
| Kim, WS | 1 |
| Park, YS | 1 |
| Park, K | 2 |
| Hayashi, T | 1 |
| Ikehata, S | 1 |
| Matsuzaki, H | 1 |
| Yasuda, K | 1 |
| Makihara, T | 1 |
| Futamura, A | 1 |
| Arakawa, Y | 1 |
| Kuki, R | 1 |
| Fukuura, K | 1 |
| Mori, N | 1 |
| Higashiguchi, T | 1 |
| Yamadaa, S | 1 |
| Przybyłowski, K | 1 |
| Tyczka, J | 1 |
| Szczesny, D | 1 |
| Bienert, A | 1 |
| Wiczling, P | 1 |
| Kut, K | 1 |
| Plenzler, E | 1 |
| Kaliszan, R | 1 |
| Grześkowiak, E | 1 |
| Thronæs, M | 1 |
| Popper, L | 1 |
| Jaatun, E | 1 |
| Kvitberg, M | 1 |
| Fredheim, OM | 1 |
| Mahic, M | 1 |
| Skurtveit, S | 1 |
| Borchgrevink, PC | 2 |
| Trinidad, JM | 1 |
| Calderón, E | 1 |
| Benitez, D | 1 |
| Handsaker, S | 1 |
| Dempsey, L | 1 |
| Fabby, C | 1 |
| Kurita, GP | 1 |
| Lundström, S | 1 |
| Sjøgren, P | 2 |
| Ekholm, O | 1 |
| Christrup, L | 2 |
| Naito, T | 3 |
| Kawakami, J | 3 |
| Cahill, K | 1 |
| Shehab, RM | 1 |
| Hassan, A | 1 |
| Lowney, A | 1 |
| McQuillan, R | 1 |
| Kullmann, T | 1 |
| Sipőcz, I | 1 |
| Csikós, Á | 1 |
| Pintér, T | 1 |
| Koike, K | 1 |
| Terui, T | 1 |
| Nagasako, T | 1 |
| Horiuchi, I | 1 |
| Machino, T | 1 |
| Kusakabe, T | 1 |
| Hirayama, Y | 1 |
| Mihara, H | 1 |
| Yamakage, M | 1 |
| Kato, J | 1 |
| Nishisato, T | 1 |
| Ishitani, K | 1 |
| Iwamoto, M | 1 |
| Higashi, T | 1 |
| Miura, H | 1 |
| Kawaguchi, T | 1 |
| Tanaka, S | 1 |
| Yamashita, I | 1 |
| Yoshida, S | 4 |
| Bortolussi, R | 1 |
| Zotti, P | 1 |
| Matovic, M | 1 |
| Morabito, A | 1 |
| Bertuzzi, C | 1 |
| Caserta, M | 1 |
| Fabiani, F | 1 |
| Fracasso, A | 1 |
| Santantonio, C | 1 |
| Zanier, C | 1 |
| Roscetti, A | 1 |
| Polesel, J | 1 |
| Gussetti, D | 1 |
| Bedin, S | 1 |
| Colussi, AM | 1 |
| Fantin, D | 1 |
| Bista, SR | 1 |
| Haywood, A | 1 |
| Norris, R | 1 |
| Good, P | 1 |
| Tapuni, A | 1 |
| Lobb, M | 1 |
| Hardy, J | 1 |
| Tayjasanant, S | 1 |
| Heung, Y | 1 |
| Wu, J | 1 |
| Yennurajalingam, S | 1 |
| de la Cruz, M | 1 |
| Rodriguez, EM | 1 |
| Waletich, J | 1 |
| Arthur, J | 1 |
| Holmes, C | 1 |
| Tallie, K | 1 |
| Wong, A | 1 |
| Rogríguez, D | 1 |
| Urrutia, G | 1 |
| Escobar, Y | 2 |
| Murillo, M | 1 |
| Wei, W | 1 |
| Tian, Y | 1 |
| Zhao, C | 1 |
| Sui, Z | 1 |
| Liu, C | 1 |
| Wang, C | 1 |
| Oosten, AW | 1 |
| Abrantes, JA | 1 |
| Jönsson, S | 1 |
| de Bruijn, P | 1 |
| Kuip, EJ | 2 |
| Falcão, A | 1 |
| van der Rijt, CC | 3 |
| Mathijssen, RH | 2 |
| Floriani, I | 1 |
| Montanari, M | 1 |
| Galli, F | 1 |
| Greco, MT | 1 |
| Dragani, TA | 1 |
| Azzarello, G | 1 |
| Luzzani, M | 1 |
| Cavanna, L | 1 |
| Bandieri, E | 2 |
| Gamucci, T | 1 |
| Lipari, G | 1 |
| Di Gregorio, R | 1 |
| Valenti, D | 1 |
| Reale, C | 2 |
| Pavesi, L | 1 |
| Iorno, V | 1 |
| Crispino, C | 1 |
| Pacchioni, M | 1 |
| Apolone, G | 1 |
| Garnock-Jones, KP | 1 |
| Meijler, WJ | 1 |
| Tanaka, R | 1 |
| Ishikawa, H | 1 |
| Sato, T | 1 |
| Shino, M | 1 |
| Matsumoto, T | 1 |
| Mori, K | 1 |
| Omae, K | 1 |
| Osaka, I | 1 |
| Lucyk, S | 1 |
| Nelson, L | 1 |
| Romualdi, P | 2 |
| Candeletti, S | 1 |
| Sako, A | 1 |
| Yoshikawa, Y | 1 |
| Kikuchi, N | 1 |
| Maeda, T | 1 |
| Hayakawa, T | 1 |
| Fanelli, G | 1 |
| Cortesi, PA | 1 |
| Pannuti, R | 1 |
| Peruselli, C | 1 |
| Ballantyne, JC | 1 |
| Shao, YJ | 1 |
| Liu, WS | 1 |
| Guan, BQ | 1 |
| Hao, JL | 1 |
| Ji, K | 1 |
| Cheng, XJ | 1 |
| Wang, K | 1 |
| Zandvliet, ML | 1 |
| Koolen, SL | 1 |
| Zin, CS | 1 |
| Rahman, NA | 1 |
| Ismail, CR | 1 |
| Choy, LW | 1 |
| Simon, ST | 1 |
| Kloke, M | 1 |
| Alt-Epping, B | 1 |
| Gärtner, J | 1 |
| Hellmich, M | 1 |
| Hein, R | 1 |
| Piel, M | 1 |
| Cornely, OA | 1 |
| Nauck, F | 2 |
| Voltz, R | 1 |
| Sande, TA | 1 |
| Laird, BJ | 1 |
| Fallon, MT | 2 |
| Ruan, X | 1 |
| Luo, JJ | 1 |
| Kaye, AD | 1 |
| Kanbayashi, Y | 2 |
| Hosokawa, T | 3 |
| Cho, HN | 1 |
| Oh, S | 1 |
| Lee, SS | 1 |
| Zecca, E | 1 |
| Brunelli, C | 2 |
| Centurioni, F | 1 |
| Manzoni, A | 1 |
| Pigni, A | 1 |
| Yamamoto, K | 2 |
| Kojima, M | 1 |
| Iguchi, H | 1 |
| Ohta, T | 1 |
| Von der Laage, D | 1 |
| Hoerauf, KH | 1 |
| Nolte, T | 3 |
| Petersen, R | 1 |
| Lundorff, L | 1 |
| Krenn, H | 1 |
| Rosland, JH | 1 |
| Saedder, EA | 1 |
| Jensen, NH | 1 |
| Hoy, SM | 1 |
| Keating, GM | 2 |
| Cuervo Pinna, MA | 1 |
| Mota Vargas, R | 1 |
| Redondo Moralo, MJ | 1 |
| Hair, PI | 1 |
| McKeage, K | 2 |
| Mathieu, N | 1 |
| Tuna, T | 1 |
| Wirz, S | 2 |
| Wittmann, M | 1 |
| Schenk, M | 2 |
| Schroeck, A | 1 |
| Schaefer, N | 1 |
| Mueller, M | 1 |
| Standop, J | 1 |
| Kloecker, N | 1 |
| Nadstawek, J | 1 |
| Dickman, A | 2 |
| Reid, C | 2 |
| Stevens, AM | 1 |
| Tirelli, W | 1 |
| Giarratano, A | 1 |
| Carmichael, M | 1 |
| Henig, S | 1 |
| Ogawa, J | 1 |
| Iizuka, K | 1 |
| Sekizuka, M | 1 |
| Horiuchi, R | 1 |
| Chiarolanza, A | 1 |
| Luppi, M | 1 |
| Magrini, N | 1 |
| Marata, AM | 1 |
| Ripamonti, C | 3 |
| Fulfaro, F | 4 |
| Weinstein, SM | 2 |
| Messina, J | 2 |
| Xie, F | 1 |
| Aurilio, C | 1 |
| Pace, MC | 1 |
| Pota, V | 1 |
| Sansone, P | 1 |
| Barbarisi, M | 1 |
| Grella, E | 1 |
| Passavanti, MB | 1 |
| Mätzke, S | 1 |
| Haakana, S | 1 |
| Gergov, M | 1 |
| Vuori, E | 1 |
| Kalso, E | 2 |
| Quigley, C | 2 |
| Bushnaq, M | 1 |
| Al-Shoubaki, M | 1 |
| Milhem, M | 1 |
| Gibbs, M | 1 |
| Sharma, SS | 1 |
| Sritharan, G | 1 |
| Mogos, M | 1 |
| Roffey, P | 2 |
| Thangathurai, D | 2 |
| Orońska, A | 1 |
| Kaczmarek, Z | 1 |
| Colberg, T | 2 |
| Takashina, Y | 2 |
| Mino, Y | 2 |
| Kagawa, Y | 2 |
| Sitte, T | 2 |
| Perkins, P | 1 |
| Camba, MA | 1 |
| Jacobsen, R | 1 |
| Møldrup, C | 1 |
| Chiou, TJ | 1 |
| Liu, CY | 1 |
| Tzeng, WF | 1 |
| Su, YC | 1 |
| Weng, YC | 1 |
| Hung, CJ | 1 |
| Tang, Y | 1 |
| Chen, YJ | 1 |
| Prommer, E | 1 |
| Rauck, RL | 2 |
| Tark, M | 1 |
| Reyes, E | 1 |
| Hayes, TG | 1 |
| Bartkowiak, AJ | 1 |
| Hassman, D | 3 |
| Nalamachu, S | 2 |
| Derrick, R | 3 |
| Howell, J | 4 |
| North, J | 1 |
| Gever, LN | 1 |
| Tagarro, I | 2 |
| Finn, AL | 1 |
| Lennernäs, B | 2 |
| Frank-Lissbrant, I | 1 |
| Lennernäs, H | 2 |
| Kälkner, KM | 1 |
| Grape, S | 1 |
| Schug, SA | 1 |
| Lauer, S | 1 |
| Schug, BS | 1 |
| Van Nimmen, NF | 1 |
| Poels, KL | 1 |
| Menten, JJ | 1 |
| Godderis, L | 1 |
| Veulemans, HA | 1 |
| Vissers, D | 1 |
| Stam, W | 1 |
| Lenre, M | 1 |
| Jansen, J | 1 |
| Kim, DY | 1 |
| Song, HS | 1 |
| Ahn, JS | 1 |
| Ryoo, BY | 1 |
| Shin, DB | 1 |
| Yim, CY | 1 |
| Kim, SY | 1 |
| Hoya, Y | 1 |
| Okamoto, T | 1 |
| Yanaga, K | 1 |
| Lossignol, DA | 1 |
| Dumitrescu, C | 1 |
| Ljuca, D | 1 |
| Yang, Q | 1 |
| Xie, DR | 1 |
| Jiang, ZM | 1 |
| Ma, W | 1 |
| Zhang, YD | 1 |
| Bi, ZF | 1 |
| Chen, DL | 1 |
| Nomura, M | 2 |
| Kamata, M | 2 |
| Kojima, H | 2 |
| Hayashi, K | 2 |
| Kozai, M | 1 |
| Sawada, S | 2 |
| Mahfudh, SS | 1 |
| Panagiotou, I | 2 |
| Mystakidou, K | 6 |
| Bakshi, SG | 1 |
| Jain, PN | 1 |
| Sareen, R | 1 |
| Portenoy, RK | 7 |
| Burton, AW | 1 |
| Gabrail, N | 2 |
| Hagelberg, NM | 1 |
| Olkkola, KT | 1 |
| Miyazaki, T | 3 |
| Namiki, A | 2 |
| Ogawa, S | 2 |
| Kitajima, T | 2 |
| Masuda, Y | 2 |
| Iwao, Y | 1 |
| Iseki, M | 2 |
| Hashizume, T | 2 |
| Ferrera, P | 8 |
| Arcuri, E | 1 |
| Jarlbaek, L | 1 |
| Kehlet, H | 1 |
| Chwieduk, CM | 1 |
| Wallace, MS | 2 |
| Dumble, S | 1 |
| Yamada, Y | 2 |
| Yago, K | 3 |
| Andersen, S | 1 |
| Damkier, A | 1 |
| Vejlgaard, T | 1 |
| Sjolund, KF | 1 |
| Stenberg, M | 1 |
| Yoshino, K | 1 |
| Nishiumi, N | 1 |
| Yamamoto, S | 1 |
| Mikami, M | 1 |
| Iwasaki, M | 1 |
| Tokuda, Y | 1 |
| Cachia, E | 1 |
| Ahmedzai, SH | 3 |
| Elsner, F | 3 |
| Espinosa, J | 1 |
| Brooks, D | 4 |
| Kawano, C | 1 |
| Hirayama, T | 1 |
| Kuroyama, M | 1 |
| Hanaoka, K | 3 |
| Yoshimura, T | 2 |
| Tomioka, T | 2 |
| Sakata, H | 2 |
| Hata, A | 1 |
| Nanjo, S | 1 |
| Otsuka, K | 2 |
| Kaji, R | 1 |
| Fujita, S | 1 |
| Iwamori, S | 1 |
| Mifune, Y | 1 |
| Orita, H | 1 |
| Fukae, M | 1 |
| Yamatani, T | 1 |
| Gatti, A | 2 |
| Luis Lerzo, G | 1 |
| Fujimoto, S | 1 |
| Konishi, H | 2 |
| Otsuji, E | 1 |
| Yoshikawa, T | 1 |
| Miki, T | 1 |
| Taniwaki, M | 1 |
| Kessler, J | 1 |
| Kim, MH | 1 |
| Park, H | 1 |
| Park, EC | 1 |
| Überall, MA | 1 |
| Müller-Schwefe, GH | 1 |
| Gouliamos, A | 1 |
| Lyseng-Williamson, KA | 1 |
| Garbe, E | 1 |
| Schmid, U | 1 |
| Loeser, B | 1 |
| Zöllner, C | 1 |
| Porta-Sales, J | 1 |
| O'Bryant, CL | 1 |
| Linnebur, SA | 1 |
| Yamashita, TE | 1 |
| Kutner, JS | 1 |
| Núñez-Olarte, JM | 1 |
| Alvarez-Jiménez, P | 1 |
| Nalamachu, SR | 1 |
| Yagi, T | 1 |
| Ohnishi, K | 1 |
| Taylor, DR | 1 |
| Yamazaki, K | 1 |
| Fujio, N | 1 |
| Ishikawa, N | 1 |
| Kameyama, M | 1 |
| Lo Presti, C | 1 |
| Reynolds, L | 1 |
| Geach, J | 1 |
| Bull, J | 1 |
| Scherlis, M | 1 |
| Yamaguchi, Y | 1 |
| Yoneta, E | 1 |
| Kunimori, K | 1 |
| Ebinuma, K | 1 |
| Takayanagi, R | 1 |
| Kaessner, N | 1 |
| Nave, R | 1 |
| Roepcke, S | 1 |
| Facius, A | 1 |
| Lahu, G | 1 |
| Alkan, I | 1 |
| Anghelescu, DL | 1 |
| Burgoyne, LL | 1 |
| Faughnan, LG | 1 |
| Hankins, GM | 1 |
| Smeltzer, MP | 1 |
| Pui, CH | 1 |
| Ripamonti, CI | 1 |
| Ibrahim, NY | 1 |
| Abou-Elela, EN | 1 |
| Hisada, T | 1 |
| Katoh, M | 1 |
| Hitoshi, K | 1 |
| Kondo, Y | 1 |
| Fujioka, M | 1 |
| Toyama, Y | 1 |
| Ieda, H | 1 |
| Gocho, S | 1 |
| Nadai, M | 1 |
| Meriggi, F | 1 |
| Zaniboni, A | 1 |
| Mañas, A | 1 |
| Juliá, J | 1 |
| Gálvez, R | 1 |
| Zaragozá, F | 1 |
| Margarit, C | 1 |
| López, R | 1 |
| Casas, A | 1 |
| Antón, A | 1 |
| Cruz, JJ | 1 |
| Takakuwa, O | 1 |
| Oguri, T | 1 |
| Maeno, K | 1 |
| Yokoyama, M | 1 |
| Hijikata, H | 1 |
| Uemura, T | 1 |
| Ozasa, H | 1 |
| Ohkubo, H | 1 |
| Miyazaki, M | 1 |
| Niimi, A | 1 |
| Bulloch, MN | 1 |
| Hutchison, AM | 1 |
| Mitra, F | 1 |
| Chowdhury, S | 1 |
| Shelley, M | 1 |
| Williams, G | 1 |
| Inoue, K | 1 |
| Matsushita, S | 1 |
| Takahari, D | 1 |
| Kondoh, C | 1 |
| Shitara, K | 1 |
| Ura, T | 1 |
| Tatematsu, M | 1 |
| Hosoda, R | 2 |
| Oka, H | 1 |
| Muro, K | 1 |
| Hwang, IC | 1 |
| Park, SM | 1 |
| Wiese, CH | 1 |
| Zimmermann, M | 2 |
| Junker, U | 1 |
| Heuser-Grannemann, E | 1 |
| Enting, RH | 1 |
| Oldenmenger, WH | 1 |
| Wilms, EB | 1 |
| Elfrink, EJ | 1 |
| Elswijk, I | 1 |
| Sillevis Smitt, PA | 1 |
| Rees, E | 1 |
| McNamara, P | 1 |
| Menten, J | 1 |
| Desmedt, M | 1 |
| Lossignol, D | 1 |
| Mullie, A | 1 |
| Farrar, JT | 3 |
| Berlin, JA | 1 |
| Strom, BL | 1 |
| Kornick, CA | 2 |
| Santiago-Palma, J | 4 |
| Schulman, G | 1 |
| O'Brien, PC | 1 |
| Weigand, S | 1 |
| Payne, R | 10 |
| Manfredi, PL | 3 |
| Hall, S | 1 |
| Gallagher, RM | 1 |
| Gracely, E | 1 |
| Knowlton, C | 1 |
| Wescules, D | 1 |
| Ross, JR | 1 |
| Tsilika, E | 4 |
| Parpa, E | 2 |
| Kouloulias, V | 2 |
| Kouvaris, I | 1 |
| Georgaki, S | 3 |
| Vlahos, L | 4 |
| Morita, T | 2 |
| Tei, Y | 1 |
| Inoue, S | 1 |
| Soares, LG | 1 |
| Martins, M | 1 |
| Uchoa, R | 1 |
| Baik, SW | 1 |
| Kim, KH | 1 |
| Kim, YC | 1 |
| Lee, SC | 1 |
| Kim, DK | 1 |
| Jung, JE | 1 |
| van Seventer, R | 1 |
| Smit, JM | 1 |
| Schipper, RM | 1 |
| Wicks, MA | 1 |
| Zuurmond, WW | 1 |
| Regnard, C | 1 |
| Pelham, A | 1 |
| Yu, SY | 1 |
| Sun, Y | 1 |
| Zhang, HC | 1 |
| Wu, YL | 1 |
| Qin, SK | 1 |
| Xie, GR | 1 |
| Liu, SJ | 1 |
| Sui, G | 1 |
| Yoshizawa, A | 2 |
| Gyouda, Y | 2 |
| Ishiguro, T | 2 |
| Yoshizawa, T | 2 |
| Berger, A | 1 |
| Hoffman, DL | 1 |
| Goodman, S | 1 |
| Delea, TE | 1 |
| Seifeldin, R | 1 |
| Oster, G | 1 |
| Wootton, M | 1 |
| Johansson, H | 1 |
| Arnér, S | 1 |
| Tawfik, MO | 1 |
| Bryuzgin, V | 1 |
| Kourteva, G | 1 |
| Katsouda, E | 1 |
| Kouvaris, J | 1 |
| Kato, K | 1 |
| Mizaki, T | 1 |
| Yamazaki, S | 1 |
| Nitta, M | 1 |
| Hasegawa, M | 1 |
| Kamiya, Y | 1 |
| Baudelet, C | 1 |
| Gallez, B | 1 |
| Clark, AJ | 1 |
| Allan, LG | 1 |
| Camacho, F | 1 |
| Horbay, GL | 1 |
| Richarz, U | 1 |
| Simpson, K | 1 |
| Rhiner, M | 3 |
| Palos, G | 1 |
| Termini, M | 1 |
| Feria, M | 1 |
| Salinas-Martín, A | 1 |
| Martínez-Castillo, LP | 1 |
| Martín-Ortega, JJ | 1 |
| Walsh, D | 1 |
| Hanks, GW | 4 |
| Nugent, M | 2 |
| Higgs, CM | 1 |
| Busch, MA | 5 |
| Hedner, T | 1 |
| Holmberg, M | 1 |
| Bredenberg, S | 1 |
| Nyström, C | 1 |
| Welsh, J | 1 |
| Reid, A | 1 |
| Graham, J | 1 |
| Curto, J | 1 |
| MacLeod, K | 1 |
| O'Neill, C | 1 |
| Hattori, S | 1 |
| Kimura, N | 1 |
| Takatani, J | 1 |
| Noguchi, T | 1 |
| Guest, JF | 1 |
| Ruiz, FJ | 1 |
| Russ, J | 1 |
| Gupta, RD | 1 |
| Mihai, A | 1 |
| Greener, M | 1 |
| Sittl, R | 4 |
| Likar, R | 1 |
| Nautrup, BP | 2 |
| Gelfand, MJ | 1 |
| O'hara, SM | 1 |
| Curtwright, LA | 1 |
| Maclean, JR | 1 |
| Onishi, H | 1 |
| Tajima, T | 1 |
| Tani, K | 1 |
| Matsubara, T | 1 |
| Miyoshi, I | 1 |
| Ikenaga, M | 1 |
| Akechi, T | 1 |
| Uchitomi, Y | 1 |
| Solassol, I | 2 |
| Bressolle, F | 2 |
| Caumette, L | 2 |
| Garcia, F | 2 |
| Poujol, S | 1 |
| Culine, S | 2 |
| Pinguet, F | 2 |
| Thézenas, S | 1 |
| Astre, C | 1 |
| Coulouma, R | 1 |
| Nuijten, M | 2 |
| Yajima, Y | 1 |
| Narita, M | 1 |
| Ozaki, M | 1 |
| Niikura, K | 1 |
| Suzuki, T | 1 |
| Ishihara, C | 1 |
| Chiba, M | 1 |
| Endo, Y | 1 |
| Yamaji, A | 1 |
| McGregor, A | 1 |
| Lidstone, V | 1 |
| Owen, R | 1 |
| Ribeiro, MD | 1 |
| Yamazaki, M | 1 |
| Aoki, T | 1 |
| Tachibana, M | 1 |
| Akashi, T | 1 |
| Fagnoni, E | 1 |
| Campa, T | 1 |
| De Conno, F | 2 |
| Gordon, DB | 1 |
| Skaer, TL | 1 |
| Coopman, V | 1 |
| Cordonnier, J | 1 |
| Pien, K | 1 |
| Van Varenbergh, D | 1 |
| Fisher, K | 2 |
| Stiles, C | 1 |
| Heim, B | 1 |
| Hagen, NA | 2 |
| Llanes, LR | 1 |
| Fassbender, K | 1 |
| Baracos, VE | 1 |
| Watanabe, S | 2 |
| Dahan, A | 1 |
| Chinellato, A | 1 |
| Terrazzani, G | 1 |
| Debetto, P | 1 |
| Zambon, P | 1 |
| Guzzinati, S | 1 |
| Walley, T | 1 |
| Giusti, P | 1 |
| Poulsen Nautrup, B | 1 |
| Barone, G | 1 |
| Liotti, L | 1 |
| Chiaretti, A | 1 |
| Lazzareschi, I | 1 |
| Riccardi, R | 1 |
| Carreyrou, J | 1 |
| Potter, MB | 1 |
| Blick, SK | 1 |
| Wagstaff, AJ | 2 |
| Kömürcü, S | 1 |
| Turhal, S | 1 |
| Altundağ, K | 1 |
| Atahan, L | 1 |
| Turna, HS | 1 |
| Manavoğlu, O | 1 |
| Yavuz, AA | 1 |
| Ozkök, S | 1 |
| Aliustaoğlu, M | 1 |
| Altinbaş, M | 1 |
| Pak, Y | 1 |
| Cooper, R | 1 |
| Yaylaci, M | 1 |
| Demirkan, B | 1 |
| Sarihan, S | 1 |
| Ozdemir, F | 1 |
| Victorino, C | 1 |
| Akiyama, Y | 1 |
| Izawa, R | 1 |
| Ishii, K | 1 |
| Tani, Y | 1 |
| Gambaro, V | 1 |
| Clemens, KE | 1 |
| Klaschik, E | 1 |
| Mangione, S | 3 |
| Intravaia, G | 2 |
| Tomiyasu, S | 1 |
| Harada, A | 1 |
| Verna, L | 2 |
| Riina, S | 2 |
| Lecybyl, R | 1 |
| Hanna, M | 2 |
| Darwish, M | 2 |
| Kirby, M | 1 |
| Robertson, P | 1 |
| Tracewell, W | 1 |
| Jiang, JG | 1 |
| Rigler, SK | 1 |
| Shireman, TI | 1 |
| Kallenbach, L | 1 |
| Tsiatas, M | 1 |
| Laverty, D | 2 |
| Marinangeli, F | 1 |
| Ciccozzi, A | 1 |
| Aloisio, L | 1 |
| Colangeli, A | 1 |
| Paladini, A | 1 |
| Bajocco, C | 1 |
| Coaccioli, S | 1 |
| Varrassi, G | 1 |
| Yasuhara, H | 1 |
| Hewitt, M | 1 |
| Goldman, A | 1 |
| Collins, GS | 1 |
| Childs, M | 1 |
| Hain, R | 1 |
| Fine, PG | 4 |
| Okazaki, M | 1 |
| Hoka, S | 2 |
| Bryan, M | 1 |
| De La Rosa, N | 1 |
| Hill, AM | 1 |
| Amadio, WJ | 1 |
| Wieder, R | 1 |
| Gebbia, V | 1 |
| Tassinari, D | 1 |
| Sartori, S | 1 |
| Tamburini, E | 1 |
| Scarpi, E | 1 |
| Raffaeli, W | 1 |
| Tombesi, P | 1 |
| Markman, JD | 1 |
| Ishida, T | 1 |
| Nogami, S | 1 |
| Mashimo, S | 1 |
| Delgado-Guay, MO | 1 |
| Gordon, D | 1 |
| Schroeder, M | 1 |
| Müller, H | 1 |
| Börner, U | 1 |
| Stoyanov, M | 1 |
| Gleumes, L | 1 |
| Hempelmann, G | 1 |
| Lees, DE | 1 |
| Kim, YD | 1 |
| Bull, JM | 1 |
| Whang-Peng, J | 1 |
| Schuette, W | 1 |
| Smith, R | 1 |
| Macnamara, TE | 1 |
| Southam, MA | 2 |
| Donner, B | 3 |
| Zenz, M | 3 |
| Zech, DF | 1 |
| Lehmann, KA | 4 |
| Singer, M | 1 |
| Noonan, KR | 1 |
| Abidin, MR | 1 |
| Arosarena, O | 1 |
| Koch, WM | 1 |
| Eisele, DW | 1 |
| Korte, W | 3 |
| Morant, R | 2 |
| Sorrell, DC | 1 |
| Patt, RB | 2 |
| Hogan, LA | 2 |
| Rose, PG | 1 |
| Macfee, MS | 1 |
| Boswell, MV | 1 |
| Gupta, SK | 2 |
| Lapin, J | 2 |
| Layman, M | 1 |
| Foley, KM | 1 |
| Kaiko, RF | 1 |
| Beilin, B | 1 |
| Shavit, Y | 1 |
| Hart, J | 1 |
| Mordashov, B | 1 |
| Cohn, S | 1 |
| Notti, I | 1 |
| Bessler, H | 1 |
| Paix, A | 1 |
| Coleman, A | 1 |
| Lees, J | 1 |
| Grigson, J | 1 |
| Brooksbank, M | 2 |
| Thorne, D | 2 |
| Ashby, M | 1 |
| Miller, RS | 1 |
| Peterson, GM | 1 |
| Abbott, F | 1 |
| Maddocks, I | 1 |
| Parker, D | 1 |
| McLean, S | 1 |
| Tryba, M | 1 |
| Strumpf, M | 2 |
| Marquardt, KA | 1 |
| Tharratt, RS | 1 |
| Musallam, NA | 1 |
| de Stoutz, N | 1 |
| Leelanuntakit, S | 1 |
| Fainsinger, RL | 1 |
| Krossnes, BK | 1 |
| Mella, O | 1 |
| Dahl, O | 1 |
| Hammack, JE | 1 |
| Mailliard, JA | 1 |
| Loprinzi, CL | 1 |
| Rospond, RM | 1 |
| O'Fallon, JR | 1 |
| Wilwerding, MB | 1 |
| Reuter, NF | 1 |
| Michalak, JC | 1 |
| Fidler, P | 1 |
| Miser, AW | 2 |
| Sachs, H | 1 |
| Uhl, M | 1 |
| Hege-Scheuing, G | 1 |
| Schneider, E | 1 |
| Woodroffe, MA | 1 |
| Hays, H | 2 |
| Ahmedzai, S | 2 |
| Ferrell, BR | 1 |
| McCaffery, M | 3 |
| Yeo, W | 1 |
| Lam, KK | 1 |
| Chan, AT | 1 |
| Leung, TW | 1 |
| Nip, SY | 1 |
| Johnson, PJ | 1 |
| Wong, JO | 1 |
| Chiu, GL | 1 |
| Tsao, CJ | 1 |
| Chang, CL | 1 |
| Polastri, D | 1 |
| Kanagasundaram, SA | 1 |
| Cooper, MG | 1 |
| Lane, LJ | 1 |
| Pasero, CL | 2 |
| Mathias, SD | 1 |
| Pasta, DJ | 1 |
| Wanke, LA | 1 |
| Williams, R | 1 |
| Mahmoud, R | 1 |
| Cleary, J | 1 |
| Busch, M | 1 |
| Nordbrock, E | 3 |
| Bral, EE | 1 |
| Raber, M | 1 |
| Hardy, JR | 1 |
| Rees, EA | 1 |
| Curtiss, CP | 1 |
| Sloan, PA | 1 |
| Moulin, DE | 1 |
| Christie, JM | 1 |
| Simmonds, M | 2 |
| Patt, R | 1 |
| Coluzzi, P | 3 |
| Pereira, J | 1 |
| Hanson, J | 1 |
| Ashby, MA | 1 |
| Martin, P | 1 |
| Jackson, KA | 1 |
| Collins, JJ | 1 |
| Dunkel, IJ | 1 |
| Palmer, LN | 1 |
| Raschko, JW | 1 |
| Lyss, A | 2 |
| Frigerio, V | 1 |
| Ingham, J | 1 |
| Loseth, DB | 2 |
| Hunt, R | 1 |
| Fazekas, B | 1 |
| Kedziera, P | 2 |
| Vielvoye-Kerkmeer, AP | 1 |
| Mattern, C | 1 |
| Uitendaal, MP | 1 |
| Loick, G | 1 |
| Kulbe, C | 1 |
| Kasper, M | 1 |
| Grond, S | 2 |
| Breitbart, W | 1 |
| Chandler, S | 1 |
| Eagel, B | 1 |
| Ellison, N | 1 |
| Enck, RE | 1 |
| Lefkowitz, M | 1 |
| Besova, N | 1 |
| Gorbounova, V | 1 |
| Saltanov, A | 1 |
| Zarouk, V | 1 |
| Luczak, J | 1 |
| Gorzelińska, L | 1 |
| Kozikowska, J | 1 |
| Borgbjerg, FM | 1 |
| Rosenberg, J | 1 |
| Makin, MK | 1 |
| Conno, F | 1 |
| Cherny, N | 1 |
| McQuay, HJ | 1 |
| Meynadier, J | 2 |
| Casas, JR | 1 |
| Sawe, J | 1 |
| Twycross, RG | 1 |
| Ventafridda, V | 1 |
| Coluzzi, PH | 1 |
| Schwartzberg, L | 1 |
| Conroy, JD | 1 |
| Charapata, S | 1 |
| Gay, M | 1 |
| Chavez, J | 1 |
| Ashley, J | 1 |
| Lebo, D | 1 |
| McCracken, M | 1 |
| Davis, C | 1 |
| D'Olimpio, J | 1 |
| Gardner-Nix, J | 1 |
| Hart, L | 1 |
| Berris, R | 1 |
| Nordbrook, E | 1 |
| Murakami, S | 1 |
| Khojainova, N | 2 |
| Kornick, C | 2 |
| Fischberg, DJ | 1 |
| Primavera, LH | 2 |
| Manfredi, P | 1 |
| Muijsers, RB | 1 |
| Befon, S | 1 |
| Dardoufas, K | 1 |
| Laval, G | 1 |
| Sang, B | 1 |
| Mallaret, M | 1 |
| Villard, ML | 1 |
| Gourlay, GK | 1 |
| Burton, A | 1 |
| Kefalianakis, F | 1 |
| Kugler, M | 1 |
| van der Auwera, R | 1 |
| Kugler, G | 1 |
| Derby, S | 1 |
| Fischberg, D | 1 |
| Fusté I Gamisans, M | 1 |
| Busquet Duran, X | 1 |
| Benítez Del Rosario, MA | 1 |
| Pérez Suárez, MC | 1 |
| Fernández Díaz, R | 1 |
| Cabrejas Sánchez, A | 1 |
| Petzke, F | 1 |
| Brunsch-Radbruch, A | 1 |
| Verhaeghe, J | 1 |
| Declercq, M | 1 |
| Beaucaire-Beal, J | 1 |
| Beague, D | 1 |
| Abe, M | 1 |
| Takahashi, M | 1 |
| Yabumoto, E | 1 |
| Onoyama, Y | 1 |
| Torizuka, K | 1 |
| Zech, DFJ | 1 |
| Grond, SUA | 1 |
| Lynch, J | 1 |
| Dauer, HG | 1 |
| Stollenwerk, B | 1 |
| Meignier, M | 1 |
| Ganansia, MF | 1 |
| Lejus, C | 1 |
| Testa, S | 1 |
| Simmonds, MA | 1 |
| Richenbacher, J | 1 |
| Slover, R | 1 |
| Levy, MH | 1 |
| Rosen, SM | 1 |
| Herbst, LH | 1 |
| Strause, LG | 1 |
| Maves, TJ | 1 |
| Barcellos, WA | 1 |
| Sandler, ES | 1 |
| Weyman, C | 2 |
| Conner, K | 2 |
| Reilly, K | 2 |
| Dickson, N | 2 |
| Luzins, J | 2 |
| McGorray, S | 1 |
| Mosser, KH | 1 |
| Sandler, E | 1 |
| Calis, KA | 1 |
| Kohler, DR | 1 |
| Corso, DM | 1 |
| Marcus, M | 1 |
| De Boer, JA | 1 |
| Van der Oord, B | 1 |
| Narang, PK | 1 |
| Dothage, JA | 1 |
| Young, RC | 1 |
| Sindelar, W | 1 |
| Miser, JS | 1 |
| Ashburn, MA | 1 |
| Stanley, TH | 1 |
| Ganta, R | 1 |
| Campbell, IT | 1 |
| Mostafa, SM | 1 |
| Monchenko, GD | 1 |
| Veniavskiĭ, AN | 1 |
| Manni, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units[NCT02840500] | 101 participants (Actual) | Observational | 2016-06-27 | Completed | |||
| A Randomized Trial to Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain in Cancer Patients in the Emergency Department Setting[NCT02459964] | Phase 4 | 84 participants (Actual) | Interventional | 2015-09-14 | Completed | ||
| Morphine or Fentanyl for Refractory Dyspnea in COPD[NCT03834363] | Phase 4 | 60 participants (Anticipated) | Interventional | 2019-11-15 | Recruiting | ||
| The Role of Vitamin D3 Supplementation in Advanced Cancer Patients With Pain[NCT05450419] | 80 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| Clinical Evaluation of the Efficacy of Methylnaltrexone in Resolving Constipation Induced by Different Opioid Subtypes, Combined With Laboratory Analysis of Immunomodulatory and Antiangiogenic Effects of Methylnaltrexone[NCT01955213] | 7 participants (Actual) | Observational | 2012-07-31 | Terminated | |||
| Effects of Prophylactic Subcutaneous Fentanyl on Exercise-Induced Breakthrough Dyspnea in Cancer Patients: A Preliminary Double-Blind, Randomized Controlled Trial[NCT01515566] | Phase 1/Phase 2 | 26 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| A Double Blind, Active Controlled Crossover Study to Evaluate the Efficacy and Safety of Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for the Management of Breakthrough Pain in Opioid Tolerant Patients With Chronic Pain[NCT00813488] | Phase 3 | 213 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain in Gynecologic Cancer Patients With Chronic Cancer Pain : A Randomized Double Blind Controlled Trial[NCT05037539] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2021-06-15 | Completed | ||
| Randomized, Placebo-controlled Study of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer[NCT01842893] | Phase 3 | 91 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Phase III Study of KW-2246 (A Double Blind Study of KW-2246 Compared to Placebo for Breakthrough Pain Episodes in Cancer Patients)[NCT01326689] | Phase 3 | 42 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients[NCT00684632] | Phase 3 | 51 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| An Observational Study to Assess the Efficacy, Safety, and Tolerability of Abstral Oral Disintegrating Tablet (ODT) for the Management of Breakthrough Cancer Pain in Korean Cancer Patients[NCT03895762] | 143 participants (Actual) | Observational | 2017-07-04 | Completed | |||
| A Dose Titrated Clinical Trial With a Placebo-controlled, Double-blind, Randomised, Cross-over Phase to Demonstrate the Efficacy of 400 μg Intranasal Fentanyl (INFS) Dose Strength, and to Evaluate 12 Weeks Safety and Nasal Tolerability of All Dose Strengt[NCT01429051] | Phase 3 | 46 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.[NCT01809106] | Phase 4 | 518 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Preliminary Study of Prophylactic Fentanyl Pectin Nasal Spray (FPNS) for Exercise-Induced Breakthrough Dyspnea[NCT01832402] | Phase 2 | 35 participants (Actual) | Interventional | 2013-06-11 | Completed | ||
| A Prospective Study Comparing the Efficacy and Safety of 100 mcg and 200 mcg of Intranasal Fentanyl Pectin Spray as an Analgesic in Adult Males Undergoing Outpatient Cystoscopic Procedures[NCT01756651] | Phase 1 | 20 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| An Open Label, Comparative, Randomised, Balanced Crossover Trial Comparing Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq®) in Breakthrough Pain in Patients With Cancer[NCT00496392] | Phase 3 | 115 participants (Anticipated) | Interventional | 2007-01-31 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients.[NCT00262678] | Phase 3 | 0 participants | Interventional | 2005-12-31 | Completed | ||
| Fentanyl Buccal Soluble Films Feasible Dose Range Study for Breakthrough Pain in Taiwanese Cancer Patients[NCT03669263] | 36 participants (Actual) | Interventional | 2014-11-25 | Completed | |||
| A Randomized Trial of Intranasal Fentanyl Versus Placebo as an Adjunct to Lidocaine Infiltration in Adults Undergoing Abscess Incision and Drainage in the Emergency[NCT03872700] | Phase 3 | 49 participants (Actual) | Interventional | 2019-08-01 | Completed | ||
| A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakthrough Pain in Cancer Patients[NCT00263575] | Phase 3 | 139 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Survey of Knowledge and Attitude of Pain in Anesthesia Residents of Thailand[NCT05369923] | 140 participants (Anticipated) | Observational | 2022-10-01 | Not yet recruiting | |||
| The Pharmacokinetics of Fentanyl in Intensive Care Patients[NCT02587273] | Phase 4 | 150 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain[NCT00538850] | Phase 3 | 130 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
| Ilioinguinal/Iliohypogastric vs. Quadratus Lumborum Nerve Blockade for Elective Open Inguinal Herniorrhaphy[NCT03007966] | Phase 2 | 60 participants (Actual) | Interventional | 2017-01-30 | Completed | ||
| Randomized Trial Comparing Anchorsure® Suture Anchoring System and the CapioTM Slim Suture Capturing Device for Sacrospinous Ligament Suspension.[NCT03565640] | 48 participants (Actual) | Interventional | 2018-10-29 | Completed | |||
| Evaluation of Ultrasound-Guided Adductor Canal Blockade for Postoperative Analgesia Following Robotic Medial Unicompartmental Knee Replacement[NCT01818531] | Phase 4 | 150 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain: A Randomized, Double-Blind Study[NCT00525967] | Phase 2/Phase 3 | 50 participants (Anticipated) | Interventional | 2006-02-28 | Recruiting | ||
| Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain[NCT01946555] | 150 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| Effects of Anesthetic Technique on Natural Killer Cell Population and Cytotoxicity[NCT02669186] | 20 participants (Anticipated) | Interventional | 2019-07-10 | Enrolling by invitation | |||
| Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease[NCT01326325] | Phase 3 | 24 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The median change in Numeric Rating Scale (NRS) pain intensity scores (assessed on an 11-point Likert scale with 0 = no pain and 10 = worst pain) from randomization, estimate of treatment initiation, to one hour post-treatment calculated for both treatment arms. (NCT02459964)
Timeframe: Baseline, One hour post time of drug delivery/treatment initiation
| Intervention | NRS Pain Intensity Score (Median) |
|---|---|
| Treatment Arm 1 (Intranasal Fentanyl) | 5.14 |
| Treatment Arm 2 (Intravenous Hydromorphone) | 4.90 |
Change in NRS pain intensity scores from randomization to one hour after treatment start based on the percentage of participants with severe pain, NRS score = 7-10, one hour after treatment start for both treatment arms. Numeric Rating Scale (NRS) pain intensity scores (assessed on an 11-point Likert scale with 0 = no pain and 10 = worst pain). (NCT02459964)
Timeframe: One (1) hour after treatment start.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm 1 (Intranasal Fentanyl) | 5 |
| Treatment Arm 2 (Intravenous Hydromorphone) | 10 |
Retention rate is defined as the percentage of subjects able to complete the study. (NCT01515566)
Timeframe: Baseline to study completion, up to 100 minutes.
| Intervention | percentage of participants (Number) |
|---|---|
| Fentanyl | 100 |
| Placebo | 100 |
Ambulatory patients with breakthrough dyspnea performed a baseline 6 minute walk test (6MWT), and then received either subcutaneous fentanyl or placebo 15 minutes before a second 6MWT. The change in walk distance was documented between the first and second 6MWT. (NCT01515566)
Timeframe: Baseline 6 minute walk test (6MWT) to second 6MWT, up to 100 minutes for study participation.
| Intervention | feet (Mean) | |
|---|---|---|
| Walk Distance (Baseline Walk Test) | Walk Distance (Second Walk Test) | |
| Fentanyl | 397.7 | 434.9 |
| Placebo | 399 | 417.9 |
"Participants receive either Fentanyl subcutaneous (SQ) 15 minutes before walking test, or Placebo (SQ) 15 minutes before walking test. During the study, trained research staff perform study assessments and monitor participant carefully throughout the study period. Six-minute walk tests were carried out following guidelines from the American Thoracic Society. The intensity of dyspnea at 0, 1, 2, 3, 4, 5 and 6 minute of each walk test were assessed using a validated numeric rating scale (NRS) ranging from 0 (no shortness of breath) to 10 (worst possible shortness of breath) and every 5 minutes during the rest period." (NCT01515566)
Timeframe: Baseline to 100 minutes for study participation.
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Dyspnea at 0 minutes (Baseline walk test) | Dyspnea at 6 minutes (Baseline walk test) | Dyspnea at 0 minutes (Second walk test) | Dyspnea at 6 minutes (Second walk test) | |
| Fentanyl | 2 | 6 | 1 | 4 |
| Placebo | 3 | 7 | 2 | 5 |
"The CGIC is a standardized tool that measures the change in a patient's overall status rating since the start of the open-label extension period, in the opinion of the clinician.~The 7-point scale includes very much worse=-3, much worse=-2, minimally worse=-1,no change=0, minimally improved=+1, much improved=+2, and very much improved=+3. Here it was assessed 2 months after the start of the open-label extension period.~The CGIC was completed by the clinicians at visits 7, 8, and 9 (or early termination)." (NCT00813488)
Timeframe: Two months after start of open-label extension period
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.4 |
| Standard of Care (SOC) | 0.7 |
"The CGIC is a standardized tool that measures the change in a patient's overall status rating since the start of the open-label extension period, in the opinion of the clinician.~The 7-point scale includes very much worse=-3, much worse=-2, minimally worse=-1,no change=0, minimally improved=+1, much improved=+2, and very much improved=+3. The CGIC was completed by the clinicians at visits 7, 8, and 9 (or early termination), which correspond to 1, 2, or 3 months after the start of the open-label extension period." (NCT00813488)
Timeframe: 3 months after start of open-label extension period
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.6 |
| Standard of Care (SOC) | 0.7 |
"The CGIC is a standardized tool that measures the change in a patient's overall status rating since the start of the open-label extension period, in the opinion of the clinician.~The 7-point scale includes very much worse=-3, much worse=-2, minimally worse=-1,no change=0, minimally improved=+1, much improved=+2, and very much improved=+3. The CGIC was completed by the clinicians at visits 7, 8, and 9 (or early termination)." (NCT00813488)
Timeframe: End of open-label extension period
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.4 |
| Standard of Care (SOC) | 0.7 |
"The CGIC is a standardized tool that measures the change in a patient's overall status rating since the start of the open-label extension period, in the opinion of the clinician.~The 7-point scale includes very much worse=-3, much worse=-2, minimally worse=-1,no change=0, minimally improved=+1, much improved=+2, and very much improved=+3. The CGIC was completed by the clinicians at visits 7, 8, and 9 (or early termination) which correspond to 1, 2, or 3 months after the start of the open-label extension period." (NCT00813488)
Timeframe: One month after start of open-label extension
| Intervention | Unit on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.4 |
| Standard of Care (SOC) | 0.6 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID10 is the difference between the PI score from the episode baseline (immediately prior to study drug administration) and 10 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 10 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | .35 |
| Immediate-release Oxycodone (OXY) | .29 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID15 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 15 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 15 minutes after dosing
| Intervention | Units on scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 0.88 |
| Immediate-release Oxycodone (OXY) | 0.76 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID30 is the difference between the PI score from the episode baseline (immediately prior to study drug administration) and 30 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 30 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 2.10 |
| Immediate-release Oxycodone (OXY) | 1.79 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID45 is the difference between the PI score from the episode baseline (immediately prior to study drug administration) and 45 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 45 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 3.13 |
| Immediate-release Oxycodone (OXY) | 2.85 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID5 is the difference between the PI score from the episode baseline (immediately prior to study drug administration) and 5 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 5 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | .08 |
| Immediate-release Oxycodone (OXY) | .06 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID60 is the difference between the PI score from the episode baseline (immediately prior to study drug administration) and 60 minutes after the administration of the study drug. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: Immediately pre-dose and 60 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 3.65 |
| Immediate-release Oxycodone (OXY) | 3.48 |
The PR score 5 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 5 minutes after treatment
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 0.11 |
| Immediate-release Oxycodone (OXY) | 0.10 |
The PR score 10 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 10 minutes after treatment with study drug
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 0.32 |
| Immediate-release Oxycodone (OXY) | 0.26 |
The PR score 15 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 15 minutes after treatment with study drug
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 0.68 |
| Immediate-release Oxycodone (OXY) | 0.56 |
The PR score 30 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 30 minutes after treatment with study drug
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.48 |
| Immediate-release Oxycodone (OXY) | 1.22 |
The PR score 45 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 45 minutes after treatment with study drug
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 2.14 |
| Immediate-release Oxycodone (OXY) | 1.90 |
The PR score 60 minutes after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). (NCT00813488)
Timeframe: 60 minutes after treatment with study drug
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 2.44 |
| Immediate-release Oxycodone (OXY) | 2.27 |
The PGIC is a standardized self-report tool that measures the change in a patient's overall status rating since the start of the open-label extension period. The 7-point scale includes very much worse= -3, much worse= -2, minimally worse= -1, no change=0, minimally improved= +1, much improved= +2, and very much improved= +3. This was assessed 1 month after start of the open-label extension period. (NCT00813488)
Timeframe: One month after start of open-label treatment
| Intervention | Unit on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.5 |
| Standard of Care (SOC) | 0.6 |
The PGIC is a standardized self-report tool that measures the change in a patient's overall status rating since the start of the open-label extension period. The 7-point scale includes very much worse= -3, much worse= -2, minimally worse= -1, no change=0, minimally improved= +1, much improved= +2, and very much improved= +3. Here it was assessed 2 months after the start of the open-label extension period. (NCT00813488)
Timeframe: 2 months after start of open-label extension period
| Intervention | Units on scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.5 |
| Standard of Care (SOC) | 0.8 |
The PGIC is a standardized self-report tool that measures the change in a patient's overall status rating since the start of the open-label extension period. The 7-point scale includes very much worse= -3, much worse= -2, minimally worse= -1, no change=0, minimally improved= +1, much improved= +2, and very much improved= +3. Here it was assessed 3 months after the start of the open-label extension period. (NCT00813488)
Timeframe: 3 months after start of open-label extension period
| Intervention | Units on scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.7 |
| Standard of Care (SOC) | 0.8 |
The PGIC is a standardized self-report tool that measures the change in a patient's overall status rating since the start of the open-label extension period. The 7-point scale includes very much worse= -3, much worse= -2, minimally worse= -1, no change=0, minimally improved= +1, much improved= +2, and very much improved= +3. Here it was assessed at the conclusion of the open-label extension period. (NCT00813488)
Timeframe: At conclusion of open-label extension period
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.5 |
| Standard of Care (SOC) | 0.9 |
The PR score at set intervals after the administration of study drug during the double-blind treatment phase was recorded in the patient's diary. The PR scale is a 5-point categorical scale of 0-4 (0=none, 1=slight, 2=moderate, 3=a lot, 4=complete). The maximum TOTPAR score that could be achieved at 60 minutes is equal to 16; thus, %TOTPAR at 60 minutes is (TOTPAR60 /16) x 100.The % TOTPAR achieved 60 minutes after the administration of study drug was calculated during the double-blind treatment phase. (NCT00813488)
Timeframe: From 5 minutes through 60 minutes after study drug treatment
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 40.11 |
| Immediate-release Oxycodone (OXY) | 35.59 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain. The PID10 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 10 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. This was assessed during the double-blind treatment period. (NCT00813488)
Timeframe: Immediately before treatment and 10 minutes after treatment.
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 4.83 |
| Immediate-release Oxycodone (OXY) | 3.89 |
Pain intensity (PI) scores were assessed during the double-blind treatment period on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain. The PID15 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 15 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. (NCT00813488)
Timeframe: Baseline (immediately pre-dose) and 15 minutes after dosing
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 12.38 |
| Immediate-release Oxycodone (OXY) | 10.38 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID30 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 30 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. (NCT00813488)
Timeframe: Pre-dose and 30 minutes after dosing
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 29.72 |
| Immediate-release Oxycodone (OXY) | 25.03 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID45 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 45 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. (NCT00813488)
Timeframe: Immediately pre-dose and 45 minutes after dosing
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 44.84 |
| Immediate-release Oxycodone (OXY) | 40.49 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID5 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 5 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. (NCT00813488)
Timeframe: Immediately pre-dose and 5 minutes after dosing
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1.01 |
| Immediate-release Oxycodone (OXY) | 0.73 |
Pain intensity (PI) scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine after each episode of breakthrough pain during the double-blind treatment period. The PID60 is the difference between the PI scores from the episode baseline (immediately prior to study drug administration)and 60 minutes after the administration of the study drug. The difference is calculated and assessed as a percentage of the baseline pain intensity score. (NCT00813488)
Timeframe: Immediately pre-dose and 60 minutes after dosing
| Intervention | Percentage change (Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 52.61 |
| Immediate-release Oxycodone (OXY) | 49.47 |
PI scores were assessed on an 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. SPID30 were derived from PID values. The SPID30 scores during the double-blind treatment phase were calculated as the time- weighted sum of the PID scores from 5 through 30 minutes,after the administration of study drug. SPID30 = (⅓ x PID5) + (⅓ x PID10) + (⅓ x PID15) + PID30. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry. (NCT00813488)
Timeframe: From 5 minutes after dosing through 30 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 2.54 |
| Immediate-release Oxycodone (OXY) | 2.16 |
"PI scores were assessed on an 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine during the double-blind treatment period. The SPID60 was derived from PID values. The SPID60 scores during the double-blind treatment phase were calculated as the time- weighted sum of the PID scores from 5 through 60 minutes,after the administration of the study drug.~SPID60 = SPID30 + PID45 + PID60. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry." (NCT00813488)
Timeframe: From 5 minutes after dosing through 60 minutes after dosing
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 9.32 |
| Immediate-release Oxycodone (OXY) | 8.50 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 5 minutes or less was compared. (NCT00813488)
Timeframe: From time study drug was taken until 5 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 55 |
| Immediate-release Oxycodone (OXY) | 50 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 10 minutes or less was compared. (NCT00813488)
Timeframe: From study drug treatment until 10 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 226 |
| Immediate-release Oxycodone (OXY) | 219 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 15 minutes or less was compared. (NCT00813488)
Timeframe: From study drug administration to 15 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 515 |
| Immediate-release Oxycodone (OXY) | 451 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 30 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug administration till 30 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1004 |
| Immediate-release Oxycodone (OXY) | 877 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 45 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug treatment until 45 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1217 |
| Immediate-release Oxycodone (OXY) | 1150 |
Time to APR (subjective perception of any reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No APR-rescue medication used, and No APR-no rescue medication used)the number of episodes which time to APR fell in that category was compared. Number of episodes where APR was achieved in 60 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug treatment until 60 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1271 |
| Immediate-release Oxycodone (OXY) | 1239 |
Time to MPR (subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point up to 60 minutes during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. (NCT00813488)
Timeframe: From time study drug was taken until 5 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 21 |
| Immediate-release Oxycodone (OXY) | 26 |
Time to MPR(subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. Number of episodes in which MPR was achieved in 10 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug treatment until 10 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 88 |
| Immediate-release Oxycodone (OXY) | 91 |
Time to MPR(subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. Number of episodes in which MPR was achieved in 15 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug administration until 15 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 230 |
| Immediate-release Oxycodone (OXY) | 212 |
Time to MPR(subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. Number of episodes in which MPR was achieved in 30 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug administration until 30 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 613 |
| Immediate-release Oxycodone (OXY) | 503 |
Time to MPR(subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. Number of episodes in which MPR was achieved in 45 minutes or less was compared. (NCT00813488)
Timeframe: From study drug administration until 45 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 983 |
| Immediate-release Oxycodone (OXY) | 864 |
Time to MPR(subjective perception of meaningful reduction in pain intensity) was measured by stopwatch and by scheduled questions at each time point during double-blind treatment period. No pain relief was defined as: patient indicated no pain relief experienced, rescue medication was used,or missing data. For each category (<5, <10, <15, <30, <45, <60 minutes, No MPR-rescue medication used, and No MPR-no rescue medication used)the number of episodes which time to MPR fell in that category was compared. Number of episodes in which MPR was achieved in 60 minutes or less was compared. (NCT00813488)
Timeframe: Time of study drug administration until 60 minutes after treatment
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 1139 |
| Immediate-release Oxycodone (OXY) | 1047 |
"The mean TOTPAR at 60 minutes will be calculated for each episode as the weighted sum of Pain Relief (PR) scores (5-point Likert scale, 0 = none to 4 = complete) at each assessment of PR (during the double-blind treatment period) until 60 minutes after study drug administration, as follows:~TOTPAR60 =(⅓ x PR5)+ (⅓ x PR10) +(⅓ x PR15)+ PR30 + PR45 + PR60. Least squared mean was from an analysis of variance (ANOVA) with treatment as randomized, phase, and sequence as fixed factors and patient as a random factor using compound symmetry." (NCT00813488)
Timeframe: From 5 minutes to 60 minutes after dosing
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 6.43 |
| Immediate-release Oxycodone (OXY) | 5.70 |
Any use of standard rescue medication after the administration of study drug for relief of Breakthrough Pain (BTP) during the double-blind treatment phase was recorded in the patient's diary. The number of breakthrough pain episodes for which study drug treatment was administered and which required rescue medication use was recorded. (NCT00813488)
Timeframe: Throughout the double-blind treatment period
| Intervention | Episodes (Number) |
|---|---|
| Fentanyl Buccal Tablet (FBT) | 39 |
| Immediate-release Oxycodone (OXY) | 41 |
The BTP preference questionnaire is a questionnaire used to measure patients' preference for FBT or immediate-release oxycodone for management of BTP. The question is used to determine a patient's preference between the study drugs given in the 2 double-blind treatment periods. The patient was asked to select 1 of the following: 1, a preference for study drug used in the 1st double-blind treatment period; 2, a preference for study drug used in the 2nd double-blind treatment period; or 3, no preference. (NCT00813488)
Timeframe: At Visit 6 ( up to 42 days depending upon how long it takes the patient to manage their BTP) after completion of both double-blind treatment periods.
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Preferred FBT | Preferred Oxycodone | No Preference | Missing | |
| Total | 62 | 46 | 23 | 12 |
"The medication performance assessment assessed study drug performance on a 5-point categorical scale of 0-4 (0=poor, 1=fair,2=good, 3=very good, 4=excellent) 30 minutes after administration of study drug during the double-blind treatment periods and for the first 5 BTP episodes after each visit during the open-label extension period were recorded in the patient's paper diary. Patients were asked How well did your study medication perform in controlling this breakthrough pain episode? The number of episodes rated for each category were recorded." (NCT00813488)
Timeframe: 30 minutes post-treatment
| Intervention | Episodes (Number) | |||||
|---|---|---|---|---|---|---|
| Excellent | Very Good | Good | Fair | Poor | No Response | |
| Fentanyl Buccal Tablet (FBT) | 49 | 125 | 378 | 416 | 341 | 33 |
| Immediate-release Oxycodone (OXY) | 16 | 104 | 304 | 391 | 489 | 30 |
"The medication performance assessment assessed study drug performance on a 5-point categorical scale of 0-4 (0=poor, 1=fair,2=good, 3=very good, 4=excellent) 60 minutes after administration of study drug during the double-blind treatment periods and for the first 5 BTP episodes after each visit during the open-label extension period were recorded in the patient's paper diary. Patients were asked How well did your study medication perform in controlling this breakthrough pain episode? The number of episodes rated for each category were recorded." (NCT00813488)
Timeframe: 60 minutes post-treatment
| Intervention | Episodes (Number) | |||||
|---|---|---|---|---|---|---|
| Excellent | Very Good | Good | Fair | Poor | No Response | |
| Fentanyl Buccal Tablet (FBT) | 160 | 371 | 508 | 181 | 92 | 30 |
| Immediate-release Oxycodone (OXY) | 119 | 313 | 565 | 179 | 136 | 22 |
"Participants assessed their general impression (GI) of treatment efficacy for treated BTP episodes at 60 minutes after first dose of study drug. The validated, categorical 5-point Verbal Rating Scale (VRS) was used for this assessment and scored as follows:~0 =poor;~1 =fair;~2 =good;~3 =very good;~4 =excellent." (NCT01429051)
Timeframe: During the efficacy phase (II), at each episode of breakthrough pain, 60 minutes after first dose of study drug.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Intranasal Fentanyl Spray (INFS) | 1.9 |
| Placebo | 1.1 |
"During the efficacy phase participants assessed their pain intensity at each breakthrough pain (BTP) episode at 0 and 10 minutes after first dose using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is worst possible pain. PID10 is calculated as the difference in pain intensity from time 0 to 10 minutes. A positive value is a decrease (improvement) of the pain; a ≥ 2-point difference is considered as clinically important." (NCT01429051)
Timeframe: During the efficacy phase (II), at each episode of breakthrough pain, at 0 and 10 minutes after first dose of study drug.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Intranasal Fentanyl Spray (INFS) | 2.5 |
| Placebo | 1.4 |
"During the efficacy phase participants assessed their pain intensity at each breakthrough pain (BTP) episode at 0, 5, 30 and 60 minutes after first dose using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is worst possible pain. PID is calculated as the difference in pain intensity from time 0 to each time point. A positive value is a decrease (improvement) of the pain; a ≥ 2-point difference is considered as clinically important." (NCT01429051)
Timeframe: During the efficacy phase (II) each episode of breakthrough pain, at 0, 5, 30 and 60 minutes after study drug.
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| PID at 5 minutes | PID at 30 minutes | PID at 60 minutes | |
| Intranasal Fentanyl Spray (INFS) | 1.3 | 3.0 | 3.3 |
| Placebo | 0.8 | 1.8 | 2.2 |
"Overall responder rate is defined as the proportion of breakthrough pain (BTP) episodes with a positive response to treatment. The following definitions of a positive response were analyzed: • greater than or equal to 1 point reduction in pain intensity (PI) from time 0, • greater than or equal to 2 point reduction in PI from time 0, and • greater than or equal to 3 point reduction in PI from time 0. Pain intensity was assessed using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is worst possible pain." (NCT01429051)
Timeframe: During the efficacy phase (II) each episode of breakthrough pain, at 0, 5, 30 and 60 minutes after study drug
| Intervention | proportion of breakthrough pain episodes (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 point reduction in PI at 5 minutes | ≥ 1 point reduction in PI at 10 minutes | ≥ 1 point reduction in PI at 30 minutes | ≥ 1 point reduction in PI at 60 minutes | ≥ 2 point reduction in PI at 5 minutes | ≥ 2 point reduction in PI at 10 minutes | ≥ 2 point reduction in PI at 30 minutes | ≥ 2 point reduction in PI at 60 minutes | ≥ 3 point reduction in PI at 5 minutes | ≥ 3 point reduction in PI at 10 minutes | ≥ 3 point reduction in PI at 30 minutes | ≥ 3 point reduction in PI at 60 minutes | |
| Intranasal Fentanyl Spray (INFS) | 0.61 | 0.74 | 0.81 | 0.86 | 0.33 | 0.51 | 0.60 | 0.65 | 0.18 | 0.32 | 0.45 | 0.50 |
| Placebo | 0.45 | 0.55 | 0.66 | 0.69 | 0.24 | 0.31 | 0.41 | 0.48 | 0.17 | 0.24 | 0.34 | 0.48 |
"Overall responder rate is defined as the proportion of breakthrough pain (BTP) episodes with a positive response to treatment. The following definitions of a positive response were analyzed: • Greater than 33% reduction in PI from time 0; • Greater than or equal to 50% reduction in PI from time 0. Pain intensity was assessed using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is worst possible pain." (NCT01429051)
Timeframe: During the efficacy phase (II) each episode of breakthrough pain, at 0, 5, 30 and 60 minutes after study drug
| Intervention | proportion of breakthrough pain episodes (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| > 33% reduction in PI at 5 minutes | > 33% reduction in PI at 10 minutes | > 33% reduction in PI at 30 minutes | > 33% reduction in PI at 60 minutes | ≥ 50% reduction in PI at 5 minutes | ≥ 50% reduction in PI at 10 minutes | ≥ 50% reduction in PI at 30 minutes | ≥ 50% reduction in PI at 60 minutes | |
| Intranasal Fentanyl Spray (INFS) | 0.23 | 0.44 | 0.55 | 0.58 | 0.11 | 0.31 | 0.49 | 0.52 |
| Placebo | 0.17 | 0.24 | 0.34 | 0.48 | 0.07 | 0.21 | 0.31 | 0.34 |
"The SPID30 and SPID60 represent the average improvement in pain intensity over the 30 minute interval and 60 minute interval, respectively. SPIDt was calculated as the area under the curve (AUC) for Pain Intensity Difference over the time interval 0 to t minutes, respectively, divided by the length of the time interval (t minutes). A positive value is a decrease (improvement) of the pain.~Pain intensity was assessed at 0, 5, 30 and 60 minutes after study drug using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is worst possible pain. PID is calculated as the difference in pain intensity from time 0 to each time point." (NCT01429051)
Timeframe: During the efficacy phase (II) each episode of breakthrough pain, at 0, 5, 30 and 60 minutes after study drug
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| SPID30 | SPID60 | |
| Intranasal Fentanyl Spray (INFS) | 0.6 | 0.7 |
| Placebo | 0.4 | 0.5 |
Medical examination of the nasal cavity by rhinoscopy was performed by an oto-rhino-laryngologist before the start of study treatment and at 12 weeks. Signs and any abnormalities were observed for each nostril using the following 4 points assessment scale: • 0 =not present; • 1 =present in a mild degree; • 2 =present in a moderate degree; • 3 =present in a severe degree. A difference in score of 1 or more from Baseline to the end of treatment represented a worsening, while a negative value indicated an improvement of the observed clinical sign. The oto-rhino-laryngologist also assessed whether worsening of a sign was related to study drug. Assessments for both left and right nostrils are presented together. The incidence is calculated as the number of assessments (n) in the improvement or worsening category divided by the number of assessments with a non-missing score for the Nasal Mucosa or Abnormality assessment. Only those signs or abnormalities with n>0 were included (NCT01429051)
Timeframe: Baseline and at 12 weeks
| Intervention | proportion of nostril assessments (Number) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change of color: Improvement | Change of color: Worsening | Change of color: Worsening related to study drug | Inflammation: Improvement | Inflammation: Worsening | Inflammation: Worsening related to study drug | Sore nose: Improvement | Sore nose: Worsening | Sore nose: Worsening related to study drug | Ulceration: Improvement | Ulceration: Worsening | Ulceration: Worsening related to study drug | Dry nose: Improvement | Dry nose: Worsening | Dry nose: Worsening related to study drug | Runny nose: Improvement | Runny nose: Worsening | Runny nose: Worsening related to study drug | Stuffed nose: Improvement | Stuffed nose: Worsening | Stuffed nose: Worsening related to study drug | Oedema: Improvement | Oedema: Worsening | Oedema: Worsening related to study drug | Epistaxis: Improvement | Epistaxis: Worsening | Epistaxis: Worsening related to study drug | |
| Intranasal Fentanyl Spray (INFS) | 0.06 | 0.09 | 0.09 | 0.04 | 0.07 | 0.07 | 0.04 | 0.04 | 0.04 | NA | 0.04 | 0.04 | 0.09 | 0.06 | NA | 0.04 | 0.13 | 0.10 | 0.06 | 0.17 | 0.08 | 0.04 | 0.17 | 0.08 | 0.02 | 0.02 | 0.02 |
The severity (intensity of each AE was assessed as mild (transient symptoms, no interference with daily activities), moderate (marked symptoms, moderate interference with daily activities), or severe (considerable interference with daily activities) by the investigator. Serious adverse events are defined as any untoward medical occurrence that at any dose results in death or is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect. The investigator assessed each AE as either related or not related to study treatment. (NCT01429051)
Timeframe: 12 weeks
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any AE | Any AE reported as related to treatment | Non-serious adverse events | Serious adverse events | Deaths | Severe adverse events | AEs leading to withdrawal | AEs possibly associated with nasal intolerability | AEs with an onset within 30 minutes of first dose | |
| Efficacy Phase | 6 | 4 | 5 | 2 | 1 | 2 | 2 | 0 | 3 |
| Titration Phase | 23 | 14 | 22 | 2 | 2 | 2 | 2 | 2 | 11 |
| Tolerability Phase | 22 | 6 | 17 | 8 | 5 | 7 | 3 | 6 | 5 |
Evaluation of the proportion of subjects who report full analgesia (full responders: FR). FR is operationally defined as a patient with a P.I.D. =/> 30% from visit 6 and visit 1 (NRS 0 to 10). (NCT01809106)
Timeframe: 28 days
| Intervention | participants (Number) |
|---|---|
| Morphine | 89 |
| Oxycodone | 90 |
| Buprenorphine | 95 |
| Fentanyl | 88 |
"Evaluation of the proportion of Non-Responder (NR) participants. NR correspond to the subjects who do not report any analgesic effects, with a P.I.D. (pain intensity difference) from visit 6 and visit 1 =/< 0%, (using a 0-10 NRS ). It includes the situations of average pain intensity stable or worsened at day 28 compared with baseline values." (NCT01809106)
Timeframe: 28 days
| Intervention | participants (Number) |
|---|---|
| Morphine | 14 |
| Oxycodone | 18 |
| Buprenorphine | 14 |
| Fentanyl | 11 |
The proportion of subjects with an increase of opioid daily dose > 5% compared with the basal dosage (OEI%). (NCT01809106)
Timeframe: 28 days
| Intervention | participants (Number) |
|---|---|
| Morphine | 13 |
| Oxycodone | 24 |
| Buprenorphine | 18 |
| Fentanyl | 45 |
"Assessed dyspnea using the modified Dyspnea Borg Scale that ranges from 0 (no shortness of breath) to 10 (worst possible shortness of breath). Measured the mean difference of modified Dyspnea Borg scale between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests." (NCT01832402)
Timeframe: 1.5 to 2 hours on a Single visit
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Mean difference between 1st and 2nd walk tests | Mean difference between 1st and 3rd walk tests | |
| Controlled Group (Placebo) | -1.7 | -2.4 |
| Intervention Group (Fentanyl Pectin Nasal Spray) | -1.8 | -1.7 |
"Our primary outcome was dyspnea intensity now using a dyspnea numeric rating scale that ranges from 0 (no shortness of breath) to 10 (worst possible shortness of breath). Measured the mean difference of dyspnea numeric rating scale between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests. 6 minute walk tests were carried out following guidelines from the American Thoracic Society." (NCT01832402)
Timeframe: 1.5 to 2 hours on a Single visit
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Mean difference between 1st and 2nd walk tests | Mean difference between 1st and 3rd walk tests | |
| Controlled Group (Placebo) | -1.7 | -2.5 |
| Intervention Group (Fentanyl Pectin Nasal Spray) | -2.0 | -2.3 |
Compared the mean difference of distance between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests. (NCT01832402)
Timeframe: 1.5 to 2 hours on a Single visit
| Intervention | meters (Mean) | |
|---|---|---|
| Mean difference between 1st and 2nd walk tests | Mean difference between 1st and 3rd walk tests | |
| Control Group (Placebo) | 16.3 | 14.6 |
| Interventional Group (Fentanyl Pectin Nasal Spray) | 23.8 | 23.3 |
Patient reported NRS pain scores after Blunt Dissection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 4.1 |
| Placebo | 4.4 |
Patient reported NRS pain scores after Irrigation. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 3.4 |
| Placebo | 2.6 |
Patient reported NRS pain scores after Lidocaine injection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Following Lidocaine injection measured once anytime up to 12 minutes after intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 8.4 |
| Placebo | 8.0 |
Patient reported pain after Packing of abscess. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once at the time of completion of application of the bandage, up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 4.5 |
| Placebo | 3.9 |
Patient reported NRS pain scores following Incision. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 3.9 |
| Placebo | 3.9 |
Patient reported pain scores at baseline. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 8.3 |
| Placebo | 8.1 |
Patient reported pain scores for overall Procedure assessed immediately after placement of dressing at the end of procedure. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once following placement of dressing at completion of procedure, up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 6.2 |
| Placebo | 7.0 |
(NCT00263575)
Timeframe: screening, 2 week titration period and 12 monthly study visits
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Patients with at least 1 AE | Patients with at least 1 AE causing discontinue | Patients with at least 1 SAE | Patients with an AE resulting in death | |
| Maintenance | 87 | 23 | 40 | 15 |
| Overall | 116 | 37 | 46 | 19 |
| Titration | 64 | 14 | 7 | 4 |
"Pain intensity was assessed by the participant using a 0-100 mm visual analog scale where 0 represented no pain and 100 represented worst possible pain at 0 (baseline, beginning of the pain episode), 5, 10, 15, and 30 minutes after each dose of study medication during each breakthrough pain episode. The pain intensity difference was defined as the difference in pain intensity at the various time points versus time 0 (baseline). SPID30 was calculated as the time-weighted sum of the PID scores using the following formula: SPID30=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30). The minimum and maximum SPID30 scores were -3000 and 3000. A higher score indicates less pain." (NCT00538850)
Timeframe: Baseline (time 0, beginning of each pain episode) through 30 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) |
|---|---|
| Fentanyl Sublingual Spray | 640.3 |
| Placebo | 399.6 |
Global evaluation of the study medication was assessed by the participant on a 5-point scale (1=Poor, 2=Fair, 3=Good, 4=Very good, 5=Excellent) at 30 and 60 minutes after each dose of study medication during each breakthrough pain episode. A higher score indicates a better evaluation. (NCT00538850)
Timeframe: 30 through 60 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| 30 minutes | 60 minutes | |
| Fentanyl Sublingual Spray | 2.8 | 3.1 |
| Placebo | 2.0 | 2.2 |
"Pain intensity was assessed by the participant using a 0-100 mm visual analog scale where 0 represented no pain and 100 represented worst possible pain at 0 (baseline, beginning of the pain episode), 5, 10, 15, 30, 45 and 60 minutes after each dose of study medication during each breakthrough pain episode. The pain intensity difference was defined as the difference in pain intensity at the various time points versus time 0 (baseline). SPID was calculated as the time-weighted sum of the PID scores using the following formulas: SPID5=(5*PID5), SPID10=(5*PID5)+(5*PID10), SPID15=(5*PID5)+(5*PID10)+(5*PID15), SPID30=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30), SPID45=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30)+(15*PID45), SPID60=(5*PID5)+(5*PID10)+(5*PID15)+(15*PID30) +(15*PID45) +(15*PID60). The minimum and maximum SPID scores were -500 to 500, -1000 to 1000, -1500 to 1500, -3000 to 3000, -4500 to 4500, and -6000 to 6000, respectively. A higher score indicates less pain." (NCT00538850)
Timeframe: Baseline (time 0, beginning of each pain episode) through 60 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| SPID5 | SPID10 | SPID15 | SPID45 | SPID60 | |
| Fentanyl Sublingual Spray | 40.3 | 115.0 | 220.6 | 1122.0 | 1649.0 |
| Placebo | 32.0 | 81.1 | 150.3 | 667.0 | 965.7 |
Pain relief (PAR) was assessed by the participant on a 5-point scale (1=No relief, 2=A little relief, 3=Moderate relief, 4=A lot of relief, 5=Complete relief) at 5, 10, 15, 30, 45 and 60 minutes after each dose of study medication during each breakthrough pain episode. TOTPAR was calculated as the time-weighted sum of the PAR scores at each time point using the following formulas: TOTPAR5=(5*PAR5), TOTPAR10=(5*PAR5)+(5*PAR10), TOTPAR15=(5*PAR5)+(5*PAR10)+(5*PAR15), TOTPAR30=(5*PAR5)+(5*PAR10)+(5*PAR15)+(15*PAR30), TOTPAR45=(5*PAR5)+(5*PAR10)+(5*PAR15)+(15*PAR30)+(15*PAR45), TOTPAR60=(5*PAR5)+(5*PAR10)+(5*PAR15)+(15*PAR30) +(15*PAR45) +(15*PAR60). The minimum and maximum TOTPAR5, TOTPAR10, TOTPAR15, TOTPAR30, TOTPAR45, and TOTPAR60 scores were 5 to 25, 10 to 50, 15 to 75, 30 to 150, 45 to 225, and 60 to 300, respectively. A higher score indicates more pain relief. (NCT00538850)
Timeframe: 5 through 60 minutes after dosing for each pain episode
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| TOTPAR5 | TOTPAR10 | TOTPAR15 | TOTPAR30 | TOTPAR45 | TOTPAR60 | |
| Fentanyl Sublingual Spray | 8.6 | 19.7 | 32.9 | 78.3 | 126.3 | 176.4 |
| Placebo | 7.6 | 16.7 | 27.1 | 61.0 | 95.5 | 131.2 |
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
| Intervention | Percent change (Mean) |
|---|---|
| 4 hr | -44 |
| 24 hr | -50 |
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
| Intervention | Percentage of participants (Number) |
|---|---|
| Patients With High Risk of CNS Relapse | 92.2 |
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
| Intervention | pmol/1,000,000,000 cells (Mean) |
|---|---|
| 4 hr | 1688 |
| 24 hr | 2521 |
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Total Therapy | 87.3 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 341.3 | 447.9 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 41.2 | 110.7 |
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
| Intervention | participants (Number) | |
|---|---|---|
| Negative <0.01% | Positive >= 0.01% | |
| Total Therapy | 390 | 102 |
(NCT03007966)
Timeframe: 24 hrs Post Nerve Block
| Intervention | Participants (Count of Participants) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 2 |
| Quadratus Lumborum Block | 3 |
(NCT03007966)
Timeframe: 8 hrs Post Nerve Block
| Intervention | Participants (Count of Participants) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 0 |
| Quadratus Lumborum Block | 4 |
(NCT03007966)
Timeframe: 24 hrs Post Nerve Block
| Intervention | Participants (Count of Participants) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 6 |
| Quadratus Lumborum Block | 3 |
(NCT03007966)
Timeframe: 8 hrs Post Nerve Block
| Intervention | Participants (Count of Participants) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 9 |
| Quadratus Lumborum Block | 5 |
(NCT03007966)
Timeframe: 24 hrs Post Nerve Block
| Intervention | Participants (Count of Participants) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 3 |
| Quadratus Lumborum Block | 2 |
(NCT03007966)
Timeframe: 8 hrs Post Nerve Block
| Intervention | Participants (Count of Participants) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 3 |
| Quadratus Lumborum Block | 3 |
Assessed on an 11 point (0-10) numeric analog scale with a higher score denoting a worse outcome (NCT03007966)
Timeframe: 24 hrs Post Nerve Block
| Intervention | score on a scale (Mean) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 3 |
| Quadratus Lumborum Block | 2.7 |
Assessed on an 11-point (0-10) numeric analog scale with a higher score denoting a worse outcome (NCT03007966)
Timeframe: 8 hrs Post Nerve Block
| Intervention | score on a scale (Mean) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 3.6 |
| Quadratus Lumborum Block | 3.3 |
Assessed on an 11 point (0-10) numeric analog scale with a higher score denoting a worse outcome (NCT03007966)
Timeframe: 24hrs Post Nerve Block
| Intervention | score on a scale (Mean) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 4.9 |
| Quadratus Lumborum Block | 5.3 |
Assessed on an 11-point (0-10) numeric analog scale with a higher score denoting a worse outcome. (NCT03007966)
Timeframe: 8 hrs Post Nerve Block
| Intervention | score on a scale (Mean) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 5.10 |
| Quadratus Lumborum Block | 5.03 |
When does the patient require their first post operative analgesic dose? (NCT03007966)
Timeframe: 24hrs Post Nerve Block
| Intervention | minutes (Median) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 141 |
| Quadratus Lumborum Block | 91 |
Total opioids consumed during the first 24hrs post operatively. Measured as 24hr Oxycodone Equivalent (NCT03007966)
Timeframe: 24 hrs Post Nerve Block
| Intervention | milligrams (Mean) |
|---|---|
| Ilioinguinal / Iliohypogastric Block | 19.7 |
| Quadratus Lumborum Block | 25.2 |
"Symptomatic success was assessed by the pelvic floor disability index (PFDI-20) questionnaire. The PFDI-20 has 20 items within 3 sub-scales of symptoms (total of 20 items). Each item produces a response of 0 to 4, the average response in each sub-scale is multiplied by 25 to obtain the sub-scale score (range 0 to 100). The total score is the sum of the three sub-scale scores with a range of 0-300. Higher value for a time-point score indicates a greater degree of symptom bother.~The difference in scores across the study time-points was calculated by subtracting the total score at baseline from the score at 12 months post-operation. A negative value for the difference in scores from baseline to 12 months indicates symptom improvement, where the more negative the difference in score is the greater the improvement in symptoms." (NCT03565640)
Timeframe: Baseline and Month 12
| Intervention | score on a scale (Mean) |
|---|---|
| Capio Slim Device | -66.3 |
| Anchorsure Device | -71.0 |
"Symptomatic success will be assessed by the Pelvic Floor Impact Questionnaire - 7 (PFIQ-7). The PFIQ-7 has 7 items for each of 3 sub-scales (total of 21 items). Each item produces a response of 0 to 3, the average response in each sub-scale is multiplied by 100/3 to obtain the total scale score (range 0 to 100). The total score is the sum of the three sub-scale scores with a range of 0-300. Higher value for a time-point score indicates a greater degree of symptom bother.~The difference in scores across the study time-points was calculated by subtracting the total score at baseline from the score at 12 months post-operation. A negative value for the difference in scores from baseline to 12 months indicates symptom improvement, where the more negative the difference in score is the greater the improvement in symptoms." (NCT03565640)
Timeframe: Baseline and Month 12
| Intervention | score on a scale (Mean) |
|---|---|
| Capio Slim Device | -26.4 |
| Anchorsure Device | -40.6 |
The stage is assigned as follows: 0 if there is no prolapse at all, 1 if there is prolapse but the leading point is not within 1cm of the hymen, 2 if the leading point is within 1 cm of the hymen (from 1cm within the hymen to 1cm beyond the hymen), 3 if the leading point is more than 1cm from the hymen but less than 2cm from being completely prolapsed, and 4 if the leading point is within 2cm of being complete prolapsed. Therefore higher POP-Q stages correlate to a worse degree of prolapse than lower POP-Q stages. (NCT03565640)
Timeframe: at 12 MONTHS
| Intervention | Units on a scale (Mean) |
|---|---|
| Capio Slim Device | 0.8 |
| Anchorsure Device | 0.9 |
This will be assessed using the numeric rating scale (NRS). The score is 0-10, with higher scores denoting a greater degree of pain. (NCT03565640)
Timeframe: postoperative 12 month
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Sacrospinous ligament fixation site Pain compared to preop | Worst pain compared to preop | |
| Anchorsure Device | -0.2 | -1.5 |
| Capio Slim Device | -0.5 | -1.8 |
Comparison of quadriceps motor strength at 6 hour post nerve block between two groups: adductor canal block and lumbar plexus block. The score range is 0-5, with higher scores denoting better outcomes. (NCT01818531)
Timeframe: 6 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Adductor Canal Block | 4 |
| Lumbar Plexus Block | 2.5 |
Time to first analgesic between two groups: adductor canal block and lumbar plexus block. (NCT01818531)
Timeframe: 24 hours
| Intervention | minutes (Mean) |
|---|---|
| Adductor Canal Block | 601 |
| Lumbar Plexus Block | 659 |
Comparison of cumulative opioid consumption over 24 hour period between adductor canal block and lumbar plexus block. (NCT01818531)
Timeframe: 6, 12, 18, and 24 hours
| Intervention | mg (Mean) | |||
|---|---|---|---|---|
| 6 hours | 12 hours | 18 hours | 24 hours | |
| Adductor Canal Block | 1.5 | 11 | 20.9 | 27.9 |
| Lumbar Plexus Block | 2.5 | 10.3 | 20.7 | 32.1 |
Occurrence of opioid related side effects (nausea, vomiting and pruritus) between two groups: adductor canal block and lumbar plexus block. (NCT01818531)
Timeframe: 6, 12, 18, and 24 hours
| Intervention | events (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nausea 6 hours | Nausea 12 hours | Nausea 18 hours | Nausea 24 hours | Vomiting 6 hours | Vomiting 12 hours | Vomiting 18 hours | Vomiting 24 hours | Pruritus 6 hours | Pruritus 12 hours | Pruritus 18 hours | Pruritus 24 hours | |
| Adductor Canal Block | 14 | 10 | 5 | 9 | 6 | 6 | 2 | 4 | 11 | 7 | 5 | 10 |
| Lumbar Plexus Block | 15 | 16 | 8 | 15 | 8 | 6 | 3 | 6 | 3 | 4 | 5 | 13 |
Comparison of verbal numerical pain scores at rest and with movement 6 hours following nerve blockade. The score range is 0-10 with higher scores denoting worse outcomes. (NCT01818531)
Timeframe: 6 hours post block.
| Intervention | score on a scale (Mean) | |
|---|---|---|
| rest | movement | |
| Adductor Canal Block | 1 | 1.6 |
| Lumbar Plexus Block | 1.1 | 1.5 |
102 reviews available for fentanyl and Neoplasms
| Article | Year |
|---|---|
Bibliometric Network Analysis on Rapid-Onset Opioids for Breakthrough Cancer Pain Treatment.
Topics: Analgesics, Opioid; Bibliometrics; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms | 2022 |
Bibliometric Network Analysis on Rapid-Onset Opioids for Breakthrough Cancer Pain Treatment.
Topics: Analgesics, Opioid; Bibliometrics; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms | 2022 |
Transdermal Fentanyl-Induced Seizures: Case Report and Literature Review.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Seizures | 2022 |
Transdermal Fentanyl-Induced Seizures: Case Report and Literature Review.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Seizures | 2022 |
Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Head and Neck Neoplasms; Humans; Neopl | 2023 |
Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Head and Neck Neoplasms; Humans; Neopl | 2023 |
Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: A case report and review of the literature.
Topics: Administration, Cutaneous; Analgesics, Opioid; Cachexia; Canada; Female; Fentanyl; Humans; Hydromorp | 2021 |
Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: A case report and review of the literature.
Topics: Administration, Cutaneous; Analgesics, Opioid; Cachexia; Canada; Female; Fentanyl; Humans; Hydromorp | 2021 |
Economic assessment of postoperative pain control strategies for treatment of adult patients with cancer.
Topics: Adult; Analgesics, Opioid; Brazil; Cost-Benefit Analysis; Fentanyl; Humans; National Health Programs | 2017 |
Economic assessment of postoperative pain control strategies for treatment of adult patients with cancer.
Topics: Adult; Analgesics, Opioid; Brazil; Cost-Benefit Analysis; Fentanyl; Humans; National Health Programs | 2017 |
Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management.
Topics: Analgesics, Opioid; Breakthrough Pain; Dyspnea; Fentanyl; Humans; Morphine; Neoplasms; Pain Manageme | 2018 |
Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management.
Topics: Analgesics, Opioid; Breakthrough Pain; Dyspnea; Fentanyl; Humans; Morphine; Neoplasms; Pain Manageme | 2018 |
Opioid Rotation in Cancer Pain Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Cancer Pain; Chronic Pain; Fentanyl; Germany; Humans; Hydromorpho | 2018 |
Opioid Rotation in Cancer Pain Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Cancer Pain; Chronic Pain; Fentanyl; Germany; Humans; Hydromorpho | 2018 |
Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials.
Topics: Administration, Cutaneous; Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Neoplasms; Odds Ratio; | 2018 |
Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials.
Topics: Administration, Cutaneous; Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Neoplasms; Odds Ratio; | 2018 |
The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients.
Topics: Analgesia; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain Measurement; Qua | 2019 |
The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients.
Topics: Analgesia; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain Measurement; Qua | 2019 |
Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies.
Topics: Administration, Intranasal; Adolescent; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Child; D | 2019 |
Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies.
Topics: Administration, Intranasal; Adolescent; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Child; D | 2019 |
Fast-acting fentanyl preparations and pain management.
Topics: Analgesics, Opioid; Breakthrough Pain; Drug Dosage Calculations; Fentanyl; Humans; Neoplasms; Pain M | 2013 |
Fast-acting fentanyl preparations and pain management.
Topics: Analgesics, Opioid; Breakthrough Pain; Drug Dosage Calculations; Fentanyl; Humans; Neoplasms; Pain M | 2013 |
Fentanyl for the treatment of tumor-related breakthrough pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Evidence-Based Medicine; Fentanyl; Humans; Neoplasms; Pain Me | 2013 |
Fentanyl for the treatment of tumor-related breakthrough pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Evidence-Based Medicine; Fentanyl; Humans; Neoplasms; Pain Me | 2013 |
[Breakthrough pain and short-acting opioids].
Topics: Administration, Intranasal; Administration, Mucosal; Analgesics, Opioid; Breakthrough Pain; Delayed- | 2013 |
[Breakthrough pain and short-acting opioids].
Topics: Administration, Intranasal; Administration, Mucosal; Analgesics, Opioid; Breakthrough Pain; Delayed- | 2013 |
[Management of breakthrough cancer pain].
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain Man | 2013 |
[Management of breakthrough cancer pain].
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain Man | 2013 |
Transdermal fentanyl for cancer pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Methadone; Morphine; Neoplasms; Pai | 2013 |
Transdermal fentanyl for cancer pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Methadone; Morphine; Neoplasms; Pai | 2013 |
Opioids for the management of breakthrough pain in cancer patients.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Fentanyl; H | 2013 |
Opioids for the management of breakthrough pain in cancer patients.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Fentanyl; H | 2013 |
Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: a review article.
Topics: Administration, Mucosal; Analgesics, Opioid; Chemistry, Pharmaceutical; Fentanyl; Humans; Neoplasms; | 2014 |
Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: a review article.
Topics: Administration, Mucosal; Analgesics, Opioid; Chemistry, Pharmaceutical; Fentanyl; Humans; Neoplasms; | 2014 |
Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Chemistry, Pharmaceu | 2012 |
Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Chemistry, Pharmaceu | 2012 |
Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain.
Topics: Analgesics, Opioid; Appetite; Codeine; Consciousness; Fentanyl; Humans; Middle Aged; Morphine; Neopl | 2014 |
Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain.
Topics: Analgesics, Opioid; Appetite; Codeine; Consciousness; Fentanyl; Humans; Middle Aged; Morphine; Neopl | 2014 |
Understanding the cancer pain experience.
Topics: Acetaminophen; Analgesics; Chronic Pain; Critical Pathways; Fentanyl; Humans; Ketamine; Neoplasms; O | 2014 |
Understanding the cancer pain experience.
Topics: Acetaminophen; Analgesics; Chronic Pain; Critical Pathways; Fentanyl; Humans; Ketamine; Neoplasms; O | 2014 |
Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
Topics: Analgesics, Opioid; Breakthrough Pain; Caregivers; Drug Administration Routes; Family; Fentanyl; Hum | 2014 |
Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
Topics: Analgesics, Opioid; Breakthrough Pain; Caregivers; Drug Administration Routes; Family; Fentanyl; Hum | 2014 |
Clinical and pharmacokinetic considerations of novel formulations of fentanyl for breakthrough cancer pain.
Topics: Breakthrough Pain; Chemistry, Pharmaceutical; Fentanyl; Humans; Neoplasms | 2014 |
Clinical and pharmacokinetic considerations of novel formulations of fentanyl for breakthrough cancer pain.
Topics: Breakthrough Pain; Chemistry, Pharmaceutical; Fentanyl; Humans; Neoplasms | 2014 |
Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Clinical Trials as Topic; Dose-Respon | 2015 |
Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Clinical Trials as Topic; Dose-Respon | 2015 |
[Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].
Topics: Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2D6; Cytochro | 2015 |
[Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].
Topics: Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2D6; Cytochro | 2015 |
[New option in the management of cancer pain in Hungary: short acting oral opioid therapy].
Topics: Administration, Oral; Analgesics, Opioid; Analgesics, Short-Acting; Drug Administration Schedule; Dr | 2015 |
[New option in the management of cancer pain in Hungary: short acting oral opioid therapy].
Topics: Administration, Oral; Analgesics, Opioid; Analgesics, Short-Acting; Drug Administration Schedule; Dr | 2015 |
WITHDRAWN: Opioids for the management of breakthrough pain in cancer patients.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Fentanyl; H | 2015 |
WITHDRAWN: Opioids for the management of breakthrough pain in cancer patients.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Fentanyl; H | 2015 |
Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.
Topics: Algorithms; Analgesics, Opioid; Breakthrough Pain; Choice Behavior; Ethnicity; Expert Testimony; Fen | 2016 |
Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.
Topics: Algorithms; Analgesics, Opioid; Breakthrough Pain; Choice Behavior; Ethnicity; Expert Testimony; Fen | 2016 |
Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review.
Topics: Administration, Buccal; Administration, Intranasal; Administration, Sublingual; Analgesics, Opioid; | 2015 |
Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review.
Topics: Administration, Buccal; Administration, Intranasal; Administration, Sublingual; Analgesics, Opioid; | 2015 |
Fentanyl Buccal Soluble Film: A Review in Breakthrough Cancer Pain.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Disease Management; Fentanyl; Humans; | 2016 |
Fentanyl Buccal Soluble Film: A Review in Breakthrough Cancer Pain.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Disease Management; Fentanyl; Humans; | 2016 |
Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
Topics: Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain | 2016 |
Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
Topics: Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain | 2016 |
A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients.
Topics: Aged; Analgesics, Opioid; Cancer Pain; Confounding Factors, Epidemiologic; Dose-Response Relationshi | 2017 |
A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients.
Topics: Aged; Analgesics, Opioid; Cancer Pain; Confounding Factors, Epidemiologic; Dose-Response Relationshi | 2017 |
The use of opioids in cancer patients with renal impairment-a systematic review.
Topics: Analgesics, Opioid; Drug-Related Side Effects and Adverse Reactions; Fentanyl; Humans; Neoplasms; Pa | 2017 |
The use of opioids in cancer patients with renal impairment-a systematic review.
Topics: Analgesics, Opioid; Drug-Related Side Effects and Adverse Reactions; Fentanyl; Humans; Neoplasms; Pa | 2017 |
Transdermal matrix fentanyl membrane patch (matrifen): in severe cancer-related chronic pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain, I | 2008 |
Transdermal matrix fentanyl membrane patch (matrifen): in severe cancer-related chronic pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain, I | 2008 |
Treatment strategies for cancer patients with breakthrough pain.
Topics: Analgesics, Opioid; Animals; Fentanyl; Humans; Neoplasms; Pain; Pain Measurement; Treatment Outcome | 2009 |
Treatment strategies for cancer patients with breakthrough pain.
Topics: Analgesics, Opioid; Animals; Fentanyl; Humans; Neoplasms; Pain; Pain Measurement; Treatment Outcome | 2009 |
Opioids in people with cancer-related pain.
Topics: Administration, Oral; Analgesics; Analgesics, Opioid; Codeine; Fentanyl; Humans; Methadone; Neoplasm | 2008 |
Opioids in people with cancer-related pain.
Topics: Administration, Oral; Analgesics; Analgesics, Opioid; Codeine; Fentanyl; Humans; Methadone; Neoplasm | 2008 |
The role of transdermal fentanyl patches in the effective management of cancer pain.
Topics: Acute Disease; Administration, Cutaneous; Analgesics, Opioid; Chemistry, Pharmaceutical; Chronic Dis | 2009 |
The role of transdermal fentanyl patches in the effective management of cancer pain.
Topics: Acute Disease; Administration, Cutaneous; Analgesics, Opioid; Chemistry, Pharmaceutical; Chronic Dis | 2009 |
The role of fentanyl in cancer-related pain.
Topics: Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Palliative Care; United States | 2009 |
The role of fentanyl in cancer-related pain.
Topics: Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Palliative Care; United States | 2009 |
Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer.
Topics: Administration, Intranasal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Placebos | 2010 |
Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer.
Topics: Administration, Intranasal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Placebos | 2010 |
Breakthrough pain: progress in management.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; P | 2010 |
Breakthrough pain: progress in management.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; P | 2010 |
Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis.
Topics: Administration, Oral; Analgesics, Opioid; Cohort Studies; Fentanyl; Humans; Morphine; Neoplasms; Pai | 2010 |
Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis.
Topics: Administration, Oral; Analgesics, Opioid; Cohort Studies; Fentanyl; Humans; Morphine; Neoplasms; Pai | 2010 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological | 2010 |
[The licit opioid consumption in Denmark].
Topics: Analgesics, Opioid; Buprenorphine; Databases, Factual; Denmark; Drug Costs; Drug Utilization; Fentan | 2010 |
[The licit opioid consumption in Denmark].
Topics: Analgesics, Opioid; Buprenorphine; Databases, Factual; Denmark; Drug Costs; Drug Utilization; Fentan | 2010 |
Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer.
Topics: Administration, Sublingual; Adult; Analgesics, Opioid; Clinical Trials as Topic; Fentanyl; Humans; N | 2010 |
Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer.
Topics: Administration, Sublingual; Adult; Analgesics, Opioid; Clinical Trials as Topic; Fentanyl; Humans; N | 2010 |
[Solutions for the clinical problems of analgesics for cancer pain treatment in Japan].
Topics: Acetaminophen; Analgesics; Drug Administration Routes; Fentanyl; Humans; Japan; Neoplasms; Oxycodone | 2011 |
[Solutions for the clinical problems of analgesics for cancer pain treatment in Japan].
Topics: Acetaminophen; Analgesics; Drug Administration Routes; Fentanyl; Humans; Japan; Neoplasms; Oxycodone | 2011 |
Integrated strategies for the successful management of breakthrough cancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Breast Neoplasms; Drug Therapy, Combination; Female; Fentanyl; Huma | 2011 |
Integrated strategies for the successful management of breakthrough cancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Breast Neoplasms; Drug Therapy, Combination; Female; Fentanyl; Huma | 2011 |
Transdermal opioids for cancer pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Evidence-Based Medicine; Fentanyl; Hum | 2011 |
Transdermal opioids for cancer pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Evidence-Based Medicine; Fentanyl; Hum | 2011 |
[Cancer breakthrough pain. Indications for rapidly effective opioids].
Topics: Administration, Intranasal; Administration, Sublingual; Administration, Topical; Aerosols; Analgesic | 2011 |
[Cancer breakthrough pain. Indications for rapidly effective opioids].
Topics: Administration, Intranasal; Administration, Sublingual; Administration, Topical; Aerosols; Analgesic | 2011 |
Fentanyl nasal spray for the treatment of cancer pain.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Drug Delivery Systems; Fentany | 2011 |
Fentanyl nasal spray for the treatment of cancer pain.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Drug Delivery Systems; Fentany | 2011 |
Fentanyl pectin nasal spray: in breakthrough pain in opioid-tolerant adults with cancer.
Topics: Analgesics, Opioid; Drug Tolerance; Fentanyl; Humans; Nasal Sprays; Neoplasms; Pain; Pectins | 2011 |
Fentanyl pectin nasal spray: in breakthrough pain in opioid-tolerant adults with cancer.
Topics: Analgesics, Opioid; Drug Tolerance; Fentanyl; Humans; Nasal Sprays; Neoplasms; Pain; Pectins | 2011 |
[Breakthrough pain--what to consider when treating with rapid onset opioids].
Topics: Administration, Intranasal; Administration, Oral; Administration, Sublingual; Algorithms; Chronic Di | 2011 |
[Breakthrough pain--what to consider when treating with rapid onset opioids].
Topics: Administration, Intranasal; Administration, Oral; Administration, Sublingual; Algorithms; Chronic Di | 2011 |
Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Europe; Fentanyl; Humans; Neoplasms; Pa | 2011 |
Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Europe; Fentanyl; Humans; Neoplasms; Pa | 2011 |
Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Controlled Clinical Trials as Topic; Dr | 2011 |
Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Controlled Clinical Trials as Topic; Dr | 2011 |
Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Clinical Trials as Topic; Fentanyl; Hum | 2012 |
Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Clinical Trials as Topic; Fentanyl; Hum | 2012 |
Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain.
Topics: Administration, Intranasal; Aerosols; Analgesics, Opioid; Area Under Curve; Breakthrough Pain; Compu | 2012 |
Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain.
Topics: Administration, Intranasal; Aerosols; Analgesics, Opioid; Area Under Curve; Breakthrough Pain; Compu | 2012 |
Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2012 |
Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2012 |
Fentanyl for breakthrough cancer pain: where are we?
Topics: Administration, Mucosal; Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Fentanyl | 2013 |
Fentanyl for breakthrough cancer pain: where are we?
Topics: Administration, Mucosal; Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Fentanyl | 2013 |
Optimal management of breakthrough cancer pain (BCP).
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Nasal Sprays; N | 2013 |
Optimal management of breakthrough cancer pain (BCP).
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Nasal Sprays; N | 2013 |
Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Causality; Comorbidity; Controlled Clin | 2013 |
Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Causality; Comorbidity; Controlled Clin | 2013 |
The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain.
Topics: Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Patient Selection | 2002 |
The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain.
Topics: Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Patient Selection | 2002 |
Morphine is not the only analgesic in palliative care: literature review.
Topics: Analgesics; Analgesics, Opioid; Fentanyl; Humans; Ketamine; Methadone; Morphine; Neoplasms; Pain; Pa | 2004 |
Morphine is not the only analgesic in palliative care: literature review.
Topics: Analgesics; Analgesics, Opioid; Fentanyl; Humans; Ketamine; Methadone; Morphine; Neoplasms; Pain; Pa | 2004 |
Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Constipation; Fentanyl; Germany; Humans; Narcot | 2004 |
Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Constipation; Fentanyl; Germany; Humans; Narcot | 2004 |
Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2004 |
Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2004 |
Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Drug Administration Sche | 2004 |
Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Drug Administration Sche | 2004 |
Cancer pain management in children.
Topics: Analgesics, Opioid; Anesthesia, Conduction; Child; Chronic Disease; Fentanyl; Humans; Injections, Sp | 2004 |
Cancer pain management in children.
Topics: Analgesics, Opioid; Anesthesia, Conduction; Child; Chronic Disease; Fentanyl; Humans; Injections, Sp | 2004 |
Advances in opioid therapy and formulations.
Topics: Administration, Cutaneous; Analgesia, Patient-Controlled; Analgesics, Opioid; Chemistry, Pharmaceuti | 2005 |
Advances in opioid therapy and formulations.
Topics: Administration, Cutaneous; Analgesia, Patient-Controlled; Analgesics, Opioid; Chemistry, Pharmaceuti | 2005 |
Contribution to variability in response to opioids.
Topics: Analgesics, Opioid; Biological Availability; Dose-Response Relationship, Drug; Drug Administration S | 2005 |
Contribution to variability in response to opioids.
Topics: Analgesics, Opioid; Biological Availability; Dose-Response Relationship, Drug; Drug Administration S | 2005 |
[Basic studies on cancer pain control].
Topics: Analgesics, Opioid; Animals; Constipation; Dose-Response Relationship, Drug; Fentanyl; Humans; Morph | 2005 |
[Basic studies on cancer pain control].
Topics: Analgesics, Opioid; Animals; Constipation; Dose-Response Relationship, Drug; Fentanyl; Humans; Morph | 2005 |
Opioids for the management of breakthrough (episodic) pain in cancer patients.
Topics: Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Morphine; Neoplasms; Pain; Pain Measurem | 2006 |
Opioids for the management of breakthrough (episodic) pain in cancer patients.
Topics: Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Morphine; Neoplasms; Pain; Pain Measurem | 2006 |
Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review.
Topics: Administration, Buccal; Administration, Oral; Administration, Sublingual; Analgesics, Opioid; Dose-R | 2006 |
Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review.
Topics: Administration, Buccal; Administration, Oral; Administration, Sublingual; Analgesics, Opioid; Dose-R | 2006 |
Transdermal opioids for cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Algorithms; Analgesics, Opioid; Buprenorphine; Dose | 2006 |
Transdermal opioids for cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Algorithms; Analgesics, Opioid; Buprenorphine; Dose | 2006 |
Transdermal buprenorphine in cancer pain and palliative care.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Drug Interactions; Fentanyl; Humans; N | 2006 |
Transdermal buprenorphine in cancer pain and palliative care.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Drug Interactions; Fentanyl; Humans; N | 2006 |
Cancer-related breakthrough pain.
Topics: Administration, Buccal; Administration, Oral; Analgesics, Opioid; Dose-Response Relationship, Drug; | 2006 |
Cancer-related breakthrough pain.
Topics: Administration, Buccal; Administration, Oral; Analgesics, Opioid; Dose-Response Relationship, Drug; | 2006 |
Opioids for management of breakthrough pain in cancer patients.
Topics: Administration, Oral; Analgesics, Opioid; Evidence-Based Medicine; Fentanyl; Humans; Neoplasms; Pain | 2006 |
Opioids for management of breakthrough pain in cancer patients.
Topics: Administration, Oral; Analgesics, Opioid; Evidence-Based Medicine; Fentanyl; Humans; Neoplasms; Pain | 2006 |
Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer.
Topics: Administration, Buccal; Analgesics, Opioid; Animals; Drug Tolerance; Fentanyl; Humans; Mouth Mucosa; | 2006 |
Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer.
Topics: Administration, Buccal; Analgesics, Opioid; Animals; Drug Tolerance; Fentanyl; Humans; Mouth Mucosa; | 2006 |
A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; | 2007 |
A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; | 2007 |
Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain?
Topics: Administration, Buccal; Analgesia; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Randomized | 2007 |
Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain?
Topics: Administration, Buccal; Analgesia; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Randomized | 2007 |
Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology.
Topics: Administration, Oral; Analgesics, Opioid; Clinical Trials as Topic; Drug Carriers; Fentanyl; Humans; | 2007 |
Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology.
Topics: Administration, Oral; Analgesics, Opioid; Clinical Trials as Topic; Drug Carriers; Fentanyl; Humans; | 2007 |
Actiq: an effective oral treatment for cancer-related breakthrough pain.
Topics: Administration, Buccal; Analgesics, Opioid; Chemistry, Pharmaceutical; Community Health Nursing; Dru | 2007 |
Actiq: an effective oral treatment for cancer-related breakthrough pain.
Topics: Administration, Buccal; Analgesics, Opioid; Chemistry, Pharmaceutical; Community Health Nursing; Dru | 2007 |
Fentanyl buccal tablet.
Topics: Administration, Buccal; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain; Pain | 2008 |
Fentanyl buccal tablet.
Topics: Administration, Buccal; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain; Pain | 2008 |
Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Buprenorphine; Delayed-Action P | 2008 |
Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Buprenorphine; Delayed-Action P | 2008 |
Management of pain in the older person with cancer. Part 2: treatment options.
Topics: Age Factors; Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Buprenorphine; Female; Fentany | 2008 |
Management of pain in the older person with cancer. Part 2: treatment options.
Topics: Age Factors; Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Buprenorphine; Female; Fentany | 2008 |
Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy.
Topics: Administration, Cutaneous; Drug Evaluation; Fentanyl; Humans; Neoplasms; Pain | 1995 |
Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy.
Topics: Administration, Cutaneous; Drug Evaluation; Fentanyl; Humans; Neoplasms; Pain | 1995 |
Comment: transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Neopl | 1993 |
Comment: transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Neopl | 1993 |
How should we use transdermal fentanyl (TF) for pain management in palliative care patients?
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Canada; Child; Female; Fentanyl; Humans; Male; | 1996 |
How should we use transdermal fentanyl (TF) for pain management in palliative care patients?
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Canada; Child; Female; Fentanyl; Humans; Male; | 1996 |
[Treatment of pain in oncology].
Topics: Administration, Cutaneous; Analgesics, Opioid; Anesthetics, Dissociative; Diphosphonates; Fentanyl; | 1997 |
[Treatment of pain in oncology].
Topics: Administration, Cutaneous; Analgesics, Opioid; Anesthetics, Dissociative; Diphosphonates; Fentanyl; | 1997 |
Current strategies for pain control.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Bone Neoplasms; Fentanyl; Humans; Neoplasms; Pain; Pai | 1997 |
Current strategies for pain control.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Bone Neoplasms; Fentanyl; Humans; Neoplasms; Pain; Pai | 1997 |
Fentanyl in the treatment of cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Biological Availability; Chronic Disease; Fentanyl; | 1997 |
Fentanyl in the treatment of cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Biological Availability; Chronic Disease; Fentanyl; | 1997 |
Caring for adults with chronic cancer pain.
Topics: Adult; Analgesics; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Neoplasms; Oncolog | 1998 |
Caring for adults with chronic cancer pain.
Topics: Adult; Analgesics; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Neoplasms; Oncolog | 1998 |
Practice guidelines for cancer pain therapy. Issues pertinent to the revision of national guidelines.
Topics: Analgesics; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Morphine; Neoplasms; Pain; Pain Mana | 1998 |
Practice guidelines for cancer pain therapy. Issues pertinent to the revision of national guidelines.
Topics: Analgesics; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Morphine; Neoplasms; Pain; Pain Mana | 1998 |
Alternatives to oral opioids for cancer pain.
Topics: Administration, Oral; Administration, Topical; Analgesics, Opioid; Buprenorphine; Fentanyl; Humans; | 1999 |
Alternatives to oral opioids for cancer pain.
Topics: Administration, Oral; Administration, Topical; Analgesics, Opioid; Buprenorphine; Fentanyl; Humans; | 1999 |
Opioid rotation for cancer pain: rationale and clinical aspects.
Topics: Analgesics, Opioid; Fentanyl; Humans; Hydromorphone; Methadone; Morphine; Narcotics; Neoplasms; Pain | 1999 |
Opioid rotation for cancer pain: rationale and clinical aspects.
Topics: Analgesics, Opioid; Fentanyl; Humans; Hydromorphone; Methadone; Morphine; Narcotics; Neoplasms; Pain | 1999 |
Managing breakthrough cancer pain: a new approach.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; Neopla | 1999 |
Managing breakthrough cancer pain: a new approach.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; Neopla | 1999 |
An alternative algorithm for dosing transdermal fentanyl for cancer-related pain.
Topics: Administration, Cutaneous; Algorithms; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain | 2000 |
An alternative algorithm for dosing transdermal fentanyl for cancer-related pain.
Topics: Administration, Cutaneous; Algorithms; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain | 2000 |
Results of the clinical trial of transdermal therapeutic system-fentanyl in strong opioid pre-treated adult patients with cancer-related pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Clinical Trials as Topic; Drug Administration | 2000 |
Results of the clinical trial of transdermal therapeutic system-fentanyl in strong opioid pre-treated adult patients with cancer-related pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Clinical Trials as Topic; Drug Administration | 2000 |
Strong opioids for cancer pain.
Topics: Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Morphine; Neoplasms; Neurotoxicity Syndromes; | 2001 |
Strong opioids for cancer pain.
Topics: Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Morphine; Neoplasms; Neurotoxicity Syndromes; | 2001 |
Contemporary drug therapy in palliative care: new directions.
Topics: Adrenal Cortex Hormones; Analgesics; Anorexia; Antiemetics; Antitussive Agents; Cachexia; Cough; Dru | 2001 |
Contemporary drug therapy in palliative care: new directions.
Topics: Adrenal Cortex Hormones; Analgesics; Anorexia; Antiemetics; Antitussive Agents; Cachexia; Cough; Dru | 2001 |
[Issues in cancer pain management].
Topics: Analgesics, Opioid; Chronic Disease; Clinical Protocols; Fentanyl; Home Care Services; Humans; Morph | 2001 |
[Issues in cancer pain management].
Topics: Analgesics, Opioid; Chronic Disease; Clinical Protocols; Fentanyl; Home Care Services; Humans; Morph | 2001 |
Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.
Topics: Absorption; Administration, Cutaneous; Analgesia; Analgesics, Opioid; Digestive System; Drug Interac | 2001 |
Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.
Topics: Absorption; Administration, Cutaneous; Analgesia; Analgesics, Opioid; Digestive System; Drug Interac | 2001 |
Treatment of cancer pain with transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Pharmaceutical Pre | 2001 |
Treatment of cancer pain with transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Pharmaceutical Pre | 2001 |
Transdermal fentanyl: long-term analgesic studies.
Topics: Administration, Cutaneous; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Neoplasms; P | 1992 |
Transdermal fentanyl: long-term analgesic studies.
Topics: Administration, Cutaneous; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Neoplasms; P | 1992 |
Transdermal fentanyl in cancer pain.
Topics: Administration, Cutaneous; Fentanyl; Humans; Neoplasms; Pain | 1992 |
Transdermal fentanyl in cancer pain.
Topics: Administration, Cutaneous; Fentanyl; Humans; Neoplasms; Pain | 1992 |
Transdermally administered fentanyl for pain management.
Topics: Administration, Cutaneous; Animals; Chronic Disease; Contraindications; Fentanyl; Humans; Neoplasms; | 1992 |
Transdermally administered fentanyl for pain management.
Topics: Administration, Cutaneous; Animals; Chronic Disease; Contraindications; Fentanyl; Humans; Neoplasms; | 1992 |
123 trials available for fentanyl and Neoplasms
| Article | Year |
|---|---|
The efficacy and safety of midazolam with fentanyl versus midazolam with ketamine for bedside invasive procedural sedation in pediatric oncology patients: A randomized, double-blinded, crossover trial.
Topics: Child; Cross-Over Studies; Fentanyl; Humans; Hypnotics and Sedatives; Ketamine; Midazolam; Neoplasms | 2022 |
The efficacy and safety of midazolam with fentanyl versus midazolam with ketamine for bedside invasive procedural sedation in pediatric oncology patients: A randomized, double-blinded, crossover trial.
Topics: Child; Cross-Over Studies; Fentanyl; Humans; Hypnotics and Sedatives; Ketamine; Midazolam; Neoplasms | 2022 |
A comparison of two techniques of postoperative analgesia: lignocaine-fentanyl intravenous infusion and ropivacaine-fentanyl epidural infusion in patients undergoing cytoreductive cancer surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)-
Topics: Analgesia, Epidural; Cytoreduction Surgical Procedures; Fentanyl; Humans; Hyperthermic Intraperitone | 2023 |
A comparison of two techniques of postoperative analgesia: lignocaine-fentanyl intravenous infusion and ropivacaine-fentanyl epidural infusion in patients undergoing cytoreductive cancer surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)-
Topics: Analgesia, Epidural; Cytoreduction Surgical Procedures; Fentanyl; Humans; Hyperthermic Intraperitone | 2023 |
Rigid Mini-Thoracoscopy Versus Semirigid Thoracoscopy in Undiagnosed Exudative Pleural Effusion: The MINT Randomized Controlled Trial.
Topics: Adult; Analgesics, Opioid; Biopsy; Exudates and Transudates; Female; Fentanyl; Humans; Hypnotics and | 2020 |
Rigid Mini-Thoracoscopy Versus Semirigid Thoracoscopy in Undiagnosed Exudative Pleural Effusion: The MINT Randomized Controlled Trial.
Topics: Adult; Analgesics, Opioid; Biopsy; Exudates and Transudates; Female; Fentanyl; Humans; Hypnotics and | 2020 |
Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Cytochrome P-450 CYP3A; Female; Fentanyl; | 2019 |
Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Cytochrome P-450 CYP3A; Female; Fentanyl; | 2019 |
Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: A randomized controlled trial.
Topics: Administration, Intranasal; Administration, Intravenous; Adult; Aged; Analgesics, Opioid; Cancer Pai | 2020 |
Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: A randomized controlled trial.
Topics: Administration, Intranasal; Administration, Intravenous; Adult; Aged; Analgesics, Opioid; Cancer Pai | 2020 |
Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Ca | 2020 |
Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Ca | 2020 |
Analgesic Effect of Intrathecal Fentanyl vs Dexmedetomidine as Adjuvants to Bupivacaine Following Abdominal Surgery for Cancer in Children, a Randomized Trial.
Topics: Analgesics; Anesthetics, Local; Bupivacaine; Child; Dexmedetomidine; Double-Blind Method; Fentanyl; | 2020 |
Analgesic Effect of Intrathecal Fentanyl vs Dexmedetomidine as Adjuvants to Bupivacaine Following Abdominal Surgery for Cancer in Children, a Randomized Trial.
Topics: Analgesics; Anesthetics, Local; Bupivacaine; Child; Dexmedetomidine; Double-Blind Method; Fentanyl; | 2020 |
Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Female; Fentanyl; Health Education; Humans; Male; Middle Ag | 2020 |
Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Female; Fentanyl; Health Education; Humans; Male; Middle Ag | 2020 |
Intranasal Fentanyl Versus Placebo for Treatment of Episodic Breathlessness in Hospice Patients With Advanced Nonmalignant Diseases.
Topics: Analgesics, Opioid; Double-Blind Method; Dyspnea; Fentanyl; Hospices; Humans; Neoplasms | 2021 |
Intranasal Fentanyl Versus Placebo for Treatment of Episodic Breathlessness in Hospice Patients With Advanced Nonmalignant Diseases.
Topics: Analgesics, Opioid; Double-Blind Method; Dyspnea; Fentanyl; Hospices; Humans; Neoplasms | 2021 |
Healthcare professionals' views of the use of oral morphine and transmucosal diamorphine in the management of paediatric breakthrough pain and the feasibility of a randomised controlled trial: A focus group study (DIPPER).
Topics: Analgesics, Opioid; Breakthrough Pain; Child; Delivery of Health Care; Feasibility Studies; Fentanyl | 2021 |
Healthcare professionals' views of the use of oral morphine and transmucosal diamorphine in the management of paediatric breakthrough pain and the feasibility of a randomised controlled trial: A focus group study (DIPPER).
Topics: Analgesics, Opioid; Breakthrough Pain; Child; Delivery of Health Care; Feasibility Studies; Fentanyl | 2021 |
Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Comorbidity; Double-Blind Method; Dyspnea; | 2017 |
Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Comorbidity; Double-Blind Method; Dyspnea; | 2017 |
Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Doubl | 2019 |
Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Doubl | 2019 |
Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl.
Topics: Analgesics, Opioid; Buprenorphine; Cancer Pain; Delayed-Action Preparations; Female; Fentanyl; Human | 2019 |
Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl.
Topics: Analgesics, Opioid; Buprenorphine; Cancer Pain; Delayed-Action Preparations; Female; Fentanyl; Human | 2019 |
[Concomitant use of strong and weak opioids in the management of chronic cancer pain].
Topics: Administration, Cutaneous; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Administration | 2013 |
[Concomitant use of strong and weak opioids in the management of chronic cancer pain].
Topics: Administration, Cutaneous; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Administration | 2013 |
Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial.
Topics: Adult; Aged; Analgesics, Opioid; Double-Blind Method; Dyspnea; Exercise; Exercise Test; Fatigue; Fea | 2014 |
Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial.
Topics: Adult; Aged; Analgesics, Opioid; Double-Blind Method; Dyspnea; Exercise; Exercise Test; Fatigue; Fea | 2014 |
Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase
Topics: Administration, Buccal; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Breakthrough Pain; C | 2013 |
Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase
Topics: Administration, Buccal; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Breakthrough Pain; C | 2013 |
A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Topics: Administration, Buccal; Aged; Analgesics, Opioid; Breakthrough Pain; Double-Blind Method; Female; Fe | 2014 |
A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Topics: Administration, Buccal; Aged; Analgesics, Opioid; Breakthrough Pain; Double-Blind Method; Female; Fe | 2014 |
A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain.
Topics: Administration, Intranasal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Drug Combinations; F | 2014 |
A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain.
Topics: Administration, Intranasal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Drug Combinations; F | 2014 |
A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer.
Topics: Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Female; Fe | 2015 |
A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer.
Topics: Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Female; Fe | 2015 |
Efficacy and safety of a six-hour continuous overlap method for converting intravenous to transdermal fentanyl in cancer pain.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Analgesics, | 2014 |
Efficacy and safety of a six-hour continuous overlap method for converting intravenous to transdermal fentanyl in cancer pain.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Analgesics, | 2014 |
Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Area Under Curve; Drug Deliv | 2014 |
Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Area Under Curve; Drug Deliv | 2014 |
Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Topics: Administration, Oral; Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Doubl | 2014 |
Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Topics: Administration, Oral; Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Doubl | 2014 |
A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cross-Over Studies; | 2014 |
A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cross-Over Studies; | 2014 |
Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cross-Sectional Studies; Dose | 2014 |
Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cross-Sectional Studies; Dose | 2014 |
Lack of association between genetic variability and multiple pain-related outcomes in a large cohort of patients with advanced cancer: the European Pharmacogenetic Opioid Study (EPOS).
Topics: Analgesics, Opioid; Cohort Studies; Europe; Female; Fentanyl; Genetic Association Studies; Genetic V | 2012 |
Lack of association between genetic variability and multiple pain-related outcomes in a large cohort of patients with advanced cancer: the European Pharmacogenetic Opioid Study (EPOS).
Topics: Analgesics, Opioid; Cohort Studies; Europe; Female; Fentanyl; Genetic Association Studies; Genetic V | 2012 |
Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; D | 2015 |
Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; D | 2015 |
Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Hu | 2015 |
Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Hu | 2015 |
[Opioid induction using rapid release drugs and the shift to fentanyl patches].
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Ma | 2014 |
[Opioid induction using rapid release drugs and the shift to fentanyl patches].
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Ma | 2014 |
Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Dose-Response Relationship, Drug; Ethnicity; Fem | 2015 |
Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Dose-Response Relationship, Drug; Ethnicity; Fem | 2015 |
Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain | 2015 |
Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Breakthrough Pain | 2015 |
Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese c
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Asian People; Breakthrou | 2015 |
Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese c
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Asian People; Breakthrou | 2015 |
Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain.
Topics: Administration, Buccal; Adult; Affect; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Huma | 2015 |
Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain.
Topics: Administration, Buccal; Adult; Affect; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Huma | 2015 |
Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain.
Topics: Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cross-Over Studies; Double-Blind Method; Female; | 2015 |
Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain.
Topics: Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cross-Over Studies; Double-Blind Method; Female; | 2015 |
The clinical effect of fentanyl in comparison with ketamine in analgesic effect for oncology procedures in children: a randomized, double-blinded, crossover trial.
Topics: Adolescent; Analgesics; Analgesics, Opioid; Child; Child, Preschool; Cross-Over Studies; Double-Blin | 2015 |
The clinical effect of fentanyl in comparison with ketamine in analgesic effect for oncology procedures in children: a randomized, double-blinded, crossover trial.
Topics: Adolescent; Analgesics; Analgesics, Opioid; Child; Child, Preschool; Cross-Over Studies; Double-Blin | 2015 |
Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Cross-Over Studies; Female; Fentanyl; | 2015 |
Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Cross-Over Studies; Female; Fentanyl; | 2015 |
A phase II study on the efficacy and safety of procedural analgesia with fentanyl buccal tablet in cancer patients for the placement of indwelling central venous access systems.
Topics: Administration, Buccal; Aged; Analgesics, Opioid; Central Venous Catheters; Female; Fentanyl; Humans | 2016 |
A phase II study on the efficacy and safety of procedural analgesia with fentanyl buccal tablet in cancer patients for the placement of indwelling central venous access systems.
Topics: Administration, Buccal; Aged; Analgesics, Opioid; Central Venous Catheters; Female; Fentanyl; Humans | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Drug-Related Side Effects and Adverse Reactions; Femal | 2016 |
Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial.
Topics: Administration, Intranasal; Analgesics, Opioid; Double-Blind Method; Dyspnea; Exercise; Female; Fent | 2016 |
Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial.
Topics: Administration, Intranasal; Analgesics, Opioid; Double-Blind Method; Dyspnea; Exercise; Female; Fent | 2016 |
EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial.
Topics: Administration, Buccal; Analgesics, Opioid; Cross-Over Studies; Disease Progression; Dyspnea; Feasib | 2016 |
EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial.
Topics: Administration, Buccal; Analgesics, Opioid; Cross-Over Studies; Disease Progression; Dyspnea; Feasib | 2016 |
Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Double- | 2017 |
Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Double- | 2017 |
A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Bandages; Delayed-Action Preparations; Europe; Female | 2008 |
A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Bandages; Delayed-Action Preparations; Europe; Female | 2008 |
Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Buprenor | 2009 |
Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Buprenor | 2009 |
Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
Topics: Administration, Buccal; Analgesics, Opioid; Chronic Disease; Disease Progression; Drug Tolerance; Fe | 2009 |
Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
Topics: Administration, Buccal; Analgesics, Opioid; Chronic Disease; Disease Progression; Drug Tolerance; Fe | 2009 |
Opioids switching with transdermal systems in chronic cancer pain.
Topics: Adult; Aged; Analgesia; Analgesics, Opioid; Buprenorphine; Chronic Disease; Female; Fentanyl; Humans | 2009 |
Opioids switching with transdermal systems in chronic cancer pain.
Topics: Adult; Aged; Analgesia; Analgesics, Opioid; Buprenorphine; Chronic Disease; Female; Fentanyl; Humans | 2009 |
Transdermal fentanyl in cachectic cancer patients.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Analgesics, Opioid; Body Mass Index; Cachexia; C | 2009 |
Transdermal fentanyl in cachectic cancer patients.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Analgesics, Opioid; Body Mass Index; Cachexia; C | 2009 |
Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatmen
Topics: Administration, Intranasal; Adult; Aged; Analgesics, Opioid; Cross-Over Studies; Disease Progression | 2009 |
Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatmen
Topics: Administration, Intranasal; Adult; Aged; Analgesics, Opioid; Cross-Over Studies; Disease Progression | 2009 |
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Algorithms; Cross-Over Studies; Dose-Respon | 2009 |
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Algorithms; Cross-Over Studies; Dose-Respon | 2009 |
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Algorithms; Cross-Over Studies; Dose-Respon | 2009 |
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Algorithms; Cross-Over Studies; Dose-Respon | 2009 |
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Algorithms; Cross-Over Studies; Dose-Respon | 2009 |
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Algorithms; Cross-Over Studies; Dose-Respon | 2009 |
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Algorithms; Cross-Over Studies; Dose-Respon | 2009 |
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Algorithms; Cross-Over Studies; Dose-Respon | 2009 |
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analgesics, Opioid; Double-B | 2009 |
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analgesics, Opioid; Double-B | 2009 |
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analgesics, Opioid; Double-B | 2009 |
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analgesics, Opioid; Double-B | 2009 |
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analgesics, Opioid; Double-B | 2009 |
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analgesics, Opioid; Double-B | 2009 |
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analgesics, Opioid; Double-B | 2009 |
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analgesics, Opioid; Double-B | 2009 |
Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Dosage Forms; Dose-Response Relationship, D | 2010 |
Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Dosage Forms; Dose-Response Relationship, D | 2010 |
Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study.
Topics: Administration, Sublingual; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cross-Ov | 2010 |
Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study.
Topics: Administration, Sublingual; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cross-Ov | 2010 |
Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Chronic Disease; Double-Blind Method; Female; F | 2011 |
Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Chronic Disease; Double-Blind Method; Female; F | 2011 |
A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Female; Fen | 2010 |
A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Female; Fen | 2010 |
[A phase II clinical study of once-a-day fentanyl citrate patch in patients with cancer pain--switching from once-every-three-days fentanyl patch to once-a-day fentanyl citrate patch].
Topics: Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain | 2010 |
[A phase II clinical study of once-a-day fentanyl citrate patch in patients with cancer pain--switching from once-every-three-days fentanyl patch to once-a-day fentanyl citrate patch].
Topics: Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain | 2010 |
[Breakthrough pain frequency in cancer patients and the efficiency of oral transmucosal fentanyl citrate].
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Narcotics; Ne | 2010 |
[Breakthrough pain frequency in cancer patients and the efficiency of oral transmucosal fentanyl citrate].
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Narcotics; Ne | 2010 |
The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Tole | 2011 |
The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Tole | 2011 |
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.
Topics: Aged; Analgesia; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentanyl; Humans; Mal | 2010 |
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.
Topics: Aged; Analgesia; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentanyl; Humans; Mal | 2010 |
Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analge | 2011 |
Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analge | 2011 |
Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain.
Topics: Administration, Intranasal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cross-Over Studies; | 2011 |
Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain.
Topics: Administration, Intranasal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cross-Over Studies; | 2011 |
[Clinical study of one-day fentanyl patch in patients with cancer pain--evaluation of the efficacy and safety in relation to treatment switch from opioid analgesic therapy].
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Dosage Forms; Female; Fentanyl; Humans; Male; M | 2011 |
[Clinical study of one-day fentanyl patch in patients with cancer pain--evaluation of the efficacy and safety in relation to treatment switch from opioid analgesic therapy].
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Dosage Forms; Female; Fentanyl; Humans; Male; M | 2011 |
[Double-blind parallel-group dose-titration study comparing a fentanyl-containing patch formulated for 1-day application for the treatment of cancer pain with Durotep MT Patch].
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Dosage Forms; Double-Blind Method; Female; Fent | 2011 |
[Double-blind parallel-group dose-titration study comparing a fentanyl-containing patch formulated for 1-day application for the treatment of cancer pain with Durotep MT Patch].
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Dosage Forms; Double-Blind Method; Female; Fent | 2011 |
Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analgesics, Opioid; Female; | 2011 |
Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Algorithms; Analgesics, Opioid; Female; | 2011 |
Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; D | 2012 |
Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; D | 2012 |
[Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Analgesics, Opioid; Drug T | 2012 |
[Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Analgesics, Opioid; Drug T | 2012 |
Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Breakthrough Pain; Dose-Response Relationship, Drug; | 2012 |
Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Breakthrough Pain; Dose-Response Relationship, Drug; | 2012 |
Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Double-Blind Method; Female; Fentanyl; Humans; | 2012 |
Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Double-Blind Method; Female; Fentanyl; Humans; | 2012 |
Prospective randomized crossover evaluation of three anesthetic regimens for painful procedures in children with cancer.
Topics: Adolescent; Anesthesia; Anesthetics, Intravenous; Bone Marrow Examination; Child; Child, Preschool; | 2013 |
Prospective randomized crossover evaluation of three anesthetic regimens for painful procedures in children with cancer.
Topics: Adolescent; Anesthesia; Anesthetics, Intravenous; Bone Marrow Examination; Child; Child, Preschool; | 2013 |
A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Disease; Chronic Pain; | 2013 |
A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Disease; Chronic Pain; | 2013 |
Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cognition Disorders; | 2002 |
Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cognition Disorders; | 2002 |
Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Analgesics, Opioid; Delayed-Action Preparatio | 2003 |
Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Analgesics, Opioid; Delayed-Action Preparatio | 2003 |
Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
Topics: Administration, Cutaneous; Analgesics, Non-Narcotic; Analgesics, Opioid; Female; Fentanyl; Gastroint | 2004 |
Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
Topics: Administration, Cutaneous; Analgesics, Non-Narcotic; Analgesics, Opioid; Female; Fentanyl; Gastroint | 2004 |
Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Follow-Up Studies; Hum | 2004 |
Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Follow-Up Studies; Hum | 2004 |
Addition of a second opioid may improve opioid response in cancer pain: preliminary data.
Topics: Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 2004 |
Addition of a second opioid may improve opioid response in cancer pain: preliminary data.
Topics: Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 2004 |
Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Drug Administratio | 2004 |
Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Drug Administratio | 2004 |
Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans | 2004 |
Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans | 2004 |
Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Analysis of Variance; Area Under Curve; | 2005 |
Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Analysis of Variance; Area Under Curve; | 2005 |
Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Analysis of Variance; Area Under Curve; | 2005 |
Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Analysis of Variance; Area Under Curve; | 2005 |
Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Analysis of Variance; Area Under Curve; | 2005 |
Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Analysis of Variance; Area Under Curve; | 2005 |
Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Analysis of Variance; Area Under Curve; | 2005 |
Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Analysis of Variance; Area Under Curve; | 2005 |
Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial.
Topics: Aged; Analgesics, Opioid; Delirium; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2005 |
Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial.
Topics: Aged; Analgesics, Opioid; Delirium; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2005 |
Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.
Topics: Acetaminophen; Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; | 2005 |
Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.
Topics: Acetaminophen; Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; | 2005 |
Rapid switching between transdermal fentanyl and methadone in cancer patients.
Topics: Administration, Cutaneous; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Methadone; Middle Age | 2005 |
Rapid switching between transdermal fentanyl and methadone in cancer patients.
Topics: Administration, Cutaneous; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Methadone; Middle Age | 2005 |
Opioid-induced respiratory effects: new data on buprenorphine.
Topics: Analgesics, Opioid; Apnea; Buprenorphine; Dose-Response Relationship, Drug; Double-Blind Method; Fen | 2006 |
Opioid-induced respiratory effects: new data on buprenorphine.
Topics: Analgesics, Opioid; Apnea; Buprenorphine; Dose-Response Relationship, Drug; Double-Blind Method; Fen | 2006 |
Safety and efficacy of transdermal fentanyl in patients with cancer pain: phase IV, Turkish oncology group trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Mi | 2007 |
Safety and efficacy of transdermal fentanyl in patients with cancer pain: phase IV, Turkish oncology group trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Mi | 2007 |
Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
Topics: Administration, Oral; Adolescent; Adult; Analgesics, Opioid; Child; Child, Preschool; Cross-Over Stu | 2007 |
Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
Topics: Administration, Oral; Adolescent; Adult; Analgesics, Opioid; Child; Child, Preschool; Cross-Over Stu | 2007 |
Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study.
Topics: Absorption; Administration, Buccal; Adult; Aged; Analgesics, Opioid; Antineoplastic Agents; Female; | 2007 |
Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study.
Topics: Absorption; Administration, Buccal; Adult; Aged; Analgesics, Opioid; Antineoplastic Agents; Female; | 2007 |
Improved cancer pain treatment using combined fentanyl-TTS and tramadol.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2007 |
Improved cancer pain treatment using combined fentanyl-TTS and tramadol.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2007 |
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Analgesia; Analgesics, Opi | 2008 |
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Analgesia; Analgesics, Opi | 2008 |
Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Endpoint Determination; Female; Fentanyl | 2008 |
Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Endpoint Determination; Female; Fentanyl | 2008 |
[Epidural application of opiates in chronic pain due to malignoma (author's transl)].
Topics: Adult; Aged; Catheterization; Female; Fentanyl; Humans; Male; Meperidine; Middle Aged; Morphine; Nar | 1981 |
[Epidural application of opiates in chronic pain due to malignoma (author's transl)].
Topics: Adult; Aged; Catheterization; Female; Fentanyl; Humans; Male; Meperidine; Middle Aged; Morphine; Nar | 1981 |
Transdermal fentanyl: a new step on the therapeutic ladder.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Bl | 1995 |
Transdermal fentanyl: a new step on the therapeutic ladder.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Bl | 1995 |
Transdermal fentanyl in combination with initial intravenous dose titration by patient-controlled analgesia.
Topics: Administration, Cutaneous; Analgesia, Patient-Controlled; Analgesics; Constipation; Dose-Response Re | 1995 |
Transdermal fentanyl in combination with initial intravenous dose titration by patient-controlled analgesia.
Topics: Administration, Cutaneous; Analgesia, Patient-Controlled; Analgesics; Constipation; Dose-Response Re | 1995 |
Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients.
Topics: Administration, Cutaneous; Administration, Oral; Fentanyl; Gastrointestinal Motility; Humans; Morphi | 1994 |
Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients.
Topics: Administration, Cutaneous; Administration, Oral; Fentanyl; Gastrointestinal Motility; Humans; Morphi | 1994 |
Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period.
Topics: Adult; Aged; Anesthetics, Intravenous; Chromium; Cytotoxicity, Immunologic; Female; Fentanyl; Humans | 1996 |
Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period.
Topics: Adult; Aged; Anesthetics, Intravenous; Chromium; Cytotoxicity, Immunologic; Female; Fentanyl; Humans | 1996 |
Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle A | 1996 |
Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle A | 1996 |
Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle A | 1996 |
Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle A | 1996 |
Management of cancer-related pain with transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Female | 1996 |
Management of cancer-related pain with transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Female | 1996 |
Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Analgesics, Opioid; Fentanyl; Humans; Middle Aged; | 1996 |
Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Analgesics, Opioid; Fentanyl; Humans; Middle Aged; | 1996 |
Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analges | 1997 |
Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analges | 1997 |
Transdermal fentanyl for severe cancer-related pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle A | 1997 |
Transdermal fentanyl for severe cancer-related pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle A | 1997 |
Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; | 1997 |
Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; | 1997 |
Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Cross-Sectional Studies; Delayed-Action Prepara | 1998 |
Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Cross-Sectional Studies; Delayed-Action Prepara | 1998 |
Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Double-Blind Method; Femal | 1998 |
Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Double-Blind Method; Femal | 1998 |
Long-term treatment of cancer pain with transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle A | 1998 |
Long-term treatment of cancer pain with transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle A | 1998 |
A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Evaluation | 1998 |
A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Evaluation | 1998 |
Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
Topics: Administration, Buccal; Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioi | 1998 |
Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
Topics: Administration, Buccal; Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioi | 1998 |
Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study.
Topics: Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Injections, Subcutaneous; Male; Neoplasms; Pain, | 1998 |
Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study.
Topics: Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Injections, Subcutaneous; Male; Neoplasms; Pain, | 1998 |
Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates.
Topics: Administration, Cutaneous; Adolescent; Analgesics, Opioid; Child; Feasibility Studies; Fentanyl; Hum | 1999 |
Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates.
Topics: Administration, Cutaneous; Adolescent; Analgesics, Opioid; Child; Feasibility Studies; Fentanyl; Hum | 1999 |
Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Double-Blin | 1999 |
Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Double-Blin | 1999 |
A comparison of subcutaneous morphine and fentanyl in hospice cancer patients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hospice Care; Humans; Injections, Sub | 1999 |
A comparison of subcutaneous morphine and fentanyl in hospice cancer patients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hospice Care; Humans; Injections, Sub | 1999 |
Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine.
Topics: Administration, Cutaneous; Analgesics, Opioid; Codeine; Fentanyl; Humans; Neoplasms; Pain | 2000 |
Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine.
Topics: Administration, Cutaneous; Analgesics, Opioid; Codeine; Fentanyl; Humans; Neoplasms; Pain | 2000 |
Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2000 |
Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2000 |
[Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)].
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2000 |
[Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)].
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2000 |
Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cross-Over Studies; Dose-R | 2001 |
Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cross-Over Studies; Dose-R | 2001 |
Long-term observations of patients receiving transdermal fentanyl after a randomized trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; F | 2001 |
Long-term observations of patients receiving transdermal fentanyl after a randomized trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; F | 2001 |
Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Analgesics, Opioid; Female; F | 2001 |
Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Analgesics, Opioid; Female; F | 2001 |
A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Infusions, Int | 2001 |
A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Infusions, Int | 2001 |
Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentan | 2002 |
Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentan | 2002 |
Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Hydromorphone; Levorphanol; Male; Methado | 2002 |
Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Hydromorphone; Levorphanol; Male; Methado | 2002 |
Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hu | 2001 |
Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hu | 2001 |
Transdermal fentanyl: clinical trial at the University of Colorado Health Sciences Center.
Topics: Administration, Cutaneous; Adult; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain | 1992 |
Transdermal fentanyl: clinical trial at the University of Colorado Health Sciences Center.
Topics: Administration, Cutaneous; Adult; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain | 1992 |
Transdermal fentanyl: seeding trial in patients with chronic cancer pain.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Female; Fentanyl; Humans; Male; Middle Aged; Neo | 1992 |
Transdermal fentanyl: seeding trial in patients with chronic cancer pain.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Female; Fentanyl; Humans; Male; Middle Aged; Neo | 1992 |
Transdermal fentanyl for chronic cancer pain: detailed case reports and the influence of confounding factors.
Topics: Administration, Cutaneous; Aged; Chronic Disease; Confounding Factors, Epidemiologic; Female; Fentan | 1992 |
Transdermal fentanyl for chronic cancer pain: detailed case reports and the influence of confounding factors.
Topics: Administration, Cutaneous; Aged; Chronic Disease; Confounding Factors, Epidemiologic; Female; Fentan | 1992 |
Transdermal fentanyl use in hospice home-care patients with chronic cancer pain.
Topics: Administration, Cutaneous; Aged; Chronic Disease; Female; Fentanyl; Home Care Services; Hospices; Hu | 1992 |
Transdermal fentanyl use in hospice home-care patients with chronic cancer pain.
Topics: Administration, Cutaneous; Aged; Chronic Disease; Female; Fentanyl; Home Care Services; Hospices; Hu | 1992 |
Management of cancer pain with transdermal fentanyl: phase IV trial, University of Iowa.
Topics: Administration, Cutaneous; Aged; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain | 1992 |
Management of cancer pain with transdermal fentanyl: phase IV trial, University of Iowa.
Topics: Administration, Cutaneous; Aged; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain | 1992 |
Midazolam versus fentanyl as premedication for painful procedures in children with cancer.
Topics: Adolescent; Anxiety; Bone Marrow Examination; Child; Child, Preschool; Conscious Sedation; Double-Bl | 1992 |
Midazolam versus fentanyl as premedication for painful procedures in children with cancer.
Topics: Adolescent; Anxiety; Bone Marrow Examination; Child; Child, Preschool; Conscious Sedation; Double-Bl | 1992 |
Intravenous midazolam versus fentanyl as premedication for painful procedures in pediatric oncology patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Double-Blind Method; Fentanyl; Humans; Midazolam; Neopla | 1991 |
Intravenous midazolam versus fentanyl as premedication for painful procedures in pediatric oncology patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Double-Blind Method; Fentanyl; Humans; Midazolam; Neopla | 1991 |
266 other studies available for fentanyl and Neoplasms
| Article | Year |
|---|---|
Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; F | 2021 |
Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; F | 2021 |
Opioid-induced adrenal insufficiency in transdermal fentanyl treatment: a revisited diagnosis in clinical setting.
Topics: Adrenal Insufficiency; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Middle Aged; Neop | 2022 |
Opioid-induced adrenal insufficiency in transdermal fentanyl treatment: a revisited diagnosis in clinical setting.
Topics: Adrenal Insufficiency; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Middle Aged; Neop | 2022 |
Transdermal Fentanyl Usage in Working-age Patients Undergoing Cancer Treatment: Prescription Pattern Analysis Using Large Claims Data in Japan.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Japan; Male; Middle Aged; Ne | 2021 |
Transdermal Fentanyl Usage in Working-age Patients Undergoing Cancer Treatment: Prescription Pattern Analysis Using Large Claims Data in Japan.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Japan; Male; Middle Aged; Ne | 2021 |
[Opioid rotation in cancer related "mixed pain" scenario : How a "chronic pain patient" becomes a "palliative patient"-a case report].
Topics: Aged; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Humans; Neoplasms | 2022 |
[Opioid rotation in cancer related "mixed pain" scenario : How a "chronic pain patient" becomes a "palliative patient"-a case report].
Topics: Aged; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Humans; Neoplasms | 2022 |
An Open-Label Study of the Pharmacokinetics and Tolerability of Once-a-Day Fentanyl Citrate Patch in Japanese Pediatric and Adolescent Patients with Cancer Pain.
Topics: Administration, Cutaneous; Adolescent; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Fen | 2021 |
An Open-Label Study of the Pharmacokinetics and Tolerability of Once-a-Day Fentanyl Citrate Patch in Japanese Pediatric and Adolescent Patients with Cancer Pain.
Topics: Administration, Cutaneous; Adolescent; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Fen | 2021 |
Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms; Palliative Care; Pr | 2022 |
Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms; Palliative Care; Pr | 2022 |
The Prevalence of Off-label Prescribing of Transmucosal Immediate-Release Fentanyl in France.
Topics: Aged; Analgesics, Opioid; Cross-Sectional Studies; Female; Fentanyl; France; Humans; Male; Neoplasms | 2022 |
The Prevalence of Off-label Prescribing of Transmucosal Immediate-Release Fentanyl in France.
Topics: Aged; Analgesics, Opioid; Cross-Sectional Studies; Female; Fentanyl; France; Humans; Male; Neoplasms | 2022 |
[For the Clinical Use-Clinical Guidelines for Pharmacological Management of Cancer Pain 2020].
Topics: Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Morphine; Neoplasms; Tramadol | 2022 |
[For the Clinical Use-Clinical Guidelines for Pharmacological Management of Cancer Pain 2020].
Topics: Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Morphine; Neoplasms; Tramadol | 2022 |
Tolerance of Fentanyl Pectin Nasal Spray for Procedural Pain in Geriatric Patients.
Topics: Aged; Analgesics, Opioid; Drug-Related Side Effects and Adverse Reactions; Fentanyl; Humans; Nasal S | 2022 |
Tolerance of Fentanyl Pectin Nasal Spray for Procedural Pain in Geriatric Patients.
Topics: Aged; Analgesics, Opioid; Drug-Related Side Effects and Adverse Reactions; Fentanyl; Humans; Nasal S | 2022 |
Fentanyl pharmacokinetics in blood of cancer patients by Gas Chromatography - Mass Spectrometry.
Topics: Fentanyl; Gas Chromatography-Mass Spectrometry; Humans; Limit of Detection; Liquid-Liquid Extraction | 2022 |
Fentanyl pharmacokinetics in blood of cancer patients by Gas Chromatography - Mass Spectrometry.
Topics: Fentanyl; Gas Chromatography-Mass Spectrometry; Humans; Limit of Detection; Liquid-Liquid Extraction | 2022 |
Trends in strong opioid prescription for cancer patients in Japan from 2010 to 2019: an analysis with large medical claims data.
Topics: Aged; Analgesics, Opioid; Drug Prescriptions; Fentanyl; Humans; Infant; Japan; Morphine; Neoplasms; | 2022 |
Trends in strong opioid prescription for cancer patients in Japan from 2010 to 2019: an analysis with large medical claims data.
Topics: Aged; Analgesics, Opioid; Drug Prescriptions; Fentanyl; Humans; Infant; Japan; Morphine; Neoplasms; | 2022 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Differences in Fentanyl Requirements in Terminally Ill Cancer Patients.
Topics: Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Humans; Male; Neoplasms; Pancreatic Neoplasms; Re | 2023 |
Abuse, dependence and withdrawal associated with fentanyl and the role of its (designated) route of administration: an analysis of spontaneous reports from Europe.
Topics: Administration, Cutaneous; Analgesics, Opioid; Europe; Female; Fentanyl; Humans; Male; Middle Aged; | 2023 |
Abuse, dependence and withdrawal associated with fentanyl and the role of its (designated) route of administration: an analysis of spontaneous reports from Europe.
Topics: Administration, Cutaneous; Analgesics, Opioid; Europe; Female; Fentanyl; Humans; Male; Middle Aged; | 2023 |
Abuse, dependence and withdrawal associated with fentanyl and the role of its (designated) route of administration: an analysis of spontaneous reports from Europe.
Topics: Administration, Cutaneous; Analgesics, Opioid; Europe; Female; Fentanyl; Humans; Male; Middle Aged; | 2023 |
Abuse, dependence and withdrawal associated with fentanyl and the role of its (designated) route of administration: an analysis of spontaneous reports from Europe.
Topics: Administration, Cutaneous; Analgesics, Opioid; Europe; Female; Fentanyl; Humans; Male; Middle Aged; | 2023 |
Abuse, dependence and withdrawal associated with fentanyl and the role of its (designated) route of administration: an analysis of spontaneous reports from Europe.
Topics: Administration, Cutaneous; Analgesics, Opioid; Europe; Female; Fentanyl; Humans; Male; Middle Aged; | 2023 |
Abuse, dependence and withdrawal associated with fentanyl and the role of its (designated) route of administration: an analysis of spontaneous reports from Europe.
Topics: Administration, Cutaneous; Analgesics, Opioid; Europe; Female; Fentanyl; Humans; Male; Middle Aged; | 2023 |
Abuse, dependence and withdrawal associated with fentanyl and the role of its (designated) route of administration: an analysis of spontaneous reports from Europe.
Topics: Administration, Cutaneous; Analgesics, Opioid; Europe; Female; Fentanyl; Humans; Male; Middle Aged; | 2023 |
Abuse, dependence and withdrawal associated with fentanyl and the role of its (designated) route of administration: an analysis of spontaneous reports from Europe.
Topics: Administration, Cutaneous; Analgesics, Opioid; Europe; Female; Fentanyl; Humans; Male; Middle Aged; | 2023 |
Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Male; Neoplasms; Pa | 2023 |
Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients.
Topics: Administration, Buccal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Male; Neoplasms; Pa | 2023 |
Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Multiple Myeloma; Neoplasms; Pain Managemen | 2023 |
Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Multiple Myeloma; Neoplasms; Pain Managemen | 2023 |
An individualized digital twin of a patient for transdermal fentanyl therapy for chronic pain management.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Pain Management | 2023 |
An individualized digital twin of a patient for transdermal fentanyl therapy for chronic pain management.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Pain Management | 2023 |
Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain.
Topics: Administration, Cutaneous; Analgesics; Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Neoplasms; | 2023 |
Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain.
Topics: Administration, Cutaneous; Analgesics; Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Neoplasms; | 2023 |
Transdermal fentanyl to parenteral morphine route switch and drug rotation in refractory cancer cachexia.
Topics: Administration, Cutaneous; Analgesics, Opioid; Cachexia; Female; Fentanyl; Humans; Morphine; Neoplas | 2022 |
Transdermal fentanyl to parenteral morphine route switch and drug rotation in refractory cancer cachexia.
Topics: Administration, Cutaneous; Analgesics, Opioid; Cachexia; Female; Fentanyl; Humans; Morphine; Neoplas | 2022 |
Does transdermal fentanyl work in patients with low BMI? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Body Mass Index; Cancer Pain; Female; Fentanyl; Human | 2019 |
Does transdermal fentanyl work in patients with low BMI? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Body Mass Index; Cancer Pain; Female; Fentanyl; Human | 2019 |
Long-term analgesic pharmacotherapy in addiction to intranasal fentanyl.
Topics: Administration, Intranasal; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Qual | 2022 |
Long-term analgesic pharmacotherapy in addiction to intranasal fentanyl.
Topics: Administration, Intranasal; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Qual | 2022 |
Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch.
Topics: Aged; Analgesics, Opioid; Cachexia; Cancer Pain; Female; Fentanyl; Humans; Male; Middle Aged; Morphi | 2020 |
Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch.
Topics: Aged; Analgesics, Opioid; Cachexia; Cancer Pain; Female; Fentanyl; Humans; Male; Middle Aged; Morphi | 2020 |
[Analysis of Symptoms Relieved in Addition to Pain after Administration of Oxycodone or Morphine to Patients with Advanced Cancer Living at Home].
Topics: Administration, Cutaneous; Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Morphine; Neoplasms; O | 2020 |
[Analysis of Symptoms Relieved in Addition to Pain after Administration of Oxycodone or Morphine to Patients with Advanced Cancer Living at Home].
Topics: Administration, Cutaneous; Analgesics, Opioid; Cancer Pain; Fentanyl; Humans; Morphine; Neoplasms; O | 2020 |
A Case of Breakthrough Pain Management with Subcutaneous Fentanyl Administration in a Female Child.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Child; Diagnostic Tests, Routine; Femal | 2020 |
A Case of Breakthrough Pain Management with Subcutaneous Fentanyl Administration in a Female Child.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Child; Diagnostic Tests, Routine; Femal | 2020 |
Severe Drowsiness with Fever Induced by Transdermal Fentanyl Administration.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms | 2020 |
Severe Drowsiness with Fever Induced by Transdermal Fentanyl Administration.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms | 2020 |
Pseudo-addiction in cancer patients and rapid-release fentanyl for breakthrough pain: An increasingly common concern.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2021 |
Pseudo-addiction in cancer patients and rapid-release fentanyl for breakthrough pain: An increasingly common concern.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2021 |
[A Case Report of Impaired Consciousness in a Patient after Receiving the Fourth Dose of Fentanyl Sublingual Tablet].
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Consciousness; Fentanyl; Hu | 2020 |
[A Case Report of Impaired Consciousness in a Patient after Receiving the Fourth Dose of Fentanyl Sublingual Tablet].
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Consciousness; Fentanyl; Hu | 2020 |
Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors.
Topics: Aged; Analgesics, Opioid; Female; Fentanyl; France; Humans; Laxatives; Male; Neoplasms; Opioid-Relat | 2022 |
Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors.
Topics: Aged; Analgesics, Opioid; Female; Fentanyl; France; Humans; Laxatives; Male; Neoplasms; Opioid-Relat | 2022 |
[A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Mouth Mu | 2017 |
[A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Mouth Mu | 2017 |
Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study.
Topics: Administration, Sublingual; Age Factors; Aged; Analgesics, Opioid; Anxiety; Breakthrough Pain; Cance | 2017 |
Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study.
Topics: Administration, Sublingual; Age Factors; Aged; Analgesics, Opioid; Anxiety; Breakthrough Pain; Cance | 2017 |
Barriers to the use of buccal and intranasal fentanyl for breakthrough pain in paediatric palliative care: an exploratory survey.
Topics: Administration, Buccal; Administration, Intranasal; Adolescent; Analgesics, Opioid; Breakthrough Pai | 2018 |
Barriers to the use of buccal and intranasal fentanyl for breakthrough pain in paediatric palliative care: an exploratory survey.
Topics: Administration, Buccal; Administration, Intranasal; Adolescent; Analgesics, Opioid; Breakthrough Pai | 2018 |
Experiences with Cutting Matrix Fentanyl Patches as a Method of Dose Titration in Cancer Patients.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Interviews as | 2017 |
Experiences with Cutting Matrix Fentanyl Patches as a Method of Dose Titration in Cancer Patients.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Interviews as | 2017 |
Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cance | 2018 |
Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cance | 2018 |
Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections-Results from a matched case-control study.
Topics: Adult; Aged; Dietary Supplements; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain Manag | 2017 |
Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections-Results from a matched case-control study.
Topics: Adult; Aged; Dietary Supplements; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain Manag | 2017 |
Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Analgesics, Non-Narcot | 2017 |
Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Analgesics, Non-Narcot | 2017 |
Factors Associated with Inadequate Pain Control among Postoperative Patients with Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesia, Epidural; Bupivacaine; Cross-Sectional Studie | 2018 |
Factors Associated with Inadequate Pain Control among Postoperative Patients with Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesia, Epidural; Bupivacaine; Cross-Sectional Studie | 2018 |
Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Drug Combinations; Drug The | 2018 |
Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Drug Combinations; Drug The | 2018 |
Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Analgesics, | 2019 |
Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Analgesics, | 2019 |
Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Topics: Administration, Buccal; Administration, Intranasal; Aged; Aged, 80 and over; Analgesics, Opioid; Bre | 2018 |
Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Topics: Administration, Buccal; Administration, Intranasal; Aged; Aged, 80 and over; Analgesics, Opioid; Bre | 2018 |
Optimal treatment of opioid induced constipation in daily clinical practice - an observational study.
Topics: Aged; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Laxatives; Male; Middle Aged; Nalt | 2019 |
Optimal treatment of opioid induced constipation in daily clinical practice - an observational study.
Topics: Aged; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Laxatives; Male; Middle Aged; Nalt | 2019 |
Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Female; Fentanyl | 2019 |
Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Female; Fentanyl | 2019 |
Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Female; Fentan | 2019 |
Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
Topics: Administration, Sublingual; Aged; Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Female; Fentan | 2019 |
The Current Practice of Opioid for Cancer Dyspnea: The Result From the Nationwide Survey of Japanese Palliative Care Physicians.
Topics: Analgesics, Opioid; Dyspnea; Fentanyl; Humans; Japan; Morphine; Neoplasms; Oxycodone; Palliative Car | 2019 |
The Current Practice of Opioid for Cancer Dyspnea: The Result From the Nationwide Survey of Japanese Palliative Care Physicians.
Topics: Analgesics, Opioid; Dyspnea; Fentanyl; Humans; Japan; Morphine; Neoplasms; Oxycodone; Palliative Car | 2019 |
Practices and perceptions regarding intravenous opioid infusion and cancer pain management.
Topics: Adult; Analgesics, Opioid; Cancer Pain; Clinical Competence; Cross-Sectional Studies; Female; Fentan | 2019 |
Practices and perceptions regarding intravenous opioid infusion and cancer pain management.
Topics: Adult; Analgesics, Opioid; Cancer Pain; Clinical Competence; Cross-Sectional Studies; Female; Fentan | 2019 |
Authors' Response to: Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial.
Topics: Analgesics, Opioid; Double-Blind Method; Dyspnea; Fentanyl; Humans; Neoplasms | 2019 |
Authors' Response to: Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial.
Topics: Analgesics, Opioid; Double-Blind Method; Dyspnea; Fentanyl; Humans; Neoplasms | 2019 |
Response to "Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial".
Topics: Analgesics, Opioid; Double-Blind Method; Dyspnea; Fentanyl; Humans; Neoplasms | 2019 |
Response to "Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial".
Topics: Analgesics, Opioid; Double-Blind Method; Dyspnea; Fentanyl; Humans; Neoplasms | 2019 |
Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2013 |
Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2013 |
Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2013 |
Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2013 |
Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain. Authors' reply.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2013 |
Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain. Authors' reply.
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms | 2013 |
Evidence-based treatment of cancer-related breakthrough pain with opioids.
Topics: Administration, Mucosal; Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Evidence | 2013 |
Evidence-based treatment of cancer-related breakthrough pain with opioids.
Topics: Administration, Mucosal; Administration, Sublingual; Analgesics, Opioid; Breakthrough Pain; Evidence | 2013 |
The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.
Topics: Administration, Buccal; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Dose-Respons | 2013 |
The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.
Topics: Administration, Buccal; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Dose-Respons | 2013 |
[Pain therapy. Treating pain patients with opioid preparations].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Pain; Cooperative Behavior; Drug Therapy, Com | 2013 |
[Pain therapy. Treating pain patients with opioid preparations].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Pain; Cooperative Behavior; Drug Therapy, Com | 2013 |
[Fentanyl: fast and furious?].
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain; Pain, Intractable | 2013 |
[Fentanyl: fast and furious?].
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain; Pain, Intractable | 2013 |
Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain.
Topics: Aged; Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily B; Base Sequence; China; Femal | 2013 |
Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain.
Topics: Aged; Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily B; Base Sequence; China; Femal | 2013 |
Correspondence (letter to the editor): Lack of precision in colloquial language results in incorrect therapeutic recommendation.
Topics: Breakthrough Pain; Evidence-Based Medicine; Fentanyl; Humans; Neoplasms; Pain Measurement | 2013 |
Correspondence (letter to the editor): Lack of precision in colloquial language results in incorrect therapeutic recommendation.
Topics: Breakthrough Pain; Evidence-Based Medicine; Fentanyl; Humans; Neoplasms; Pain Measurement | 2013 |
Correspondence (reply): In reply.
Topics: Breakthrough Pain; Evidence-Based Medicine; Fentanyl; Humans; Neoplasms; Pain Measurement | 2013 |
Correspondence (reply): In reply.
Topics: Breakthrough Pain; Evidence-Based Medicine; Fentanyl; Humans; Neoplasms; Pain Measurement | 2013 |
Orphan symptoms in advanced cancer patients followed at home.
Topics: Aged; Analgesics, Opioid; Female; Fentanyl; Hiccup; Home Care Services; Hospitalization; Humans; Ita | 2013 |
Orphan symptoms in advanced cancer patients followed at home.
Topics: Aged; Analgesics, Opioid; Female; Fentanyl; Hiccup; Home Care Services; Hospitalization; Humans; Ita | 2013 |
Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics; Breakthrough Pain; Constipation; Female; Fentanyl; | 2014 |
Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics; Breakthrough Pain; Constipation; Female; Fentanyl; | 2014 |
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily D, M | 2014 |
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily D, M | 2014 |
The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study.
Topics: Administration, Intranasal; Aged; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Humans; M | 2014 |
The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study.
Topics: Administration, Intranasal; Aged; Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Humans; M | 2014 |
Assisted suicide by fentanyl intoxication due to excessive transdermal application.
Topics: Administration, Cutaneous; Anti-Anxiety Agents; Bromazepam; Chromatography, Liquid; Female; Fentanyl | 2014 |
Assisted suicide by fentanyl intoxication due to excessive transdermal application.
Topics: Administration, Cutaneous; Anti-Anxiety Agents; Bromazepam; Chromatography, Liquid; Female; Fentanyl | 2014 |
What is your gut feeling about opioid rotation?
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Biological Availability; Delaye | 2015 |
What is your gut feeling about opioid rotation?
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Biological Availability; Delaye | 2015 |
How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion.
Topics: Administration, Buccal; Administration, Intranasal; Administration, Mucosal; Administration, Subling | 2011 |
How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion.
Topics: Administration, Buccal; Administration, Intranasal; Administration, Mucosal; Administration, Subling | 2011 |
Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Cost-Benefit Analysis; Fentanyl; | 2014 |
Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Cost-Benefit Analysis; Fentanyl; | 2014 |
Efficacy of rapid-onset oral fentanyl: what does it mean?
Topics: Breakthrough Pain; Evidence-Based Medicine; Female; Fentanyl; Humans; Male; Morphine; Neoplasms | 2014 |
Efficacy of rapid-onset oral fentanyl: what does it mean?
Topics: Breakthrough Pain; Evidence-Based Medicine; Female; Fentanyl; Humans; Male; Morphine; Neoplasms | 2014 |
[Use of fendivia transdermal therapeutic system in Russian patients with malignant neoplasms during palliative care: pharmacoeconomic aspects].
Topics: Ambulances; Analgesics, Opioid; Cost-Benefit Analysis; Economics, Pharmaceutical; Fentanyl; Health C | 2014 |
[Use of fendivia transdermal therapeutic system in Russian patients with malignant neoplasms during palliative care: pharmacoeconomic aspects].
Topics: Ambulances; Analgesics, Opioid; Cost-Benefit Analysis; Economics, Pharmaceutical; Fentanyl; Health C | 2014 |
A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; Neo | 2014 |
A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; Neo | 2014 |
Authors' reply to Davis.
Topics: Breakthrough Pain; Evidence-Based Medicine; Female; Fentanyl; Humans; Male; Morphine; Neoplasms | 2014 |
Authors' reply to Davis.
Topics: Breakthrough Pain; Evidence-Based Medicine; Female; Fentanyl; Humans; Male; Morphine; Neoplasms | 2014 |
Breakthrough cancer pain: a comparison of surveys with European and Canadian patients.
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Canada; Data Collection; E | 2015 |
Breakthrough cancer pain: a comparison of surveys with European and Canadian patients.
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Canada; Data Collection; E | 2015 |
[The cognitive effects of using transdermal fentanyl in cancer pain].
Topics: Administration, Cutaneous; Analgesics, Opioid; Cognition Disorders; Female; Fentanyl; Humans; Male; | 2014 |
[The cognitive effects of using transdermal fentanyl in cancer pain].
Topics: Administration, Cutaneous; Analgesics, Opioid; Cognition Disorders; Female; Fentanyl; Humans; Male; | 2014 |
Relationship between onset of pain relief and patient satisfaction with fentanyl pectin nasal spray for breakthrough pain in cancer.
Topics: Administration, Intranasal; Analgesics, Opioid; Double-Blind Method; Female; Fentanyl; Humans; Male; | 2014 |
Relationship between onset of pain relief and patient satisfaction with fentanyl pectin nasal spray for breakthrough pain in cancer.
Topics: Administration, Intranasal; Analgesics, Opioid; Double-Blind Method; Female; Fentanyl; Humans; Male; | 2014 |
Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Blood Chemical Ana | 2015 |
Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Blood Chemical Ana | 2015 |
Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cohort Studies; Fema | 2015 |
Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Cohort Studies; Fema | 2015 |
Intravenous Fentanyl for Dyspnea at the End of Life: Lessons for Future Research in Dyspnea.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anxiety; Dyspnea; Female; Fentanyl; Humans; Infusions, | 2016 |
Intravenous Fentanyl for Dyspnea at the End of Life: Lessons for Future Research in Dyspnea.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anxiety; Dyspnea; Female; Fentanyl; Humans; Infusions, | 2016 |
Patients' acceptability of different fentanyl products for breakthrough cancer pain.
Topics: Administration, Mucosal; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Patient Acceptance of Healt | 2014 |
Patients' acceptability of different fentanyl products for breakthrough cancer pain.
Topics: Administration, Mucosal; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Patient Acceptance of Healt | 2014 |
Pharmacologic management of adult breakthrough cancer pain.
Topics: Adult; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Sufentanil | 2014 |
Pharmacologic management of adult breakthrough cancer pain.
Topics: Adult; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Sufentanil | 2014 |
The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum | 2015 |
The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum | 2015 |
Influence of serum albumin levels during opioid rotation from morphine or oxycodone to fentanyl for cancer pain.
Topics: Analgesics, Opioid; Fentanyl; Humans; Morphine; Neoplasms; Oxycodone; Pain; Serum Albumin | 2014 |
Influence of serum albumin levels during opioid rotation from morphine or oxycodone to fentanyl for cancer pain.
Topics: Analgesics, Opioid; Fentanyl; Humans; Morphine; Neoplasms; Oxycodone; Pain; Serum Albumin | 2014 |
Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery.
Topics: Aged; Anesthetics, Intravenous; Dose-Response Relationship, Drug; Female; Fentanyl; Humans; Infusion | 2015 |
Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery.
Topics: Aged; Anesthetics, Intravenous; Dose-Response Relationship, Drug; Female; Fentanyl; Humans; Infusion | 2015 |
Use of nasal fentanyl for cancer pain: A pharmacoepidemiological study.
Topics: Administration, Intranasal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Chronic Pain; Cohort | 2015 |
Use of nasal fentanyl for cancer pain: A pharmacoepidemiological study.
Topics: Administration, Intranasal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Chronic Pain; Cohort | 2015 |
Fentanyl pectin nasal spray for breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pect | 2015 |
Fentanyl pectin nasal spray for breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pect | 2015 |
Use of oral formulations of fentanyl for breakthrough cancer pain.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cost-Benefit Analysis; Fentanyl; Humans | 2015 |
Use of oral formulations of fentanyl for breakthrough cancer pain.
Topics: Administration, Oral; Analgesics, Opioid; Breakthrough Pain; Cost-Benefit Analysis; Fentanyl; Humans | 2015 |
Renal function and symptoms/adverse effects in opioid-treated patients with cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cross-Sectional Studies; Fentanyl; G | 2015 |
Renal function and symptoms/adverse effects in opioid-treated patients with cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cross-Sectional Studies; Fentanyl; G | 2015 |
Addiction to transmucosal fentanyl: Is it a cause for concern in cancer pain management?
Topics: Administration, Mucosal; Analgesics, Opioid; Attitude of Health Personnel; Fentanyl; Humans; Neoplas | 2015 |
Addiction to transmucosal fentanyl: Is it a cause for concern in cancer pain management?
Topics: Administration, Mucosal; Analgesics, Opioid; Attitude of Health Personnel; Fentanyl; Humans; Neoplas | 2015 |
A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Breakthrough Pain; Cross-Sectional Studies; Fem | 2016 |
A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Breakthrough Pain; Cross-Sectional Studies; Fem | 2016 |
Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cognition Disorders; | 2015 |
Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cognition Disorders; | 2015 |
Accuracy of using Diagnosis Procedure Combination administrative claims data for estimating the amount of opioid consumption among cancer patients in Japan.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Codeine; Drug Prescriptions; Female; Fentanyl; H | 2015 |
Accuracy of using Diagnosis Procedure Combination administrative claims data for estimating the amount of opioid consumption among cancer patients in Japan.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Codeine; Drug Prescriptions; Female; Fentanyl; H | 2015 |
Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chromatography, High | 2015 |
Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chromatography, High | 2015 |
The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Drug Admi | 2016 |
The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Drug Admi | 2016 |
Sublingual Fentanyl Tablets for Relief of Breakthrough Pain in Cancer Patients and Association with Quality-of-Life Outcomes.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; F | 2015 |
Sublingual Fentanyl Tablets for Relief of Breakthrough Pain in Cancer Patients and Association with Quality-of-Life Outcomes.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; F | 2015 |
Correlation of ADRB1 rs1801253 Polymorphism with Analgesic Effect of Fentanyl After Cancer Surgeries.
Topics: Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain, Posto | 2015 |
Correlation of ADRB1 rs1801253 Polymorphism with Analgesic Effect of Fentanyl After Cancer Surgeries.
Topics: Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain, Posto | 2015 |
Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Female; | 2016 |
Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Female; | 2016 |
Re: The Influence of Low Salivary Flow Rates on Sublingual Fentanyl Absorption for Breakthrough Cancer Pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms | 2016 |
Re: The Influence of Low Salivary Flow Rates on Sublingual Fentanyl Absorption for Breakthrough Cancer Pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasms | 2016 |
Incidence of Delirium Among Patients Having Cancer Injected With Different Opioids for the First Time.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Delirium; Drug-Related Side Effects | 2017 |
Incidence of Delirium Among Patients Having Cancer Injected With Different Opioids for the First Time.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Delirium; Drug-Related Side Effects | 2017 |
Consequences of unsafe prescribing of transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain | 2016 |
Consequences of unsafe prescribing of transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain | 2016 |
[Use of Transdermal Fentanyl in a Hospital].
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum | 2016 |
[Use of Transdermal Fentanyl in a Hospital].
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum | 2016 |
Combined Effect of Opioids and Corticosteroids for Alleviating Dyspnea in Terminal Cancer Patients: A Retrospective Review.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Dr | 2016 |
Combined Effect of Opioids and Corticosteroids for Alleviating Dyspnea in Terminal Cancer Patients: A Retrospective Review.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Dr | 2016 |
Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Expert Testimony; Fentanyl; Humans; Neoplasms | 2016 |
Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Expert Testimony; Fentanyl; Humans; Neoplasms | 2016 |
Breakthrough pain: just pain?
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain; Pain Measurement | 2016 |
Breakthrough pain: just pain?
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain; Pain Measurement | 2016 |
Contribution of Opiate Analgesics to the Development of Infections in Advanced Cancer Patients.
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentanyl; Follow-Up Studies; Humans; I | 2017 |
Contribution of Opiate Analgesics to the Development of Infections in Advanced Cancer Patients.
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentanyl; Follow-Up Studies; Humans; I | 2017 |
Dose and Duration of Opioid Use in Patients with Cancer and Noncancer Pain at an Outpatient Hospital Setting in Malaysia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Cross-Sectional Studies | 2017 |
Dose and Duration of Opioid Use in Patients with Cancer and Noncancer Pain at an Outpatient Hospital Setting in Malaysia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Cross-Sectional Studies | 2017 |
Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
Topics: Analgesics, Opioid; Fentanyl; Head and Neck Neoplasms; Humans; Methadone; Neoplasms; Neuralgia; Pain | 2016 |
Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
Topics: Analgesics, Opioid; Fentanyl; Head and Neck Neoplasms; Humans; Methadone; Neoplasms; Neuralgia; Pain | 2016 |
Predictors of the Usefulness of Corticosteroids for Cancer-Related Fatigue in End-of-Life Patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Betamethasone; Fatigue; Female; Fentanyl; G | 2017 |
Predictors of the Usefulness of Corticosteroids for Cancer-Related Fatigue in End-of-Life Patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Betamethasone; Fatigue; Female; Fentanyl; G | 2017 |
Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Femal | 2018 |
Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthrough Pain; Femal | 2018 |
[Measurement of amount of fentanyl remaining in used patches: investigation of clinical factors affecting the remaining amounts in 4 patients].
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Body Mass Index; Dosage Forms; Female; Fentanyl | 2008 |
[Measurement of amount of fentanyl remaining in used patches: investigation of clinical factors affecting the remaining amounts in 4 patients].
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Body Mass Index; Dosage Forms; Female; Fentanyl | 2008 |
Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Area Under Curve; Clinical Trials, Phase II as | 2008 |
Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Area Under Curve; Clinical Trials, Phase II as | 2008 |
Pharmacologic intervention for cancer-related dyspnea.
Topics: Analgesics, Opioid; Chlorpromazine; Dyspnea; Fentanyl; Humans; Neoplasms; Palliative Care; Randomize | 2008 |
Pharmacologic intervention for cancer-related dyspnea.
Topics: Analgesics, Opioid; Chlorpromazine; Dyspnea; Fentanyl; Humans; Neoplasms; Palliative Care; Randomize | 2008 |
[Analgesics and palliative care].
Topics: Analgesics; Analgesics, Opioid; Fentanyl; Humans; Methadone; Morphine; Neoplasms; Pain; Palliative C | 2008 |
[Analgesics and palliative care].
Topics: Analgesics; Analgesics, Opioid; Fentanyl; Humans; Methadone; Morphine; Neoplasms; Pain; Palliative C | 2008 |
Breakthrough cancer pain.
Topics: Analgesics, Opioid; Fentanyl; Humans; Morphine; Neoplasms; Pain | 2008 |
Breakthrough cancer pain.
Topics: Analgesics, Opioid; Fentanyl; Humans; Morphine; Neoplasms; Pain | 2008 |
Safety alert for fentanyl buccal tablets.
Topics: Administration, Buccal; Adverse Drug Reaction Reporting Systems; Analgesics, Opioid; Fentanyl; Human | 2008 |
Safety alert for fentanyl buccal tablets.
Topics: Administration, Buccal; Adverse Drug Reaction Reporting Systems; Analgesics, Opioid; Fentanyl; Human | 2008 |
Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Buprenorphine; Dose-Response Relationship, Drug | 2009 |
Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Buprenorphine; Dose-Response Relationship, Drug | 2009 |
Lollipops & lawsuits.
Topics: Analgesics, Opioid; Drug Labeling; Fentanyl; Humans; Marketing; Neoplasms; Pain; United States; Unit | 2007 |
Lollipops & lawsuits.
Topics: Analgesics, Opioid; Drug Labeling; Fentanyl; Humans; Marketing; Neoplasms; Pain; United States; Unit | 2007 |
[Optimal conversion ratio of oral morphine to transdermal fentanyl patches to the cancer pain].
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2009 |
[Optimal conversion ratio of oral morphine to transdermal fentanyl patches to the cancer pain].
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2009 |
Prescription of opioids in Italy: everything, but the morphine.
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Buprenorphine; Drug and Narcoti | 2009 |
Prescription of opioids in Italy: everything, but the morphine.
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Buprenorphine; Drug and Narcoti | 2009 |
The feasibility of using intravenous fentanyl as sublingual drops in the treatment of incidental pain in patients with cancer.
Topics: Adult; Aged; Anesthetics, Intravenous; Feasibility Studies; Female; Fentanyl; Humans; Infusions, Int | 2009 |
The feasibility of using intravenous fentanyl as sublingual drops in the treatment of incidental pain in patients with cancer.
Topics: Adult; Aged; Anesthetics, Intravenous; Feasibility Studies; Female; Fentanyl; Humans; Infusions, Int | 2009 |
Fentanyl and ketamine used for postoperative pain control in high-risk patients with malignancy.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Fentanyl; Humans; Ketamine; Neoplasms; Pain, Postoper | 2009 |
Fentanyl and ketamine used for postoperative pain control in high-risk patients with malignancy.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Fentanyl; Humans; Ketamine; Neoplasms; Pain, Postoper | 2009 |
Validated LC coupled to ESI-MS/MS analysis for fentanyl in human plasma and UV analysis in applied reservoir transdermal patches using a simple and rapid procedure.
Topics: Administration, Cutaneous; Calibration; Chromatography, Liquid; Drug Stability; Fentanyl; Humans; Ne | 2009 |
Validated LC coupled to ESI-MS/MS analysis for fentanyl in human plasma and UV analysis in applied reservoir transdermal patches using a simple and rapid procedure.
Topics: Administration, Cutaneous; Calibration; Chromatography, Liquid; Drug Stability; Fentanyl; Humans; Ne | 2009 |
Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems--a delphi study.
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Data Collection; Decision Suppo | 2009 |
Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems--a delphi study.
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Data Collection; Decision Suppo | 2009 |
The use of transdermal fentanyl in cancer pain--a compliance study of outpatients in Taiwan.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Ambulatory Care; Analgesics, Opioid; Coho | 2010 |
The use of transdermal fentanyl in cancer pain--a compliance study of outpatients in Taiwan.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Ambulatory Care; Analgesics, Opioid; Coho | 2010 |
Fentanyl effervescent buccal tablets: new formulation. For cancer patients with breakthrough pain: a second buccal formulation with minimal evaluation.
Topics: Administration, Buccal; Analgesics, Opioid; Biological Availability; Chemistry, Pharmaceutical; Dosa | 2009 |
Fentanyl effervescent buccal tablets: new formulation. For cancer patients with breakthrough pain: a second buccal formulation with minimal evaluation.
Topics: Administration, Buccal; Analgesics, Opioid; Biological Availability; Chemistry, Pharmaceutical; Dosa | 2009 |
Formulations of fentanyl for the management of pain.
Topics: Administration, Buccal; Administration, Cutaneous; Administration, Oral; Analgesia, Patient-Controll | 2010 |
Formulations of fentanyl for the management of pain.
Topics: Administration, Buccal; Administration, Cutaneous; Administration, Oral; Analgesia, Patient-Controll | 2010 |
Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Dose | 2010 |
Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Dose | 2010 |
The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Delayed-Action Preparations; Drug Administration | 2010 |
The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Delayed-Action Preparations; Drug Administration | 2010 |
Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fenta | 2010 |
Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fenta | 2010 |
Fentanyl buccal soluble film (Onsolis) for breakthrough cancer pain.
Topics: Administration, Buccal; Chemistry, Pharmaceutical; Cross-Over Studies; Double-Blind Method; Drug Tol | 2010 |
Fentanyl buccal soluble film (Onsolis) for breakthrough cancer pain.
Topics: Administration, Buccal; Chemistry, Pharmaceutical; Cross-Over Studies; Double-Blind Method; Drug Tol | 2010 |
Recent development in therapeutics for breakthrough pain.
Topics: Administration, Buccal; Analgesics, Opioid; Drug Administration Routes; Fentanyl; Humans; Narcotics; | 2010 |
Recent development in therapeutics for breakthrough pain.
Topics: Administration, Buccal; Analgesics, Opioid; Drug Administration Routes; Fentanyl; Humans; Narcotics; | 2010 |
Fentanyl sublingual tablets. Breakthrough pain: new formulation, no therapeutic advantage.
Topics: Administration, Sublingual; Analgesics, Opioid; Chemistry, Pharmaceutical; Fentanyl; Humans; Neoplas | 2010 |
Fentanyl sublingual tablets. Breakthrough pain: new formulation, no therapeutic advantage.
Topics: Administration, Sublingual; Analgesics, Opioid; Chemistry, Pharmaceutical; Fentanyl; Humans; Neoplas | 2010 |
Treatment of severe cancer pain by transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Bone Neoplasms; Female; Fentanyl; Hemody | 2010 |
Treatment of severe cancer pain by transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Bone Neoplasms; Female; Fentanyl; Hemody | 2010 |
Historical perspectives and trends in the management of pain for cancer patients in oman.
Topics: Analgesics, Opioid; Fentanyl; Humans; Morphine; Neoplasms; Oman; Pain | 2010 |
Historical perspectives and trends in the management of pain for cancer patients in oman.
Topics: Analgesics, Opioid; Fentanyl; Humans; Morphine; Neoplasms; Oman; Pain | 2010 |
Posttraumatic stress disorder in cancer ICUs.
Topics: Anesthetics, Dissociative; Drug Therapy, Combination; Fentanyl; Humans; Intensive Care Units; Ketami | 2010 |
Posttraumatic stress disorder in cancer ICUs.
Topics: Anesthetics, Dissociative; Drug Therapy, Combination; Fentanyl; Humans; Intensive Care Units; Ketami | 2010 |
Patient controlled analgesia: redefining its role in an Indian cancer hospital.
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Cancer Care Facilities; | 2010 |
Patient controlled analgesia: redefining its role in an Indian cancer hospital.
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Cancer Care Facilities; | 2010 |
Fentanyl for breakthrough cancer pain--what's new?
Topics: Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain | 2010 |
Fentanyl for breakthrough cancer pain--what's new?
Topics: Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain | 2010 |
Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; Mor | 2011 |
Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; Mor | 2011 |
Fentanyl intranasal. Breakthrough cancer pain: unsafe packaging.
Topics: Administration, Intranasal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Product Packaging | 2010 |
Fentanyl intranasal. Breakthrough cancer pain: unsafe packaging.
Topics: Administration, Intranasal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain; Product Packaging | 2010 |
Ten cases of palliation of cancer pain with morphine.
Topics: Abdominal Pain; Adult; Aged; Analgesics, Opioid; Child; Female; Fentanyl; Humans; Male; Middle Aged; | 2010 |
Ten cases of palliation of cancer pain with morphine.
Topics: Abdominal Pain; Adult; Aged; Analgesics, Opioid; Child; Female; Fentanyl; Humans; Male; Middle Aged; | 2010 |
Dose conversion in opioid rotation from continuous intravenous infusion of morphine hydrochloride injection to fentanyl patch in the management of cancer pain.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Fen | 2011 |
Dose conversion in opioid rotation from continuous intravenous infusion of morphine hydrochloride injection to fentanyl patch in the management of cancer pain.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Fen | 2011 |
[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain].
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Male; Mi | 2011 |
[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain].
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Male; Mi | 2011 |
Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.
Topics: Absorption; Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; | 2012 |
Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.
Topics: Absorption; Administration, Intranasal; Administration, Oral; Analgesics, Opioid; Breakthrough Pain; | 2012 |
Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Child; Fe | 2011 |
Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Child; Fe | 2011 |
Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Dose-Response Relationsh | 2011 |
Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Breakthrough Pain; Dose-Response Relationsh | 2011 |
Attitude and knowledge of physicians about cancer pain management: young doctors of South Korea in their early career.
Topics: Adrenal Cortex Hormones; Adult; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Attitude | 2011 |
Attitude and knowledge of physicians about cancer pain management: young doctors of South Korea in their early career.
Topics: Adrenal Cortex Hormones; Adult; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Attitude | 2011 |
In brief: fentanyl sublingual tablets (Abstral) for breathrough cancer pain.
Topics: Administration, Sublingual; Fentanyl; Humans; Neoplasms; Pain; Tablets | 2011 |
In brief: fentanyl sublingual tablets (Abstral) for breathrough cancer pain.
Topics: Administration, Sublingual; Fentanyl; Humans; Neoplasms; Pain; Tablets | 2011 |
Utilisation of transdermal fentanyl in Germany from 2004 to 2006.
Topics: Aged; Analgesics, Opioid; Databases, Factual; Dose-Response Relationship, Drug; Female; Fentanyl; Ge | 2012 |
Utilisation of transdermal fentanyl in Germany from 2004 to 2006.
Topics: Aged; Analgesics, Opioid; Databases, Factual; Dose-Response Relationship, Drug; Female; Fentanyl; Ge | 2012 |
Inconsistencies in opioid equianalgesic ratios: clinical and research implications.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Analgesics, Opioid; Delayed-Action Preparati | 2008 |
Inconsistencies in opioid equianalgesic ratios: clinical and research implications.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Analgesics, Opioid; Delayed-Action Preparati | 2008 |
Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain.
Topics: Adult; Analgesics, Opioid; Bone Neoplasms; Breakthrough Pain; Fatal Outcome; Female; Fentanyl; Human | 2011 |
Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain.
Topics: Adult; Analgesics, Opioid; Bone Neoplasms; Breakthrough Pain; Fatal Outcome; Female; Fentanyl; Human | 2011 |
Fentanyl nasal spray (Lazanda) for pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Drug Approval; Drug Interactions; Drug Therapy, Comb | 2011 |
Fentanyl nasal spray (Lazanda) for pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Drug Approval; Drug Interactions; Drug Therapy, Comb | 2011 |
Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily B; | 2012 |
Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily B; | 2012 |
Fentanyl pectin nasal spray for breakthrough cancer pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Humans; Male; Nasal Sprays; Neoplasms; Trea | 2012 |
Fentanyl pectin nasal spray for breakthrough cancer pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Female; Fentanyl; Humans; Male; Nasal Sprays; Neoplasms; Trea | 2012 |
[Efficacy and safety of low-dose matrix-type transdermal fentanyl applied for opioid initiation].
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Neoplasms; Pain | 2012 |
[Efficacy and safety of low-dose matrix-type transdermal fentanyl applied for opioid initiation].
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Neoplasms; Pain | 2012 |
Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Cytochrome P-450 CYP3A; Dose-Response Re | 2012 |
Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Cytochrome P-450 CYP3A; Dose-Response Re | 2012 |
[Comparison of transdermal fentanyl for the management of cancer pain in adults and elders].
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum | 2012 |
[Comparison of transdermal fentanyl for the management of cancer pain in adults and elders].
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum | 2012 |
Pain management.
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Fentanyl; Humans; Neoplasms; Pain; Pain Manage | 2012 |
Pain management.
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Fentanyl; Humans; Neoplasms; Pain; Pain Manage | 2012 |
Opioid consumption before and after the establishment of a palliative medicine unit in an Egyptian cancer centre.
Topics: Analgesics, Opioid; Drug Utilization Review; Egypt; Fentanyl; Humans; Morphine; Neoplasms; Pain Mana | 2012 |
Opioid consumption before and after the establishment of a palliative medicine unit in an Egyptian cancer centre.
Topics: Analgesics, Opioid; Drug Utilization Review; Egypt; Fentanyl; Humans; Morphine; Neoplasms; Pain Mana | 2012 |
A simple liquid chromatography-tandem mass spectrometry method for determination of plasma fentanyl concentration in rats and patients with cancer pain.
Topics: Aged; Analgesics, Opioid; Animals; Chromatography, Liquid; Female; Fentanyl; Humans; Male; Middle Ag | 2013 |
A simple liquid chromatography-tandem mass spectrometry method for determination of plasma fentanyl concentration in rats and patients with cancer pain.
Topics: Aged; Analgesics, Opioid; Animals; Chromatography, Liquid; Female; Fentanyl; Humans; Male; Middle Ag | 2013 |
Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer.
Topics: Administration, Cutaneous; Analgesics, Opioid; Citric Acid; Fentanyl; Humans; Lung Neoplasms; Neopla | 2013 |
Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer.
Topics: Administration, Cutaneous; Analgesics, Opioid; Citric Acid; Fentanyl; Humans; Lung Neoplasms; Neopla | 2013 |
Fentanyl pectin nasal spray: a novel intranasal delivery method for the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Carriers; Fen | 2013 |
Fentanyl pectin nasal spray: a novel intranasal delivery method for the treatment of breakthrough cancer pain.
Topics: Administration, Intranasal; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Carriers; Fen | 2013 |
Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Albumins; Analgesics, Opioid; B | 2013 |
Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Albumins; Analgesics, Opioid; B | 2013 |
Use of intravenous fentanyl against morphine tolerance in breakthrough cancer pain: a case series and literature review.
Topics: Analgesics, Opioid; Drug Administration Routes; Drug Tolerance; Female; Fentanyl; Humans; Male; Midd | 2014 |
Use of intravenous fentanyl against morphine tolerance in breakthrough cancer pain: a case series and literature review.
Topics: Analgesics, Opioid; Drug Administration Routes; Drug Tolerance; Female; Fentanyl; Humans; Male; Midd | 2014 |
[Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society].
Topics: Advertising; Analgesics, Opioid; Breakthrough Pain; Drug Industry; Drug Tolerance; Education; Fentan | 2013 |
[Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society].
Topics: Advertising; Analgesics, Opioid; Breakthrough Pain; Drug Industry; Drug Tolerance; Education; Fentan | 2013 |
A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids.
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Codeine; Female; Fentany | 2002 |
A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids.
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Codeine; Female; Fentany | 2002 |
Oral transmucosal fentanyl: new preparation. For breakthrough cancer pain when morphine fails.
Topics: Administration, Buccal; Administration, Oral; Adult; Analgesics, Opioid; Child; Dosage Forms; Fentan | 2002 |
Oral transmucosal fentanyl: new preparation. For breakthrough cancer pain when morphine fails.
Topics: Administration, Buccal; Administration, Oral; Adult; Analgesics, Opioid; Child; Dosage Forms; Fentan | 2002 |
Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Constipation; Female; Fentanyl; Follow-Up Studi | 2002 |
Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Constipation; Female; Fentanyl; Follow-Up Studi | 2002 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
Clinically important changes in acute pain outcome measures: a validation study.
Topics: Acute Disease; Administration, Buccal; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Outcome Asse | 2003 |
A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Female; F | 2003 |
A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Female; F | 2003 |
The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose.
Topics: Age Factors; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentanyl; Humans; M | 2003 |
The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose.
Topics: Age Factors; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentanyl; Humans; M | 2003 |
Transdermal fentanyl: informed prescribing is essential.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Dose-Respon | 2003 |
Transdermal fentanyl: informed prescribing is essential.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Dose-Respon | 2003 |
Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Female; Fentanyl; Humans; Male; Middle Ag | 2003 |
Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Female; Fentanyl; Humans; Male; Middle Ag | 2003 |
Agitated terminal delirium and association with partial opioid substitution and hydration.
Topics: Analgesics, Opioid; Delirium; Drug Administration Schedule; Female; Fentanyl; Humans; Japan; Male; M | 2003 |
Agitated terminal delirium and association with partial opioid substitution and hydration.
Topics: Analgesics, Opioid; Delirium; Drug Administration Schedule; Female; Fentanyl; Humans; Japan; Male; M | 2003 |
Intravenous fentanyl for cancer pain: a "fast titration" protocol for the emergency room.
Topics: Adult; Aged; Analgesics, Opioid; Emergency Medical Services; Fentanyl; Humans; Injections, Intraveno | 2003 |
Intravenous fentanyl for cancer pain: a "fast titration" protocol for the emergency room.
Topics: Adult; Aged; Analgesics, Opioid; Emergency Medical Services; Fentanyl; Humans; Injections, Intraveno | 2003 |
Initial dose cascade of TTS fentanyl with proper adjuvant medications in cancer pain.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relatio | 2003 |
Initial dose cascade of TTS fentanyl with proper adjuvant medications in cancer pain.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relatio | 2003 |
Severe respiratory depression and sedation with transdermal fentanyl: four case studies.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Fatal Outcome; Female | 2003 |
Severe respiratory depression and sedation with transdermal fentanyl: four case studies.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Fatal Outcome; Female | 2003 |
[Transdermal fentanyl for the management of cancer pain: a survey of 1,664 elderly patients].
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Ma | 2003 |
[Transdermal fentanyl for the management of cancer pain: a survey of 1,664 elderly patients].
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Ma | 2003 |
[Usefulness of fentanyl patch in home palliative care].
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Caregivers; Female; Fentanyl; Home Care | 2003 |
[Usefulness of fentanyl patch in home palliative care].
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Caregivers; Female; Fentanyl; Home Care | 2003 |
Therapy switching in patients receiving long-acting opioids.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Comorbidity; Delayed-Action Preparations; Femal | 2004 |
Therapy switching in patients receiving long-acting opioids.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Comorbidity; Delayed-Action Preparations; Femal | 2004 |
[Use of opioids against severe cancer pain].
Topics: Analgesics, Opioid; Fentanyl; Humans; Morphine; Neoplasms; Oxycodone; Pain; Palliative Care | 2004 |
[Use of opioids against severe cancer pain].
Topics: Analgesics, Opioid; Fentanyl; Humans; Morphine; Neoplasms; Oxycodone; Pain; Palliative Care | 2004 |
[Breakthrough pain--analysis and therapy. A pilot study of a new drug, transmucosal fentanyl (Actiq)].
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; | 2004 |
[Breakthrough pain--analysis and therapy. A pilot study of a new drug, transmucosal fentanyl (Actiq)].
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; | 2004 |
A study of transdermal fentanyl in cancer pain at Aichi-Cancer Center.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Cancer Care Facilities; Chronic Disease; | 2004 |
A study of transdermal fentanyl in cancer pain at Aichi-Cancer Center.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Cancer Care Facilities; Chronic Disease; | 2004 |
Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: comparison with flow measurements by Laser Doppler flowmetry and oxygen measurements by luminescence-based probes.
Topics: Anesthetics; Animals; Droperidol; Fentanyl; Isoflurane; Ketamine; Laser-Doppler Flowmetry; Magnetic | 2004 |
Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: comparison with flow measurements by Laser Doppler flowmetry and oxygen measurements by luminescence-based probes.
Topics: Anesthetics; Animals; Droperidol; Fentanyl; Isoflurane; Ketamine; Laser-Doppler Flowmetry; Magnetic | 2004 |
[Usefulness of fentanyl patch in home palliative care].
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Fentanyl; Home Care Services; Humans; Mi | 2003 |
[Usefulness of fentanyl patch in home palliative care].
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Fentanyl; Home Care Services; Humans; Mi | 2003 |
[Therapy of break-through pain].
Topics: Administration, Oral; Analgesics, Opioid; Biological Availability; Clinical Trials as Topic; Drug De | 2004 |
[Therapy of break-through pain].
Topics: Administration, Oral; Analgesics, Opioid; Biological Availability; Clinical Trials as Topic; Drug De | 2004 |
[Chronic pain--new patch size expands therapy spectrum].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Fentanyl; | 2004 |
[Chronic pain--new patch size expands therapy spectrum].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Fentanyl; | 2004 |
Physicians' knowledge of transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Clinical Competence; Family Practice; Fentanyl | 2005 |
Physicians' knowledge of transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Clinical Competence; Family Practice; Fentanyl | 2005 |
[Parenteral opioids in end-of-life care in cancer patients].
Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Delayed-Action Preparations; Drug Administration | 2005 |
[Parenteral opioids in end-of-life care in cancer patients].
Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Delayed-Action Preparations; Drug Administration | 2005 |
A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Analgesics, Opioid; Child; Child, Preschool; Del | 2005 |
A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Analgesics, Opioid; Child; Child, Preschool; Del | 2005 |
Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chroni | 2005 |
Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chroni | 2005 |
Pre-medication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients.
Topics: Adipose Tissue, Brown; Administration, Oral; Adolescent; Adult; Age Factors; Analgesics, Opioid; Chi | 2005 |
Pre-medication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients.
Topics: Adipose Tissue, Brown; Administration, Oral; Adolescent; Adult; Age Factors; Analgesics, Opioid; Chi | 2005 |
Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Drug Delivery Systems; Female; Fentanyl; Humans | 2005 |
Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Drug Delivery Systems; Female; Fentanyl; Humans | 2005 |
Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Cohort | 2005 |
Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Cohort | 2005 |
Pain recurrence on the third day after application of a transdermal fentanyl patch.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum | 2005 |
Pain recurrence on the third day after application of a transdermal fentanyl patch.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum | 2005 |
Physicians' knowledge of transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Clinical Competence; Fentanyl; Health Knowledge, Atti | 2005 |
Physicians' knowledge of transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Clinical Competence; Fentanyl; Health Knowledge, Atti | 2005 |
Physicians' knowledge of transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Clinical Competence; Fentanyl; Health Knowledge, Atti | 2005 |
Physicians' knowledge of transdermal fentanyl.
Topics: Administration, Cutaneous; Analgesics, Opioid; Clinical Competence; Fentanyl; Health Knowledge, Atti | 2005 |
[Direct conversion from low-dose morphine to transdermal fentanyl: efficacy for cancer pain and quality of life].
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesia; Analgesics, Opioid; Female; Fe | 2006 |
[Direct conversion from low-dose morphine to transdermal fentanyl: efficacy for cancer pain and quality of life].
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesia; Analgesics, Opioid; Female; Fe | 2006 |
Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Gui | 2006 |
Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Gui | 2006 |
[Medico-legal aspects of the use of fentanyl patches].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Drug Overdose; Fentanyl; Germany; Hu | 2006 |
[Medico-legal aspects of the use of fentanyl patches].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Drug Overdose; Fentanyl; Germany; Hu | 2006 |
LC-MS/MS analysis of fentanyl and norfentanyl in a fatality due to application of multiple Durogesic transdermal therapeutic systems.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Bile; Chromatography, Liquid; Female; Fentanyl; | 2007 |
LC-MS/MS analysis of fentanyl and norfentanyl in a fatality due to application of multiple Durogesic transdermal therapeutic systems.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Bile; Chromatography, Liquid; Female; Fentanyl; | 2007 |
Can fentanyl be systemically absorbed when administered vaginally? A feasibility study.
Topics: Administration, Intravaginal; Adult; Alberta; Analgesics, Opioid; Chemistry, Pharmaceutical; Drug Ad | 2006 |
Can fentanyl be systemically absorbed when administered vaginally? A feasibility study.
Topics: Administration, Intravaginal; Adult; Alberta; Analgesics, Opioid; Chemistry, Pharmaceutical; Drug Ad | 2006 |
Drug utilization review on a tertiary palliative care unit.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Anxiety Agents; Cost-Benefit Analysis; Drug | 2006 |
Drug utilization review on a tertiary palliative care unit.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Anxiety Agents; Cost-Benefit Analysis; Drug | 2006 |
Retrospective analysis of opioid prescriptions in cancer patients in a northern Italian region.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Buprenorphine; Child; Chil | 2006 |
Retrospective analysis of opioid prescriptions in cancer patients in a northern Italian region.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Buprenorphine; Child; Chil | 2006 |
Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Dose-R | 2006 |
Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Dose-R | 2006 |
Safety and efficacy of fentanyl administered by patient controlled analgesia in children with cancer pain.
Topics: Adolescent; Anesthetics, Intravenous; Child; Female; Fentanyl; Humans; Italy; Male; Neoplasms; Pain; | 2007 |
Safety and efficacy of fentanyl administered by patient controlled analgesia in children with cancer pain.
Topics: Adolescent; Anesthetics, Intravenous; Child; Female; Fentanyl; Humans; Italy; Male; Neoplasms; Pain; | 2007 |
Cephalon used improper tactics to sell drug, probe finds.
Topics: Analgesics, Opioid; Drug Industry; Drug Labeling; Fentanyl; Humans; Marketing; Neoplasms; Pain | 2006 |
Cephalon used improper tactics to sell drug, probe finds.
Topics: Analgesics, Opioid; Drug Industry; Drug Labeling; Fentanyl; Humans; Marketing; Neoplasms; Pain | 2006 |
[Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Ma | 2007 |
[Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Ma | 2007 |
Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Drug Administration Schedule; Female; Fe | 2007 |
Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Drug Administration Schedule; Female; Fe | 2007 |
Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2007 |
Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2007 |
[Validity of recommended minimum dose of prior morphine to initiate transdermal fentanyl patch in prescribing information - multicenter survey of on prescriptions by palliative care specialists in Japan].
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Drug Prescriptions; Fentanyl; H | 2007 |
[Validity of recommended minimum dose of prior morphine to initiate transdermal fentanyl patch in prescribing information - multicenter survey of on prescriptions by palliative care specialists in Japan].
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Drug Prescriptions; Fentanyl; H | 2007 |
Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Buprenorphine; Fem | 2007 |
Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Buprenorphine; Fem | 2007 |
Predictors of long-acting opioid use and oral versus transdermal route among older Medicaid beneficiaries.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Cohort Studies; Comorbidity; | 2007 |
Predictors of long-acting opioid use and oral versus transdermal route among older Medicaid beneficiaries.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Cohort Studies; Comorbidity; | 2007 |
Treating cancer-related breakthrough pain: the oral transmucosal route.
Topics: Administration, Oral; Drug Administration Routes; Fentanyl; Humans; Mouth Mucosa; Neoplasms; Pain; P | 2007 |
Treating cancer-related breakthrough pain: the oral transmucosal route.
Topics: Administration, Oral; Drug Administration Routes; Fentanyl; Humans; Mouth Mucosa; Neoplasms; Pain; P | 2007 |
Fentanyl buccal tablet (Fentora) for breakthrough pain.
Topics: Administration, Buccal; Analgesics, Opioid; Drug Interactions; Fentanyl; Humans; Neoplasms; Pain; Pa | 2007 |
Fentanyl buccal tablet (Fentora) for breakthrough pain.
Topics: Administration, Buccal; Analgesics, Opioid; Drug Interactions; Fentanyl; Humans; Neoplasms; Pain; Pa | 2007 |
Toward freedom from cancer pain in Japan.
Topics: Analgesics, Opioid; Drug Utilization; Fentanyl; Humans; Japan; Morphine; Neoplasms; Pain; Practice G | 2007 |
Toward freedom from cancer pain in Japan.
Topics: Analgesics, Opioid; Drug Utilization; Fentanyl; Humans; Japan; Morphine; Neoplasms; Pain; Practice G | 2007 |
Opioid use in palliative care of children and young people with cancer.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Analgesics, Opioid; Child; Child, P | 2008 |
Opioid use in palliative care of children and young people with cancer.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Analgesics, Opioid; Child; Child, P | 2008 |
[Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Human | 2008 |
[Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Human | 2008 |
Influence of prescription benefits on reported pain in cancer patients.
Topics: Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Insurance Coverage; Male; Medicaid; Middl | 2008 |
Influence of prescription benefits on reported pain in cancer patients.
Topics: Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Insurance Coverage; Male; Medicaid; Middl | 2008 |
Not so fast: the reformulation of fentanyl and breakthrough chronic non-cancer pain.
Topics: Analgesics, Opioid; Chronic Disease; Drug Approval; Fentanyl; Humans; Neoplasms; Opioid-Related Diso | 2008 |
Not so fast: the reformulation of fentanyl and breakthrough chronic non-cancer pain.
Topics: Analgesics, Opioid; Chronic Disease; Drug Approval; Fentanyl; Humans; Neoplasms; Opioid-Related Diso | 2008 |
Oral transmucosal fentanyl citrate--OTFC (ACTIQ) #103.
Topics: Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain | 2008 |
Oral transmucosal fentanyl citrate--OTFC (ACTIQ) #103.
Topics: Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain | 2008 |
Anesthetic management of whole-body hyperthermia for the treatment of cancer.
Topics: Adolescent; Adult; Aged; Anesthetics; Body Temperature; Body Temperature Regulation; Chemical and Dr | 1980 |
Anesthetic management of whole-body hyperthermia for the treatment of cancer.
Topics: Adolescent; Adult; Aged; Anesthetics; Body Temperature; Body Temperature Regulation; Chemical and Dr | 1980 |
Transdermal fentanyl in cancer pain: conversion from oral morphine.
Topics: Administration, Cutaneous; Administration, Oral; Fentanyl; Humans; Morphine; Neoplasms; Palliative C | 1995 |
Transdermal fentanyl in cancer pain: conversion from oral morphine.
Topics: Administration, Cutaneous; Administration, Oral; Fentanyl; Humans; Morphine; Neoplasms; Palliative C | 1995 |
Day-to-day titration of transdermal fentanyl is unwise.
Topics: Administration, Cutaneous; Delayed-Action Preparations; Drug Monitoring; Drug Overdose; Fentanyl; Hu | 1995 |
Day-to-day titration of transdermal fentanyl is unwise.
Topics: Administration, Cutaneous; Delayed-Action Preparations; Drug Monitoring; Drug Overdose; Fentanyl; Hu | 1995 |
Continuous intravenous infusion of fentanyl: case reports of use in patients with advanced cancer and intractable pain.
Topics: Adult; Female; Fentanyl; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pain, Intract | 1993 |
Continuous intravenous infusion of fentanyl: case reports of use in patients with advanced cancer and intractable pain.
Topics: Adult; Female; Fentanyl; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pain, Intract | 1993 |
Transdermal fentanyl.
Topics: Administration, Cutaneous; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain | 1994 |
Transdermal fentanyl.
Topics: Administration, Cutaneous; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain | 1994 |
Titration with TTS fentanyl systems for previously uncontrolled cancer pain.
Topics: Administration, Cutaneous; Fentanyl; Humans; Neoplasms; Pain, Intractable | 1994 |
Titration with TTS fentanyl systems for previously uncontrolled cancer pain.
Topics: Administration, Cutaneous; Fentanyl; Humans; Neoplasms; Pain, Intractable | 1994 |
Managing pain with transdermal fentanyl.
Topics: Administration, Cutaneous; Fentanyl; Humans; Neoplasms; Pain; Therapeutic Equivalency | 1994 |
Managing pain with transdermal fentanyl.
Topics: Administration, Cutaneous; Fentanyl; Humans; Neoplasms; Pain; Therapeutic Equivalency | 1994 |
Fentanyl transdermal system overdose secondary to cutaneous hyperthermia.
Topics: Administration, Cutaneous; Adult; Drug Overdose; Female; Fentanyl; Hot Temperature; Humans; Neoplasm | 1993 |
Fentanyl transdermal system overdose secondary to cutaneous hyperthermia.
Topics: Administration, Cutaneous; Adult; Drug Overdose; Female; Fentanyl; Hot Temperature; Humans; Neoplasm | 1993 |
Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics.
Topics: Administration, Cutaneous; Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fentanyl; Human | 1993 |
Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics.
Topics: Administration, Cutaneous; Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fentanyl; Human | 1993 |
Use of transdermal fentanyl for cancer pain management.
Topics: Administration, Cutaneous; Fentanyl; Humans; Injections, Intravenous; Morphine; Neoplasms; Pain; The | 1993 |
Use of transdermal fentanyl for cancer pain management.
Topics: Administration, Cutaneous; Fentanyl; Humans; Injections, Intravenous; Morphine; Neoplasms; Pain; The | 1993 |
Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentan | 1995 |
Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentan | 1995 |
Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Injections, Subcutaneous; Mal | 1995 |
Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Injections, Subcutaneous; Mal | 1995 |
Oral morphine termed narcotic standard in severe cancer pain.
Topics: Administration, Oral; Analgesics, Opioid; Delayed-Action Preparations; Fentanyl; Humans; Morphine; N | 1996 |
Oral morphine termed narcotic standard in severe cancer pain.
Topics: Administration, Oral; Analgesics, Opioid; Delayed-Action Preparations; Fentanyl; Humans; Morphine; N | 1996 |
Fentanyl remaining in a transdermal system following three days of continuous use.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Medical Waste Disp | 1995 |
Fentanyl remaining in a transdermal system following three days of continuous use.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Medical Waste Disp | 1995 |
Use of the vasodilator sodium nitroprusside during local hyperthermia: effects on tumor temperature and tumor response in a rat tumor model.
Topics: Animals; Blood Pressure; Body Temperature; Butyrophenones; Fentanyl; Glioma; Hyperthermia, Induced; | 1996 |
Use of the vasodilator sodium nitroprusside during local hyperthermia: effects on tumor temperature and tumor response in a rat tumor model.
Topics: Animals; Blood Pressure; Body Temperature; Butyrophenones; Fentanyl; Glioma; Hyperthermia, Induced; | 1996 |
Analysis of fentanyl and sufentanil in hair by GC/MS/MS.
Topics: Anesthetics, Intravenous; Dose-Response Relationship, Drug; Fentanyl; Gas Chromatography-Mass Spectr | 1996 |
Analysis of fentanyl and sufentanil in hair by GC/MS/MS.
Topics: Anesthetics, Intravenous; Dose-Response Relationship, Drug; Fentanyl; Gas Chromatography-Mass Spectr | 1996 |
[Tumor pain. Fentanyl TTS: a transdermal system for tumor pain therapy].
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain | 1995 |
[Tumor pain. Fentanyl TTS: a transdermal system for tumor pain therapy].
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Neoplasms; Pain | 1995 |
Fentanyl transdermal system. Pain management at home.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Drug Costs; Female; F | 1997 |
Fentanyl transdermal system. Pain management at home.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Drug Costs; Female; F | 1997 |
[A transdermal method for the therapy of cancer pain. Status quo of cancer pain therapy in Germany].
Topics: Analgesics, Opioid; Fentanyl; Germany; Humans; Neoplasms; Pain, Postoperative; Palliative Care; Term | 1995 |
[A transdermal method for the therapy of cancer pain. Status quo of cancer pain therapy in Germany].
Topics: Analgesics, Opioid; Fentanyl; Germany; Humans; Neoplasms; Pain, Postoperative; Palliative Care; Term | 1995 |
Nurses' knowledge about equianalgesia and opioid dosing.
Topics: Administration, Cutaneous; Analgesics, Opioid; Delayed-Action Preparations; Educational Measurement; | 1997 |
Nurses' knowledge about equianalgesia and opioid dosing.
Topics: Administration, Cutaneous; Analgesics, Opioid; Delayed-Action Preparations; Educational Measurement; | 1997 |
Nurse-controlled analgesia using a patient-controlled analgesia device: an alternative strategy in the management of severe cancer pain in children.
Topics: Adolescent; Analgesia, Patient-Controlled; Analgesics, Opioid; Child; Child, Preschool; Dose-Respons | 1997 |
Nurse-controlled analgesia using a patient-controlled analgesia device: an alternative strategy in the management of severe cancer pain in children.
Topics: Adolescent; Analgesia, Patient-Controlled; Analgesics, Opioid; Child; Child, Preschool; Dose-Respons | 1997 |
Transdermal fentanyl for chronic pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Morphine; Neoplasm | 1997 |
Transdermal fentanyl for chronic pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Morphine; Neoplasm | 1997 |
Breakthrough pain with the fentanyl patch.
Topics: Administration, Oral; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain; Salvag | 1997 |
Breakthrough pain with the fentanyl patch.
Topics: Administration, Oral; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain; Salvag | 1997 |
A survey of transdermal fentanyl use in a major cancer center.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Health Care Surveys; Humans; Neoplasms; Pai | 1998 |
A survey of transdermal fentanyl use in a major cancer center.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Health Care Surveys; Humans; Neoplasms; Pai | 1998 |
Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain; Q | 1998 |
Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain; Q | 1998 |
Chronic cancer pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Neo | 1998 |
Chronic cancer pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Neo | 1998 |
Opioid substitution to reduce adverse effects in cancer pain management.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hospice Care; Humans; Male; Medical A | 1999 |
Opioid substitution to reduce adverse effects in cancer pain management.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hospice Care; Humans; Male; Medical A | 1999 |
Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain.
Topics: Administration, Inhalation; Administration, Intranasal; Aged; Aged, 80 and over; Analgesics, Opioid; | 2000 |
Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain.
Topics: Administration, Inhalation; Administration, Intranasal; Aged; Aged, 80 and over; Analgesics, Opioid; | 2000 |
Transdermal fentanyl: new preparation. An alternative to morphine.
Topics: Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Morphine; Neoplasms | 1998 |
Transdermal fentanyl: new preparation. An alternative to morphine.
Topics: Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Morphine; Neoplasms | 1998 |
An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study.
Topics: Administration, Intranasal; Aged; Aged, 80 and over; Analgesia; Dose-Response Relationship, Drug; Dr | 2000 |
An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study.
Topics: Administration, Intranasal; Aged; Aged, 80 and over; Analgesia; Dose-Response Relationship, Drug; Dr | 2000 |
[Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
Topics: Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Mouth Mucosa; Neoplasms; Pain; Tablets | 2000 |
[Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
Topics: Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Mouth Mucosa; Neoplasms; Pain; Tablets | 2000 |
Morphine and alternative opioids in cancer pain: the EAPC recommendations.
Topics: Administration, Oral; Analgesics, Opioid; Chemistry, Pharmaceutical; Drug Administration Schedule; F | 2001 |
Morphine and alternative opioids in cancer pain: the EAPC recommendations.
Topics: Administration, Oral; Analgesics, Opioid; Chemistry, Pharmaceutical; Drug Administration Schedule; F | 2001 |
Oral transmucosal fentanyl and sufentanil for incident pain.
Topics: Administration, Sublingual; Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Middle Aged; Neopla | 2001 |
Oral transmucosal fentanyl and sufentanil for incident pain.
Topics: Administration, Sublingual; Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Middle Aged; Neopla | 2001 |
Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Drug Administration Schedule; Female | 2001 |
Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Drug Administration Schedule; Female | 2001 |
[New Level III opioids of the World Health Organization].
Topics: Administration, Oral; Analgesics, Opioid; Clinical Trials as Topic; Delayed-Action Preparations; Fen | 2002 |
[New Level III opioids of the World Health Organization].
Topics: Administration, Oral; Analgesics, Opioid; Clinical Trials as Topic; Delayed-Action Preparations; Fen | 2002 |
Pain in Spain could be on the wane.
Topics: Administration, Cutaneous; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Neoplasms; Pain Measu | 2002 |
Pain in Spain could be on the wane.
Topics: Administration, Cutaneous; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Neoplasms; Pain Measu | 2002 |
[Opioid rotation in pain therapy. Case report].
Topics: Administration, Cutaneous; Chronic Disease; Fentanyl; Humans; Hydromorphone; Injections, Subcutaneou | 2002 |
[Opioid rotation in pain therapy. Case report].
Topics: Administration, Cutaneous; Chronic Disease; Fentanyl; Humans; Hydromorphone; Injections, Subcutaneou | 2002 |
[Impact of the commercialisation of transdermic fentanyl on the home care of terminal cancer patients].
Topics: Administration, Cutaneous; Analgesics, Opioid; Commerce; Fentanyl; Home Care Services; Humans; Neopl | 2002 |
[Impact of the commercialisation of transdermic fentanyl on the home care of terminal cancer patients].
Topics: Administration, Cutaneous; Analgesics, Opioid; Commerce; Fentanyl; Home Care Services; Humans; Neopl | 2002 |
[Paliative treatment: Treatment of chronic cancer pain (ii): the use of opiates].
Topics: Administration, Cutaneous; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Analgesics, O | 2002 |
[Paliative treatment: Treatment of chronic cancer pain (ii): the use of opiates].
Topics: Administration, Cutaneous; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Analgesics, O | 2002 |
Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Drug Administration S | 2001 |
Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Drug Administration S | 2001 |
[Sequential anesthesia-analgesia in cancerology].
Topics: Analgesia; Anesthesia; Fentanyl; Humans; Neoplasms; Preanesthetic Medication | 1977 |
[Sequential anesthesia-analgesia in cancerology].
Topics: Analgesia; Anesthesia; Fentanyl; Humans; Neoplasms; Preanesthetic Medication | 1977 |
Techniques, indications and results of intraoperative radiotherapy of advanced cancers.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alcuronium; Anesthesia, Inhalation; Anesthesia, Intravenous | 1975 |
Techniques, indications and results of intraoperative radiotherapy of advanced cancers.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alcuronium; Anesthesia, Inhalation; Anesthesia, Intravenous | 1975 |
Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients.
Topics: Administration, Cutaneous; Adult; Aged; Analgesia; Dose-Response Relationship, Drug; Female; Fentany | 1992 |
Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients.
Topics: Administration, Cutaneous; Adult; Aged; Analgesia; Dose-Response Relationship, Drug; Female; Fentany | 1992 |
[Intrathecal morphine therapy in children with cancer].
Topics: Bupivacaine; Child; Child, Preschool; Female; Fentanyl; Humans; Infant; Injections, Spinal; Male; Mo | 1992 |
[Intrathecal morphine therapy in children with cancer].
Topics: Bupivacaine; Child; Child, Preschool; Female; Fentanyl; Humans; Infant; Injections, Spinal; Male; Mo | 1992 |
An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Fentanyl; Humans; Middle Aged; Mouth Mucosa; Neop | 1991 |
An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Fentanyl; Humans; Middle Aged; Mouth Mucosa; Neop | 1991 |
TTS-fentanyl.
Topics: Administration, Cutaneous; Fentanyl; Humans; Neoplasms; Pain | 1989 |
TTS-fentanyl.
Topics: Administration, Cutaneous; Fentanyl; Humans; Neoplasms; Pain | 1989 |
Transdermal fentanyl for pain control in patients with cancer.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chronic Disease; Female; Fentanyl; Humans; Male; | 1989 |
Transdermal fentanyl for pain control in patients with cancer.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chronic Disease; Female; Fentanyl; Humans; Male; | 1989 |
Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: a case report.
Topics: Absorption; Administration, Oral; Fentanyl; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasms; Pain | 1989 |
Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: a case report.
Topics: Absorption; Administration, Oral; Fentanyl; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasms; Pain | 1989 |
Anaesthesia and acute dermatomyositis/polymyositis.
Topics: Acute Disease; Aged; Alfentanil; Anesthesia, General; Atracurium; Dermatomyositis; Etomidate; Fentan | 1988 |
Anaesthesia and acute dermatomyositis/polymyositis.
Topics: Acute Disease; Aged; Alfentanil; Anesthesia, General; Atracurium; Dermatomyositis; Etomidate; Fentan | 1988 |
[Objective control of the depth of neuroleptoanalgesia].
Topics: Droperidol; Electroencephalography; Electronystagmography; Fentanyl; Hexobarbital; Humans; Hydroxybu | 1974 |
[Objective control of the depth of neuroleptoanalgesia].
Topics: Droperidol; Electroencephalography; Electronystagmography; Fentanyl; Hexobarbital; Humans; Hydroxybu | 1974 |
[Possibilities of the use of neuroleptoanalgesic substances in therapy of pain in cancer patients].
Topics: Analgesics; Anesthesia; Fentanyl; Humans; Neoplasms; Neuroleptanalgesia; Palliative Care | 1965 |
[Possibilities of the use of neuroleptoanalgesic substances in therapy of pain in cancer patients].
Topics: Analgesics; Anesthesia; Fentanyl; Humans; Neoplasms; Neuroleptanalgesia; Palliative Care | 1965 |